Original Article
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
N Engl J Med 2005; 352:1425-1435April 7, 2005
- Abstract
Background
Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD).
Methods
A total of 10,001 patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non–procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke.
Results
The mean LDL cholesterol levels were 77 mg per deciliter (2.0 mmol per liter) during treatment with 80 mg of atorvastatin and 101 mg per deciliter (2.6 mmol per liter) during treatment with 10 mg of atorvastatin. The incidence of persistent elevations in liver aminotransferase levels was 0.2 percent in the group given 10 mg of atorvastatin and 1.2 percent in the group given 80 mg of atorvastatin (P<0.001). A primary event occurred in 434 patients (8.7 percent) receiving 80 mg of atorvastatin, as compared with 548 patients (10.9 percent) receiving 10 mg of atorvastatin, representing an absolute reduction in the rate of major cardiovascular events of 2.2 percent and a 22 percent relative reduction in risk (hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P<0.001). There was no difference between the two treatment groups in overall mortality.
Conclusions
Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.
Media in This Article
Figure 1
Screening, Enrollment, and Outcomes.Figure 2
Mean Lipid Levels during the Study.Article Activity
- Article
The value of lowering low-density lipoprotein (LDL) cholesterol levels in preventing major cardiovascular events and stroke has been well documented. Recent studies have raised the issue of optimal treatment targets for patients with coronary heart disease (CHD).1-4 The value of reducing LDL cholesterol levels substantially below 100 mg per deciliter (2.6 mmol per liter) in patients with CHD, particularly those with stable nonacute disease, has not been clearly demonstrated.
The Third Report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel5 and the most recent guidelines of the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice6 have recommended an LDL cholesterol level of less than 100 mg per deciliter as the goal of therapy for patients at high risk for CHD. On the basis of data from the Heart Protection Study (HPS)1 and the Pravastatin or Atorvastatin Evaluation and Infection Trial (PROVE IT),2 the NCEP in conjunction with the American Heart Association and the American College of Cardiology subsequently introduced a more aggressive, but optional, LDL cholesterol goal of less than 70 mg per deciliter (1.8 mmol per liter) for patients at very high risk for CHD, even if baseline LDL cholesterol levels were below 100 mg per deciliter.7 However, PROVE IT was conducted in a population of patients with acute coronary syndromes who were at very high risk for cardiovascular disease, and although many patients in the HPS who began with an LDL cholesterol level of less than 100 mg per deciliter benefited from statin therapy, this benefit was in comparison with placebo. Thus, there is no definitive evidence that intensive statin therapy, with a goal of reducing LDL cholesterol levels to approximately 70 mg per deciliter, is associated with better outcomes than moderate statin therapy, with a goal of reducing LDL cholesterol levels to about 100 mg per deciliter in patients with stable CHD. Data from the Treating to New Targets (TNT) Study make it possible to test this hypothesis.
Methods
The design of the TNT Study has been described in detail previously.8 All patients gave written informed consent, and the study was approved by the local research ethics committee or institutional review board at each center.
Primary Hypothesis
The primary hypothesis of the study was that reducing LDL cholesterol levels to well below 100 mg per deciliter in patients with stable CHD and slightly elevated LDL cholesterol levels (despite previous therapy with low-dose atorvastatin) could yield an incremental clinical benefit. This hypothesis was tested in a double-blind, parallel-group design. The occurrence of major cardiovascular outcomes was compared in two groups of patients: one group received 10 mg of atorvastatin daily with the goal of an average LDL cholesterol level of 100 mg per deciliter, and the other group received 80 mg of atorvastatin daily with the goal of an average LDL cholesterol level of 75 mg per deciliter (1.9 mmol per liter).
Patient Population
Eligible patients were men and women 35 to 75 years of age who had clinically evident CHD, defined by one or more of the following: previous myocardial infarction, previous or current angina with objective evidence of atherosclerotic CHD, and a history of coronary revascularization. The exclusion criteria have been described in detail previously.8 Randomization occurred between July 1998 and December 1999.
Study Protocol
Any previously prescribed lipid-regulating drugs were discontinued at screening, and all patients completed a washout period of one to eight weeks. To ensure that, at baseline, all patients had LDL cholesterol levels consistent with then-current guidelines for the treatment of stable CHD, patients with LDL cholesterol levels between 130 and 250 mg per deciliter (3.4 and 6.5 mmol per liter, respectively) and triglyceride levels of 600 mg per deciliter (6.8 mmol per liter) or less entered an eight-week run-in period of open-label treatment with 10 mg of atorvastatin per day. At the end of the run-in phase (week 0), patients with a mean LDL cholesterol level of less than 130 mg per deciliter (3.4 mmol per liter) (determined four weeks and two weeks before randomization) were randomly assigned to double-blind therapy with either 10 mg or 80 mg of atorvastatin per day. During the double-blind period, follow-up visits occurred at week 12 and at months 6, 9, and 12 in the first year and every 6 months thereafter.
Efficacy Outcomes
The primary efficacy outcome was the occurrence of a major cardiovascular event, defined as death from CHD, nonfatal non–procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. Secondary outcomes included a major coronary event (defined as death from CHD, nonfatal non–procedure-related myocardial infarction, or resuscitation after cardiac arrest), a cerebrovascular event, hospitalization for congestive heart failure, peripheral-artery disease, death from any cause, any cardiovascular event, and any coronary event.
Statistical Analysis
Epidemiologic data suggested that the treatment-related difference in LDL cholesterol levels between the two groups would translate into 20 to 30 percent fewer recurrent coronary events at five years in the group given 80 mg of atorvastatin than in the group given 10 mg of atorvastatin. The study's original target enrollment was approximately 8600 patients on the basis of a projected number of 750 major coronary events during an average follow-up of 5.5 years. However, the recruitment rate was higher than expected, and 10,003 patients underwent randomization, all but 2 of whom received the study drug.
In February 2003, the steering committee added stroke (fatal or nonfatal) to the primary efficacy outcome. This change was made before any data were reviewed and preceded the first interim analysis by the independent data and safety monitoring board. At the time, evidence was accumulating of the beneficial role of statins in reducing the risk of stroke. The change in the primary end point was made to clarify this role. This modification led to an increase in the projected number of primary events to 950 (750 coronary events plus 200 strokes) during the trial, providing the study with a statistical power of 85 percent to detect an absolute reduction of 17 percent in the five-year cumulative rate of the primary efficacy outcome in the group given 80 mg of atorvastatin, as compared with the group given 10 mg of atorvastatin, with the use of a two-sided test at an alpha level of 0.05.
All analyses were performed on an intention-to-treat basis. All randomized patients who were dispensed one dose of the study drug were included in the analyses. The primary and secondary composite end points were analyzed from the time of the first dose of study drug to the first event, according to the Kaplan–Meier method. The study had a statistical power of only 40 percent to detect a 10 percent reduction in the risk of death from any cause with the use of a two-sided test at an alpha level of 0.05.
Two interim efficacy analyses were performed and were based on a two-sided Peto type of monitoring boundary. For the final primary analysis, an adjusted P value of 0.049 was considered to indicate statistical significance, given a type I error rate of 0.05. For all secondary outcomes, a P value of 0.05 was considered to indicate statistical significance, and all tests were two-sided.
The sponsor initiated the study. The steering committee developed the protocol in collaboration with the sponsor and took responsibility for the final version. ICON Clinical Research (North Wales, Pennsylvania) managed all data. ICON and Pfizer provided site monitoring throughout the study. An independent end-points committee adjudicated all potential end points in a blinded fashion. An independent data and safety monitoring board with its independent statistical-support group from the University of Wisconsin performed interim monitoring and analyses of efficacy, safety, and data quality. The data were analyzed by the sponsor according to the statistical-analysis plan approved by the steering committee. The steering committee had unrestricted, request-based access to the study data, which were retained by the sponsor, and wrote the article without constraints from the sponsor. The steering committee assumes overall responsibility for the integrity of the data, for the accuracy of the data analyses, and for the completeness of the material reported. The data reported were those available to the steering committee as of January 29, 2005.
Results
Patient Population
A total of 18,469 patients were screened at 256 sites in 14 countries (Figure 1Figure 1
Screening, Enrollment, and Outcomes.). Of these, 15,464 patients (83.7 percent) were deemed eligible to enter the open-label run-in period. A further 5461 patients were excluded after the open-label run-in phase. Most of these excluded patients (4634, or 84.9 percent) did not meet randomization criteria. Other reasons included adverse events in 197 (3.6 percent), death or an ischemic event in 211 (3.9 percent), and lack of compliance in 70 (1.3 percent).A total of 10,001 patients underwent randomization and received double-blind treatment with either 10 mg or 80 mg of atorvastatin. The time of randomization was taken as the baseline for the study. Patients were followed for a median of 4.9 years.
The two groups were well matched at baseline (Table 1Table 1
Baseline Characteristics of the Patients.), and the pattern of use of concomitant medications was similar in the two groups. Blood pressure was controlled for the duration of the study in both groups.Change in Laboratory Values
During the open-label period, the LDL cholesterol level was reduced by 35 percent in the overall patient population, from a mean of 152 mg per deciliter (3.9 mmol per liter) to a mean of 98 mg per deciliter (2.6 mmol per liter). Figure 2Figure 2
Mean Lipid Levels during the Study. summarizes post-randomization lipid values in the two groups. Mean LDL cholesterol levels during the study were 77 mg per deciliter (2.0 mmol per liter) among patients receiving 80 mg of atorvastatin and 101 mg per deciliter (2.6 mmol per liter) among those receiving 10 mg of atorvastatin (Figure 2A).Total cholesterol levels (Figure 2B) and triglyceride levels (Figure 2C) decreased significantly from baseline to week 12 in the group given 80 mg of atorvastatin (P<0.001 for both comparisons), and the levels remained stable during the treatment period. Both doses of atorvastatin produced nonsignificant increases over baseline in high-density lipoprotein (HDL) cholesterol levels, with no significant difference between the groups during the course of the study (Figure 2D).
Efficacy Outcomes
A total of 434 patients in the group given 80 mg of atorvastatin and 548 patients in the group given 10 mg of atorvastatin had a primary event during the study, representing an event rate of 8.7 percent and 10.9 percent, respectively. This rate was equivalent to an absolute reduction of 2.2 percent in the group given 80 mg of atorvastatin. As compared with the group given 10 mg of atorvastatin, the group given 80 mg had a 22 percent relative reduction in the primary composite efficacy outcome of death from CHD, nonfatal non–procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke (hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P<0.001) (Figure 3Figure 3
Cumulative Incidence of a First Major Cardiovascular Event (Panel A), a First Major Coronary Event (Panel B), Nonfatal Myocardial Infarction (MI) or Death from CHD (Panel C), and a First Fatal or Nonfatal Stroke (Panel D).). There were 545 major cardiovascular events (as a first or subsequent event) in the group given 80 mg of atorvastatin and 715 events in the group given 10 mg of atorvastatin (Table 2Table 2
Estimated Hazard Ratio for Individual Components of the Primary and Secondary Efficacy Outcomes. shows only first events). Outcomes for individual components of the primary end point are shown in Table 2. Relative reductions in the risk of death from CHD, nonfatal non–procedure-related myocardial infarction, and fatal or nonfatal stroke with treatment with 80 mg of atorvastatin, as compared with 10 mg of atorvastatin, were all consistent with the reduction observed for the primary composite outcome. There was no statistical interaction for age or sex in the primary outcome measure.As compared with patients given 10 mg of atorvastatin, patients given 80 mg of atorvastatin also had significant reductions in the risk of a major coronary event (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002), any coronary event (hazard ratio, 0.79; 95 percent confidence interval, 0.73 to 0.86; P<0.001), a cerebrovascular event (hazard ratio, 0.77; 95 percent confidence interval, 0.64 to 0.93; P=0.007), hospitalization with a primary diagnosis of congestive heart failure (hazard ratio, 0.74; 95 percent confidence interval, 0.59 to 0.94; P=0.01), and any cardiovascular event (hazard ratio, 0.81; 95 percent confidence interval, 0.75 to 0.87; P<0.001) (Table 2). The effect of 80 mg of atorvastatin on the risk of peripheral-artery disease did not differ significantly from that of 10 mg of atorvastatin (hazard ratio, 0.97; 95 percent confidence interval, 0.83 to 1.15; P=0.76).
The risk of death from any cause also did not differ significantly between the two drug regimens (hazard ratio, 1.01; 95 percent confidence interval, 0.85 to 1.19; P=0.92). There were 155 deaths from cardiovascular causes in the group given 10 mg of atorvastatin (3.1 percent) and 126 in the group given 80 mg of atorvastatin (2.5 percent; hazard ratio, 0.80; 95 percent confidence interval, 0.64 to 1.08; P=0.08). There were 127 deaths from noncardiovascular causes in the group given 10 mg of atorvastatin (2.5 percent) and 158 in the group given 80 mg of atorvastatin (3.2 percent; hazard ratio, 1.25; 95 percent confidence interval, 0.99 to 1.57; P=0.06).
Cancer accounted for more than half the deaths from noncardiovascular causes in both groups — 75 in the group given 10 mg of atorvastatin (1.5 percent) and 85 in the group given 80 mg of atorvastatin (1.7 percent; hazard ratio, 1.13; 95 percent confidence interval, 0.83 to 1.55; P=0.42) — and there were 43 deaths (0.9 percent) and 58 deaths (1.2 percent), respectively, from nontraumatic causes other than cancer (hazard ratio, 1.35; 95 percent confidence interval, 0.91 to 2.00; P=0.13). There were 16 hemorrhagic strokes in the group given 80 mg of atorvastatin and 17 in the group given 10 mg of atorvastatin. Deaths from hemorrhagic stroke or trauma (including accidental death, suicide, and homicide) were infrequent, and the rates did not differ significantly between the two groups.
No significant increase in adverse events of any type was identified among patients who had very low levels of LDL cholesterol (less than 70 mg per deciliter [1.8 mmol per liter]), as compared with those with higher levels.
Safety
Adverse events related to treatment occurred in 406 patients in the group given 80 mg of atorvastatin, as compared with 289 patients in the group given 10 mg of atorvastatin (8.1 percent vs. 5.8 percent, P<0.001). The respective rates of discontinuation due to treatment-related adverse events were 7.2 percent and 5.3 percent (P<0.001). Treatment-related myalgia was reported by 241 patients in the group given 80 mg of atorvastatin and by 234 patients in the group given 10 mg of atorvastatin (4.8 percent and 4.7 percent, respectively; P=0.72). A total of 60 patients receiving 80 mg of atorvastatin had a persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both (defined as two consecutive measurements obtained 4 to 10 days apart that were more than three times the upper limit of the normal range), as compared with 9 patients receiving 10 mg of atorvastatin (1.2 percent vs. 0.2 percent, P<0.001). There were no persistent elevations in creatine kinase (defined as two consecutive measurements obtained 4 to 10 days apart that were more than 10 times the upper limit of the normal range). Five cases of rhabdomyolysis were reported (two in the group given 80 mg of atorvastatin and three in the group given 10 mg of atorvastatin); relevant clinical information about these cases is presented in Table 3Table 3
Characteristics of Five Patients with Rhabdomyolysis..Discussion
This trial provides evidence that the use of intensive atorvastatin therapy to reduce LDL cholesterol levels below 100 mg per deciliter is associated with substantial clinical benefit in patients with stable CHD. Both atorvastatin groups had low rates of CHD events. The rate in the group given 10 mg of atorvastatin was lower than rates reported with statin treatment in placebo-controlled, secondary-prevention trials of populations with a baseline risk similar to that of our patients.1,10,11
The relative reduction in the risk of the primary composite end point of death from CHD, nonfatal non–procedure-related myocardial infarction, resuscitation after cardiac arrest, and fatal or nonfatal stroke was 22 percent in the group given 80 mg of atorvastatin, as compared with the group given 10 mg of atorvastatin. Our findings indicate that the quantitative relationship between reduced LDL cholesterol levels and reduced CHD risk demonstrated in prior secondary-prevention trials of statins holds true even at very low levels of LDL cholesterol (Figure 4Figure 4
Event Rates Plotted against LDL Cholesterol Levels during Statin Therapy in Secondary-Prevention Studies.). If these results were extrapolated to clinical practice, the use of an 80-mg dose of atorvastatin to reduce LDL cholesterol levels from a baseline of 101 mg per deciliter to 77 mg per deciliter in 1000 patients with stable CHD would prevent 34 major cardiovascular events over a period of five years; in other words, approximately 30 patients would need to be treated to prevent one event.Evaluation of individual components of the primary and secondary end points shows that treatment with 80 mg of atorvastatin had a consistent and significant beneficial effect on most measures of CHD-related morbidity and mortality. The clinical benefit of reducing LDL cholesterol levels substantially below 100 mg per deciliter extended beyond the CHD-related vasculature. As compared with the 10-mg dose of atorvastatin, intensive therapy with high-dose atorvastatin reduced the risk of cerebrovascular events by 23 percent. There was no significant difference between groups in the numbers of hemorrhagic strokes as a first event.
The study was not adequately powered to detect changes in the risk of death from any cause. There were no significant differences between the two atorvastatin groups in the risk of death from cardiovascular or noncardiovascular causes. The rates of death from coronary causes in both groups were very low as compared with those in previous secondary-prevention trials of statins, accounting for only about one third of all deaths. As a consequence, the 20 percent reduction in the risk of death from CHD in the group given 80 mg of atorvastatin as compared with the group given 10 mg of atorvastatin was not large enough to have a significant effect on the risk of death from any cause.
In both groups, cancer (mainly lung and gastrointestinal) was the leading noncardiovascular cause of death; other causes included respiratory diseases, infection, degenerative diseases, and metabolic abnormalities. Although for most of these noncardiovascular causes, the number of deaths was slightly higher in the group given 80 mg of atorvastatin than in the group given 10 mg of atorvastatin, no single cause (according to body system or pathologic process) and no single type of cancer accounted for the nonsignificant difference in deaths from any cause between the groups.
The findings regarding drug safety are consistent with the adverse-event profiles of these two doses of atorvastatin reported in other large-scale trials of atorvastatin.2,3 The exclusion of 131 patients because of abnormal liver-function tests or myalgia during the run-in phase is unlikely to account for the low incidence of persistent elevations in liver aminotransferase levels and the low rate of muscle-related adverse events during the study.
In summary, our findings demonstrate that the use of an 80-mg dose of atorvastatin to reduce LDL cholesterol levels to 77 mg per deciliter provides additional clinical benefit in patients with stable CHD that is perceived to be well controlled at an LDL level of approximately 100 mg per deciliter. These data confirm and extend the growing body of evidence indicating that lowering LDL cholesterol levels well below currently recommended levels can have clinical benefit.
Funded by Pfizer.
Dr. LaRosa reports having received consulting fees from Pfizer, Merck, Bristol-Myers Squibb, and AstraZeneca and lecture fees from Pfizer; Dr. Grundy lecture fees from Merck, Pfizer, Kos Pharmaceutical, Abbott, and AstraZeneca and grant support from Kos Pharmaceutical and Merck; and Dr. Waters consulting fees from AstraZeneca and Pfizer; lecture fees from Merck, Pfizer, and Novartis; and grant support from Merck and Johnson & Johnson. Dr. Shear is an employee of Pfizer and owns stock in that company. Dr. Barter reports having received consulting fees from Pfizer, AstraZeneca, and Sanofi-Aventis; lecture fees from Pfizer, AstraZeneca, FournierPharma, and Sanofi-Aventis; and grant support from Pfizer; and Dr. Fruchart consulting fees from Pfizer and Fournier and lecture fees from Merck, Fournier, Pierre Fabrie, and AstraZeneca. Dr. Gotto reports having received consulting fees from AstraZeneca, Bristol-Myers Squibb, Merck, ScheringPlough, Pfizer, Novartis, and Reliant and lecture fees from AstraZeneca, Merck, ScheringPlough, Pfizer, and Reliant and having testified before the Food and Drug Administration on behalf of Johnson & Johnson–Merck. Dr. Greten reports having received consulting and lecture fees from Pfizer, Merck, and ScheringPlough; Dr. Kastelein consulting fees, lecture fees, and grant support from Pfizer, Merck, ScheringPlough, AstraZeneca, Bristol-Myers Squibb, and Sankyo; Dr. Shepherd consulting fees from AstraZeneca, GlaxoSmithKline, Merck, ScheringPlough and Oxford Biosensors and lecture fees from AstraZeneca, Merck, and ScheringPlough; and Dr. Wenger consulting fees from Eli Lilly, Merck, Bristol-Myers Squibb, Pfizer, and Kos Pharmaceuticals; lecture fees from Eli Lilly, Pfizer, Novartis, Merck, Bristol-Myers Squibb, and Kos Pharmaceuticals; and grant support from Eli Lilly, Novartis, Bristol-Myers Squibb, and AstraZeneca.
This article was published at www.nejm.org on March 8, 2005.
We are indebted to all the trial participants; to the large number of doctors, nurses, and hospital administrative staff in various countries for their long-term commitment to the study; and to Diane Hessinger, Roger Chan, Andrei Breazna, Eric Gibson, Liz Cusenza, Sheila Auster, Patrick Ferrebee, and Roddy Carter (all full-time employees of Pfizer) for their contributions.
Source Information
From the State University of New York Health Science Center, Brooklyn (J.C.L.); the University of Texas Southwestern Medical Center, Dallas (S.M.G.); San Francisco General Hospital, San Francisco (D.D.W.); Pfizer, Groton, Conn. (C.S.); the Heart Research Institute, Sydney (P.B.); Institut Pasteur, Lille, France (J.-C.F.); Weill Medical College of Cornell University, New York (A.M.G.); Universitätsklinikum Eppendorf, Hamburg, Germany (H.G.); Academic Medical Center, University of Amsterdam, Amsterdam (J.J.P.K.); the University of Glasgow, Glasgow, United Kingdom (J.S.); and Emory University School of Medicine, Atlanta (N.K.W.).
Address reprint requests to Dr. LaRosa at the State University of New York Health Science Center, 450 Clarkson Ave., Brooklyn, NY 11203, or at jclarosa@downstate.edu.
Participants in the TNT Study are listed in the Appendix.
Appendix
The following persons participated in the TNT Study: Steering Committee: J. LaRosa (chair), New York; P. Barter, Sydney; J.-C. Fruchart, Lille, France; A. Gotto, New York; H. Greten, Hamburg, Germany; S. Grundy, Dallas; D. Hunninghake, Minneapolis; J. Kastelein, Amsterdam; J. Shepherd, Glasgow; D. Waters, San Francisco; N. Wenger, Atlanta; End-Points Committee: L. Cohen (chair), New Haven, Conn.; J.-M. LaBlanche, Lille, France; H. Levine, Boston; U. Sechtem, Stuttgart, Germany; F. Welty, Boston; Data and Safety Monitoring Board: C. Hennekens (chair), Miami; V. Brown, Atlanta; R. Carmena, Valencia, Spain; R. D'Agostino, Boston; S. Haffner, San Antonio, Tex.; E. Leitersdorf, Jerusalem; Investigators (numbers of randomized patients in parentheses): Australia (608 patients): C. Aroney, P. Barter, J. Bradley, D. Colquhoun, A. Dart, M. d'Emden, J. Lefkovits, R. Minson, G. Nelson, R. O'Brien, P. Roberts-Thomson, A. Thomson, D. Sullivan, P. Thompson; Austria (29 patients): H. Drexel, H. Sinzinger, F. Stockenhuber; Belgium (300 patients): P. Chenu, G. Heyndrickx, J. Van Cleemput, A. Van Dorpe, W. Van Mieghem, P. Vermeersch; Canada (1052 patients): M. Arnold, R. Baigrie, J. Bergeron, C. Gagné, J. Davignon, J. Ducas, J. Genest, L. Higginson, G. Hoag, J. Bonet, A. Ignaszewski, L. Leiter, S. LePage, P. Ma, M. McQueen, D. Mymin, B. O'Neill, B. Sussex, P. Theroux, G. Tremblay, W. Tymchak, J. Warnica; France (207 patients): P. Attali, J. Bonnet, L. Caster, R. Constans, J. Demarcq, I. Ginon, J. Leymarie, J. Mansourati, J. Ollivier, F. Paillard, J. Ponsonnaille; Germany (144 patients): U. Beil, H. Fritz, D. Hüwel, W. Huppertz, W. Liebscher, K Schussmann, E. Steinhagen-Thiessen; Ireland (53 patients): B. Buckley, P. Crean; Italy (75 patients): A. Branzi, P. Fioretti, G. Gensini, N. Mininni, G. Pinelli, E. Uslenghi; the Netherlands (788 patients): R. Anthonio, J. Bonnier, H. Crijns, H. Dohmen, P. Dunselman, M. Galjee, B. Hamer, J. Hoorntje, J. Jukema, A. Oude-Ophuis, H. Plokker, J. Posma, J. Ruiter, M. Trip, A. van Boven; South Africa (523 patients): A. Dalby, L. Disler, A. Doubell, J. King, E. Lloyd, J. Marx, P. Roux; Spain (525 patients): M. Anguita, C. Brotons, C. Calvo, J. Cruz-Fernandez, F. Fernandez-Aviles, A. Fernandez-Cruz, I. Ferreira, E. Gonzalez, E. Lage, P. Mata, J. Mostaza, R. Muñoz-Aguilera, E. Lopez de Sa, G. Pedro, G. Permanyer, A. Pozuelo, R. Querejeta, J. Ribera, E. Ros-Rahola, M. Vela; Switzerland (91 patients): W. Angehrn, L. Kappenberger, T. Moccetti, H. Saner; United Kingdom (299 patients): D. Brydie, A. Chauhan, R. Greenbaum, H. Kadr, C. Kaski, R. Mattu, W. McCrea, J. McMurray, D. Mikhailidis, A. Salmasi, N. Samani, M. Shiu, A. Timmis, S. Turley, J. Wictome; United States (5309 patients): R. Abadier, S. Alexander, B. Asbill, J. Bagdade, B. Beard, J. Becker, V. Bittner, R. Blumenthal, M. Bolton, W. Bremner, D. Brewer, C. Brown, K. Browne, J. Carstens, W. Cefalu, J. Chambers, J. Cohen, M. Collins, S. Crespin, M. Cressman, R. Curry, M. Davidson, G. De Gent, J. de Lemos, P. Deedwania, D. Dixon, J. Duncan, C. East, D. Edmundowicz, B. Effron, M. Elam, M. Ettinger, R. Feldman, D. Fiske, J. Forrester, G. Fraser, Z. Freedman, S. Freeman, V. Fonseca, D. Frid, K. Friday, J. Geohas, H. Ginsberg, A. Goldberg, E. Goldenberg, D. Goldner, D. Goldscher, B. Gordon, S. Gottlieb, M. Grayson, R. Guthrie, J. Guyton, J. Haas, F. Handel, R. Hartman, J. Henry, M. Hepp, R. Heuser, D. Herrington, M. Hibbard, C. Hjemdahl-Monsen, G. Hopkins, V. Howard, J. Hsia, D. Hunninghake, S. Jafri, P. Jones, P. Kakavas, J. Kane, L. Keilson, E. Kerut, R. Kloner, R. Knopp, J. Kostis, L. Kozlowski, R. Krasuski, A. Kugelmass, K. LaBresh, J. Larry, C. Lavie, B. Lewis, S. Lewis, M. Linton, P. Linz, R. Lloret, V. Lucarella, J. Maciejko, D. McElroy, J. McGhee, M. McGowan, W. McGuinn, M. Melucci, J. Merillat, M. Michalski, D. Miller, L. Miller, M. Miller, M. Mirro, V. Miscia, J. Mossberg, B. Musa, S. Nash, R. Nesto, M. Neustel, T. Noonan, J. O'Keefe, B. Olafsson, S. Oparil, T. Pearson, C. Pepine, G. Peterson, G. Pogson, K. Powers, D. Rader, R. Reeves, J. Reusch, G. Revtyak, D. Robertson, J. Robinson, W. Robinson, M. Rocco, J. Robinson, J. Rodgers, R. Rosenson, E. Roth, S. Sadanandan, K. Salisbury, D. Sato, J. Saucedo, E. Schaefer, H. Schrott, L. Seman, G. Schectman, C. Schmalfuss, D. Schneider, B. Sobel, R. Schneider, S. Schwartz, P. Seigel, M. Seyal, S. Sharp, D. Shindler, D. Smith, D. Sprecher, L. Solberg, E. Sontz, J. Stamper, E. Stein, V. Subbarao, A. Susmano, A. Talle, P. Thompson, J. Torelli, F. Torres, D. Triffon, G. Vetrovec, N. Vijay, W. Wickermeyer, K. Wool, M. Zakrzewski, S. Zarich, J. Zavoral, F. Zieve.
- References
References
1
Heart Protection Study Collaborative Group
CrossRef | Web of Science | Medline2
Cannon CP ,Braunwald E ,McCabe CH , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
Full Text | Web of Science | Medline3
Sever PS ,Dahlof B ,Poulter NR , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158
CrossRef | Web of Science | Medline4
Koren MJ ,Hunninghake DB . Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004;44:1772-1779
CrossRef | Web of Science | Medline5
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
CrossRef | Web of Science6
De Backer G ,Ambrosioni E ,Borch-Johnsen K , et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-1610
CrossRef | Web of Science | Medline7
Grundy SM ,Cleeman JI ,Merz CN , et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239[Erratum, Circulation 2004;110:763.]
CrossRef | Web of Science | Medline8
Waters DD ,Guyton JR ,Herrington DM , et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004;93:154-158
CrossRef | Web of Science | Medline9
Pasternak RC ,Smith SC Jr ,Bairey-Merz CN , et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-1028
CrossRef | Web of Science | Medline10
Sacks FM ,Pfeffer MA ,Moye LA , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009
Full Text | Web of Science | Medline11
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Full Text | Web of Science | Medline12
Scandinavian Simvastatin Survival Study Group
Web of Science | Medline
- Citing Articles (972)
Citing Articles
1
2013. H. , 447-566.
CrossRef2
Allan D. Sniderman, Curt D. Furberg. (2012) Pluralism of viewpoints as the antidote to intellectual conflict of interest in guidelines. Journal of Clinical Epidemiology 65:7, 705-707
CrossRef3
Jennifer E. Ho, David D. Waters, Allison Kean, Daniel J. Wilson, David A. DeMicco, Andrei Breazna, Chuan-Chuan Wun, Prakash C. Deedwania, Kiran K. Khush. (2012) Relation of Improvement in Estimated Glomerular Filtration Rate With Atorvastatin to Reductions in Hospitalizations for Heart Failure (from the Treating to New Targets [TNT] Study). The American Journal of Cardiology 109:12, 1761-1766
CrossRef4
Angharad N de Cates, Matthew RB Farr, Karen Rees, Juan P Casas, Mark Huffman, Juan P Casas. 2012. Fixed-dose combination therapy for the prevention of cardiovascular disease. .
CrossRef5
Christian Philipp Kamm, Marwan El-Koussy, Sebastian Humpert, Oliver Findling, Ferdinand Bredow, Yuliya Burren, Guido Schwegler, Dagmar Schött, Filippo Donati, Martin Müller, Norbert Goebels, Felix Müller, Johannes Slotboom, Barbara Tettenborn, Ludwig Kappos, Yvonne Naegelin, Heinrich Paul Mattle. (2012) Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. Journal of Neurology
CrossRef6
, J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Syvanne, W. J. M. Scholte Op Reimer, C. Vrints, D. Wood, J. L. Zamorano, F. Zannad, , M. T. Cooney, , J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, , C. Funck-Brentano, P. A. Sirnes, V. Aboyans, E. A. Ezquerra, C. Baigent, C. Brotons, G. Burell, A. Ceriello, J. De Sutter, J. Deckers, S. Del Prato, H.-C. Diener, D. Fitzsimons, Z. Fras, R. Hambrecht, P. Jankowski, U. Keil, M. Kirby, M. L. Larsen, G. Mancia, A. J. Manolis, J. McMurray, A. Pajak, A. Parkhomenko, L. Rallidis, F. Rigo, E. Rocha, L. M. Ruilope, E. van der Velde, D. Vanuzzo, M. Viigimaa, M. Volpe, O. Wiklund, C. Wolpert. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal
CrossRef7
Robert J. Glynn, Joshua J. Gagne, Sebastian Schneeweiss. (2012) Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiology and Drug Safety 21, 138-147
CrossRef8
Jing Liu, Wei Wang, Miao Wang, Jiayi Sun, Jun Liu, Yan Li, Yue Qi, Zhaosu Wu, Dong Zhao. (2012) Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: A 15-year follow-up of the Chinese Multi-provincial Cohort Study. Diabetes Research and Clinical Practice 96:2, 217-224
CrossRef9
Roeland Huijgen, S. Matthijs Boekholdt, Benoit J. Arsenault, Weihang Bao, Jean-Michel Davaine, Fatiha Tabet, Francine Petrides, Kerry-Anne Rye, David A. DeMicco, Philip J. Barter, John J.P. Kastelein, Gilles Lambert. (2012) Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial. Journal of the American College of Cardiology 59:20, 1778-1784
CrossRef10
Futoshi Yamanaka, Myung Ho Jeong, Shigeru Saito, Youngkeun Ahn, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jin Kim, Donghoon Choi, Yang Soo Jang, Junghan Yoon, Wook Sung Chung, Jeong Gwan Cho, Ki Bae Seung, Seung Jung Park. (2012) Effectiveness of statin therapy for elderly acute myocardial infarction patients with normal levels of low-density lipoprotein cholesterol. International Journal of Cardiology
CrossRef11
Y. Asamiya, A. Yajima, Y. Tsuruta, S. Otsubo, K. Nitta. (2012) Oxidised LDL/LDL-cholesterol ratio and coronary artery calcification in haemodialysis patients. Nutrition, Metabolism and Cardiovascular Diseases
CrossRef12
Darren Green, Rosica Panayotova, James P. Ritchie, Edmond O’Riordan, John McDonald. (2012) LIPID-LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?. Journal of Renal Careno-no
CrossRef13
Richard W Grant, Deborah J Wexler. (2012) Personalized medicine in Type 2 diabetes: what does the future hold?. Diabetes Management 2:3, 199-204
CrossRef14
Sung Woo Kwon, Byoung Kwon Lee, Bum-Kee Hong, Jong-Youn Kim, Eui-Young Choi, Ji Min Sung, Ji-Hyuck Rhee, Yoo Mi Park, Dae Won Ma, Hyemoon Chung, Hee-Sun Mun, Sung-Joo Lee, Jong-Kwan Park, Pil-Ki Min, Young Won Yoon, Se-Joong Rim, Hyuck Moon Kwon. (2012) Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. International Journal of Cardiology
CrossRef15
W. Koenig, N. Marx, J. Thiery, G. Klose. (2012) Kommentar zu den neuen Leitlinien (2011) der Europäischen Gesellschaft für Kardiologie zum Management von Dyslipidämien. Der Kardiologe
CrossRef16
QiPing Feng, Russell A Wilke, Tesfaye M Baye. (2012) Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 13:5, 579-594
CrossRef17
Jannet A. Eindhoven, Yoshinobu Onuma, Rohit M. Oemrawsingh, Joost Daemen, Josephine van Nierop, Peter de Jaegere, Eric Boersma, Patrick Serruys, Ron van Domburg. (2012) Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study. EuroIntervention 7:12, 1420-1427
CrossRef18
Vimal Ramjee, Danny J. Eapen, Laurence S. Sperling. (2012) Optimal lipid targets for the new era of cardiovascular prevention. Annals of the New York Academy of Sciences 1254:1, 106-114
CrossRef19
Lina Badimon, Gemma Vilahur. (2012) LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Annals of the New York Academy of Sciences 1254:1, 18-32
CrossRef20
Yuhei Shiga, Shin-ichiro Miura, Hiroaki Nishikawa, Ayumi Nakamura, Tadaaki Arimura, Ryoko Mitsutake, Atsushi Iwata, Keijiro Saku. (2012) Regression of coronary plaque after coronary artery bypass graft. Journal of Cardiology Cases 5:2, e92-e95
CrossRef21
Laurent Querton, Martin Buysschaert, Michel P. Hermans. (2012) Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. Journal of Clinical Lipidology
CrossRef22
Tadaaki Arimura, Shin-ichiro Miura, Amane Ike, Makoto Sugihara, Atsushi Iwata, Hiroaki Nishikawa, Akira Kawamura, Keijiro Saku. (2012) Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. Journal of Cardiology
CrossRef23
John G. F. Cleland, Saqib Mumtaz, Luca Cecchini. (2012) Role of Antithrombotic Agents in Heart Failure. Current Cardiology Reports
CrossRef24
Vasu Babu Ravi, Ramesh Mullangi, Jaswanth Kumar Inamadugu, Nageswara Rao Pilli, Ramakrishna Gajula, Venkateswarlu Ponneri. (2012) Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical Chromatographyn/a-n/a
CrossRef25
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
CrossRef26
K. Rahimi, W. Majoni, A. Merhi, J. Emberson. (2012) Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. European Heart Journal
CrossRef27
Tsuyoshi Nozue, Shingo Yamamoto, Shinichi Tohyama, Shigeo Umezawa, Tomoyuki Kunishima, Akira Sato, Shogo Miyake, Youichi Takeyama, Yoshihiro Morino, Takao Yamauchi, Toshiya Muramatsu, Kiyoshi Hibi, Takashi Sozu, Mitsuyasu Terashima, Ichiro Michishita. (2012) Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. American Heart Journal 163:2, 191-199.e1
CrossRef28
Fathimath Faiz, Amanda J. Hooper, Frank M. van Bockxmeer. (2012) Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins. Critical Reviews in Clinical Laboratory Sciences1-17
CrossRef29
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary. The Journal of Thoracic and Cardiovascular Surgery 143:1, 4-34
CrossRef30
Cassandra D. Benge, Brandon Markley, Michael Shawn McFarland. (2012) Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease. Southern Medical Journal 105:1, 48-55
CrossRef31
Kevin A. Buhr. (2012) Surrogate End Points in Secondary Analyses of Cardiovascular Trials. Progress in Cardiovascular Diseases 54:4, 343-350
CrossRef32
Noriko Makihara, Yasushi Okada, Masatoshi Koga, Yoshiaki Shiokawa, Jyoji Nakagawara, Eisuke Furui, Kazumi Kimura, Hiroshi Yamagami, Yasuhiro Hasegawa, Kazuomi Kario, Satoshi Okuda, Masaki Naganuma, Kazunori Toyoda. (2012) Effect of Serum Lipid Levels on Stroke Outcome after rt-PA Therapy: SAMURAI rt-PA Registry. Cerebrovascular Diseases 33:3, 240-247
CrossRef33
Ragavendra R. Baliga. (2012) HDL–Cholesterol: Perfection is the Enemy of Good?. Medical Clinics of North America 96:1, 27-37
CrossRef34
Seth S. Martin, Roger S. Blumenthal, Michael Miller. (2012) LDL Cholesterol: The Lower the Better. Medical Clinics of North America 96:1, 13-26
CrossRef35
Tsuyoshi Kanaoka, Junichiro Takahashi, Yutaka Wakamatsu, Kouji Ishii, Toshihiro Gohda, Shigeyuki Sasaki, Yoshiro Matsui. (2012) Lowered Postoperative Ldl-C/Hdl-C Ratio Reduces Later Cardiovascular Events after Abdominal Aortic Aneurysm Surgery. Annals of Vascular Diseases 5:1, 36-44
CrossRef36
David A. Morrow, William E. Boden. 2012. Stable Ischemic Heart Disease. , 1210-1269.
CrossRef37
Prakash Deedwania, Joel A. Lardizabal. 2012. Non-antiarrhythmic Therapies for Cardiac Arrhythmias. , 1167-1174.
CrossRef38
Janice B. Schwartz, Douglas P. Zipes. 2012. Cardiovascular Disease in the Elderly. , 1727-1756.
CrossRef39
Kausik K. Ray, Christopher P. Cannon. 2012. Lipid Lowering in Coronary Artery Disease. , 126-141.
CrossRef40
Katsuki Okada, Yasunori Ueda, Tadateru Takayama, Junko Honye, Sei Komatsu, Osamu Yamaguchi, Yuxin Li, Junji Yajima, Kenji Takazawa, Shinsuke Nanto, Satoshi Saito, Atsushi Hirayama, Kazuhisa Kodama. (2012) Influence of Achieved Low-Density Lipoprotein Cholesterol Level With Atorvastatin Therapy on Stabilization of Coronary Plaques. Circulation Journal 76:5, 1197-1202
CrossRef41
H P Rang, M M Dale, J M Ritter, R J Flower, G Henderson. 2012. Atherosclerosis and lipoprotein metabolism. , 285-293.
CrossRef42
Clay F. Semenkovich. 2012. Disorders of Lipid Metabolism. , 1346-1354.
CrossRef43
Jamal S. Rana, S. Matthijs Boekholdt, John J. P. Kastelein, Prediman K. Shah. (2011) The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. Current Atherosclerosis Reports
CrossRef44
J. P. Miller. (2011) Comment on 'The great cholesterol myth: unfortunate consequences of Brown and Goldstein's mistake'. QJM
CrossRef45
Rishi Puri, MyNgan Duong, Kiyoko Uno, Yu Kataoka, Stephen J Nicholls. (2011) The emerging role of plasma lipidomics in cardiovascular drug discovery. Expert Opinion on Drug Discovery1-10
CrossRef46
Alexander Mauskop, William B. Borden. (2011) Predictors of Statin Adherence. Current Cardiology Reports 13:6, 553-558
CrossRef47
B. Sjouke, D. M. Kusters, J. J. P. Kastelein, G. K. Hovingh. (2011) Familial Hypercholesterolemia: Present and Future Management. Current Cardiology Reports 13:6, 527-536
CrossRef48
Pascale M. Ohnsorg, Jean-Luc Mary, Lucia Rohrer, Michael Pech, Jürgen Fingerle, Arnold von Eckardstein. (2011) Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin:cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1811:12, 1115-1123
CrossRef49
Agnieszka Belter, Miroslawa Skupinska, Malgorzata Giel-Pietraszuk, Tomasz Grabarkiewicz, Leszek Rychlewski, Jan Barciszewski. (2011) Squalene monooxygenase – a target for hypercholesterolemic therapy. Biological Chemistry 392:12, 1053-1075
CrossRef50
David Preiss, Naveed Sattar. (2011) Statins and the risk of new-onset diabetes. Current Opinion in Lipidology 22:6, 460-466
CrossRef51
Rodrigo Antonini Ribeiro, Patricia Klarmann Ziegelmann, Bruce Bartholow Duncan, Steffan Frosi Stella, José Luiz da Costa Vieira, Luciane Maria Fabian Restelatto, Emílio Hideyuki Moriguchi, Carisi Anne Polanczyk. (2011) Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. International Journal of Cardiology
CrossRef52
Julio A. Carbayo Herencia. (2011) Nuevos marcadores de riesgo cardiovascular. ¿Pueden influir en la clasificación del riesgo cardiovascular?. Clínica e Investigación en Arteriosclerosis
CrossRef53
Nicholls, Stephen J., Ballantyne, Christie M., Barter, Philip J., Chapman, M. John, Erbel, Raimund M., Libby, Peter, Raichlen, Joel S., Uno, Kiyoko, Borgman, Marilyn, Wolski, Kathy, Nissen, Steven E., . (2011) Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine 365:22, 2078-2087
Full Text54
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology 58:24, 2550-2583
CrossRef55
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology 58:24, e123-e210
CrossRef56
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. Journal of the American College of Cardiology 58:24, 2584-2614
CrossRef57
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:24, e44-e122
CrossRef58
Alejandro de la Sierra. (2011) Renin–angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy 9:12, 1585-1591
CrossRef59
Manuel Anguita, Eduardo Alegría, Vivencio Barrios, José A. Casasnovas, Carlos Escobar, Monserrat León, Emilio Luengo, José L. Llisterri, Ángel Alonso, Ángel Cequier, Josep Comín, Antonio Fernández-Ortiz, Magda Heras, Manuel Pan, Fernando Worner, Gonzalo Barón, Eva Bernal, Xavier Borrás, Fernando Civeira, Alberto Cordero, Eliseo Guallar, Borja Ibáñez, Martín Laclaustra, Carmen de Pablo, Domingo Pascual, Tomás Ripoll, Ginés Sanz, Silvia Serrano. (2011) Comments on the 2011 ESC/EAS guidelines for the management of dyslipidemias. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Revista Española de Cardiología (English Edition) 64:12, 1090-1095
CrossRef60
Manuel Anguita, Eduardo Alegría, Vivencio Barrios, José A. Casasnovas, Carlos Escobar, Monserrat León, Emilio Luengo, José L. Llisterri, Ángel Alonso, Ángel Cequier, Josep Comín, Antonio Fernández-Ortiz, Magda Heras, Manuel Pan, Fernando Worner, Gonzalo Barón, Eva Bernal, Xavier Borrás, Fernando Civeira, Alberto Cordero, Eliseo Guallar, Borja Ibáñez, Martín Laclaustra, Carmen de Pablo, Domingo Pascual, Tomás Ripoll, Ginés Sanz, Silvia Serrano. (2011) Comentarios a las guías de práctica clínica sobre manejo de las dislipemias de la Sociedad Europea de Cardiología y la Sociedad Europea de Aterosclerosis 2011. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. Revista Española de Cardiología 64:12, 1090-1095
CrossRef61
Denise E. Bonds. (2011) Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes. Current Cardiovascular Risk Reports
CrossRef62
Uchechukwu K. Sampson, Sergio Fazio, MacRae F. Linton. (2011) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports
CrossRef63
F. Akdim, D. L. Tribble, J. D. Flaim, R. Yu, J. Su, R. S. Geary, B. F. Baker, R. Fuhr, M. K. Wedel, J. J. P. Kastelein. (2011) Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. European Heart Journal 32:21, 2650-2659
CrossRef64
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology 58:23, 2432-2446
CrossRef65
Ross J Simpson, James Signorovitch, Karthik Ramakrishnan, Jasmina Ivanova, Howard Birnbaum, Andreas Kuznik. (2011) Cardiovascular and Economic Outcomes After Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk. American Journal of Therapeutics 18:6, 436-448
CrossRef66
David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS. Canadian Journal of Cardiology 27:6, S387-S401
CrossRef67
Alexander Kulik, Marc Ruel. (2011) Lipid-lowering therapy and coronary artery bypass graft surgery. Current Opinion in Cardiology 26:6, 508-517
CrossRef68
Stephen J Nicholls, Kiyoko Uno, Yu Kataoka. (2011) Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Expert Review of Cardiovascular Therapy 9:11, 1383-1390
CrossRef69
Agnieszka Belter,, Miroslawa Skupinska,, Malgorzata Giel-Pietraszuk,, Tomasz Grabarkiewicz,, Leszek Rychlewski,, Jan Barciszewski,. (2011) Squalene monooxygenase - a target for hypercholesterolemic therapy. Biological Chemistry---
CrossRef70
Alberto Zambon. (2011) Residual cardiovascular risk in secondary prevention. Internal and Emergency Medicine 6:S1, 61-68
CrossRef71
Michael Grabner, Wallace Johnson, Abdulla M. Abdulhalim, Andreas Kuznik, C. Daniel Mullins. (2011) The Value of Atorvastatin Over the Product Life Cycle in the United States. Clinical Therapeutics 33:10, 1433-1443
CrossRef72
Diego Vanuzzo. (2011) The epidemiological concept of residual risk. Internal and Emergency Medicine 6:S1, 45-51
CrossRef73
Luca Mascitelli, Mark R. Goldstein. (2011) Statins, cholesterol depletion and risk of incident diabetes. International Journal of Cardiology 152:2, 275-276
CrossRef74
Heinz Drexel, Francois Chazelle, Christiane Fauer, Dominik Lautsch, Anselm K Gitt. (2011) Persistent Dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events – Results of the dyslipidemia international study (DYSIS). Wiener klinische Wochenschrift 123:19-20, 611-617
CrossRef75
José Ramón González-Juanatey, Alberto Cordero, Gustavo C. Vitale, Belén González-Timón, Pilar Mazón, Vicente Bertomeu. (2011) Magnitud y características del riesgo residual lipídico en pacientes con antecedentes de revascularización coronaria: estudio ICP-Bypass. Revista Española de Cardiología 64:10, 862-868
CrossRef76
Nivee P. Amin, Michael J. Blaha, Grant V. Chow, Roger S. Blumenthal, Dominique Ashen. (2011) Comprehensive Lipid Management in the Coronary Artery Disease Patient. Current Cardiovascular Risk Reports 5:5, 399-406
CrossRef77
José Ramón González-Juanatey, Alberto Cordero, Gustavo C. Vitale, Belén González-Timón, Pilar Mazón, Vicente Bertomeu. (2011) Magnitude and Characteristics of Residual Lipid Risk in Patients With a History of Coronary Revascularization: The ICP-Bypass Study. Revista Española de Cardiología (English Edition) 64:10, 862-868
CrossRef78
Jennifer B. Christian, Nancy E. Bourgeois, Kimberly A. Lowe. (2011) Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population. Journal of Cardiovascular Medicine 12:10, 714-722
CrossRef79
Karen E. Porter, Neil A. Turner. (2011) Statins and myocardial remodelling: cell and molecular pathways. Expert Reviews in Molecular Medicine 13,
CrossRef80
Alexander Kulik, Pierre Voisine, Patrick Mathieu, Roy G. Masters, Thierry G. Mesana, Michel R. Le May, Marc Ruel. (2011) Statin Therapy and Saphenous Vein Graft Disease After Coronary Bypass Surgery: Analysis From the CASCADE Randomized Trial. The Annals of Thoracic Surgery 92:4, 1284-1291
CrossRef81
Ki Hong Lee, Myung Ho Jeong, Ha Mi Kim, Youngkeun Ahn, Jong Hyun Kim, Shung Chull Chae, Young Jo Kim, Seung Ho Hur, In Whan Seong, Taek Jong Hong, Dong Hoon Choi, Myeong Chan Cho, Chong Jin Kim, Ki Bae Seung, Wook Sung Chung, Yang Soo Jang, Seung Woon Rha, Jang Ho Bae, Jeong Gwan Cho, Seung Jung Park. (2011) Benefit of Early Statin Therapy in Patients With Acute Myocardial Infarction Who Have Extremely Low Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 58:16, 1664-1671
CrossRef82
Kazuhiro Nakatani, Taizo Sugimoto, Daisaku Masuda, Rieko Okano, Tomoko Oya, Yasumasa Monden, Taiji Yamashita, Ryota Kawase, Hajime Nakaoka, Miwako Inagaki, Miyako Yuasa-Kawase, Kazumi Tsubakio-Yamamoto, Tohru Ohama, Makoto Nishida, Masato Ishigami, Issei Komuro, Shizuya Yamashita. (2011) Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis 218:1, 226-232
CrossRef83
Alireza Garjani, Sina Andalib, Sajjad Biabani, Hamid Soraya, Yousef Doustar, Afagh Garjani, Nasrin Maleki-Dizaji. (2011) Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. European Journal of Pharmacology 666:1-3, 135-141
CrossRef84
Michael H. Davidson, Christie M. Ballantyne, Terry A. Jacobson, Vera A. Bittner, Lynne T. Braun, Alan S. Brown, W.Virgil Brown, William C. Cromwell, Ronald B. Goldberg, James M. McKenney, Alan T. Remaley, Allan D. Sniderman, Peter P. Toth, Sotirios Tsimikas, Paul E. Ziajka, Kevin C. Maki, Mary R. Dicklin. (2011) Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology 5:5, 338-367
CrossRef85
Teresa Padró, Maisa García-Arguinzonis, Lina Badimon. (2011) Effects of rosuvastatin on the coordinated proteomic response of human coronary smooth muscle cells to low density lipoproteins. Clínica e Investigación en Arteriosclerosis 23:5, 191-200
CrossRef86
G.B. John Mancini, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A. Hegele, Dominic Ng, Janet Pope. (2011) Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology 27:5, 635-662
CrossRef87
Paul Frey, David D. Waters. (2011) Tobacco smoke and cardiovascular risk. Current Opinion in Cardiology 26:5, 424-428
CrossRef88
Chul Min Ahn, Soon Jun Hong, Jae Hyung Park, Jae Sang Kim, Do-Sun Lim. (2011) Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart and Vessels 26:5, 502-510
CrossRef89
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2011) Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. Clínica e Investigación en Arteriosclerosis 23:5, 230-239
CrossRef90
D. K. Y. Chan, F. O’Rourke, Q. Shen, J. C. S. Mak, W. T. Hung. (2011) Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurologica Scandinavica 124:3, 188-195
CrossRef91
Elizabeth Gorevski, Boyang Bian, Christina M.L. Kelton, Jill E. Martin Boone, Jeff J. Guo. (2011) Evidence-Based Prediction of Statin Use with Lipid-Panel Data from the National Health and Nutrition Examination Survey. Value in Health
CrossRef92
Nageswara Rao Pilli, Ramesh Mullangi, Jaswanth Kuamr Inamadugu, Indira Kumari Nallapati, J. V. L. N Seshagiri Rao. (2011) Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical Chromatographyn/a-n/a
CrossRef93
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef94
J.-D. R. Schwalm, S. Yusuf. (2011) Commentary: 'The end of clinical freedom': relevance in the era of evidence-based medicine. International Journal of Epidemiology 40:4, 855-858
CrossRef95
Christopher C. Afendulis, Yulei He, Alan M. Zaslavsky, Michael E. Chernew. (2011) The Impact of Medicare Part D on Hospitalization Rates. Health Services Research 46:4, 1022-1038
CrossRef96
Loukianos S. Rallidis, Katerina Fountoulaki, Maria Anastasiou-Nana. (2011) Managing the underestimated risk of statin-associated myopathy. International Journal of Cardiology
CrossRef97
T. A. Jacobson. (2011) Opening a New Lipid "Apo-thecary": Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Mayo Clinic Proceedings 86:8, 762-780
CrossRef98
, , Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, , J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 32:14, 1769-1818
CrossRef99
Vimal Ramjee, Laurence S. Sperling, Terry A. Jacobson. (2011) Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification. Journal of the American College of Cardiology 58:5, 457-463
CrossRef100
Kensuke Toyama, Seigo Sugiyama, Hideki Oka, Yuri Iwasaki, Hitoshi Sumida, Tomoko Tanaka, Shinji Tayama, Hideaki Jinnouchi, Kunihiko Matsui, Hisao Ogawa. (2011) Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Atherosclerosis 217:1, 158-164
CrossRef101
S. Agewall. (2011) The large clinical statin trials. International Journal of Cardiology 150:1, 108-111
CrossRef102
Updesh Bedi, Mukesh Singh, Param Singh, Janos Molnar, Sandeep Khosla, Rohit Arora. (2011) Effects of Statins on Progression of Coronary Artery Disease as Measured by Intravascular Ultrasound. The Journal of Clinical Hypertension 13:7, 492-496
CrossRef103
Loukianos S Rallidis, Christos Kotakos, Vassilios Sourides, Christos Varounis, Athanasios Charalampopoulos, Maria Zolindaki, Nikolaos Dagres, Costas Papadopoulos, Maria Anastasiou-Nana. (2011) Attainment of optional low-density lipoprotein cholesterol goal of less than 70 mg/dl and impact on prognosis of very high risk stable coronary patients: a 3-year follow-up. Expert Opinion on Pharmacotherapy 12:10, 1481-1489
CrossRef104
Genovefa Kolovou, Vana Kolovou, Ioannis Vasiliadis, Anthony S Wierzbicki, Dimitri P Mikhailidis. (2011) Ideal lipid profile and genes for an extended life span. Current Opinion in Cardiology 26:4, 348-355
CrossRef105
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217, 1-44
CrossRef106
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217:1, 3-46
CrossRef107
Stephen J. Nicholls, Marilyn Borgman, Steven E. Nissen, Joel S. Raichlen, Christie Ballantyne, Philip Barter, M. John Chapman, Raimund Erbel, Peter Libby. (2011) Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion 27:6, 1119-1129
CrossRef108
Michael Derks, Hitoshi Kawamura, Markus Abt, Georgina Meneses-Lorente, Mary Phelan, Tomohiro Ishikawa. (2011) Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers. Clinical Therapeutics 33:6, 754-765
CrossRef109
E. J. Mills, C. O'Regan, O. Eyawo, P. Wu, F. Mills, O. Berwanger, M. Briel. (2011) Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. European Heart Journal 32:11, 1409-1415
CrossRef110
Tarek AN Ahmed, Ioannis Karalis, J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, 203-233
CrossRef111
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis, Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, 247-270
CrossRef112
Chi Chiu Mok, Chun Kwok Wong, Chi Hung To, Judy Po Shan Lai, Cheuk Sum Lam. (2011) Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Arthritis Care & Research 63:6, 875-883
CrossRef113
Xiaorong Li, Lijuan Wang, Yuhang Li, Yeung Ho, Dongxu Yang, Yi Chen, Xiaomin Hu, Ming Xue. (2011) Polysorbates as novel lipid-modulating candidates for reducing serum total cholesterol and low-density lipoprotein levels in hyperlipidemic C57BL/6J mice and rats. European Journal of Pharmacology 660:2-3, 468-475
CrossRef114
George S. Abela, Ameeth Vedre, Abed Janoudi, Ruiping Huang, Sridevi Durga, Umesh Tamhane. (2011) Effect of Statins on Cholesterol Crystallization and Atherosclerotic Plaque Stabilization. The American Journal of Cardiology 107:12, 1710-1717
CrossRef115
M. Hartmann, J. Huisman, D. Bose, L. O. Jensen, P. Schoenhagen, G. S. Mintz, R. Erbel, C. von Birgelen. (2011) Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque dimensions and composition: an update. European Journal of Echocardiography 12:4, 313-321
CrossRef116
David D. Waters, Jennifer E. Ho, David A. DeMicco, Andrei Breazna, Benoit J. Arsenault, Chuan-Chuan Wun, John J. Kastelein, Helen Colhoun, Philip Barter. (2011) Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Journal of the American College of Cardiology 57:14, 1535-1545
CrossRef117
Vimal Ramjee, Terry A Jacobson. (2011) Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. Clinical Lipidology 6:2, 131-136
CrossRef118
Peter M Clifton. (2011) Nutrition and metabolism. Current Opinion in Lipidology 22:2, 142-143
CrossRef119
Ibrahim Al-Zakwani, Kadhim Sulaiman, Khalid Al-Rasadi, Dimitri P. Mikhailidis. (2011) Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. Current Medical Research and Opinion 27:4, 879-885
CrossRef120
Alejandro de la Sierra, Eduardo Alegría, Alberto Martínez-Castelao, Carlos Morillas, Diego González-Segura. (2011) Características de los pacientes con hipertensión y síndrome metabólico atendidos por diferentes especialistas. Medicina Clínica
CrossRef121
D. A. Fryburg, M. T. Vassileva. (2011) Atherosclerosis Drug Development in Jeopardy: The Need for Predictive Biomarkers of Treatment Response. Science Translational Medicine 3:72, 72cm6-72cm6
CrossRef122
Anne Holbrook, Mitchell Wright, Melani Sung, Christine Ribic, Steven Baker. (2011) Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?. Canadian Journal of Cardiology 27:2, 146-151
CrossRef123
Bertrand Cariou. (2011) Que choisir en association aux statines chez les patients à haut risque cardiovasculaire : la niacine ou l’ezetimibe ?. Médecine des Maladies Métaboliques 5:1, H7-H8
CrossRef124
D. Allan Butterfield. (2011) Atorvastatin and Aβ(1–40): Not as Simple as Cholesterol Reduction in Brain and Relevance to Alzheimer Disease. Experimental Neurology 228:1, 15-18
CrossRef125
A. de la Sierra. (2011) Prevención de la progresión y regresión de la lesión orgánica. Estrategias de futuro. Revista Clínica Española 211, 8-14
CrossRef126
Pamela M. Katz, Aurora A. Mendelsohn, Shaun G. Goodman, Anatoly Langer, Hwee Teoh, Lawrence A. Leiter. (2011) Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Canadian Journal of Cardiology 27:2, 138-145
CrossRef127
Arash Alipour, Manuel Castro Cabezas, Jan Willem F. Elte, Joan-Carles Vallvé, Josep Ribalta, Aeilko H. Zwinderman, Joep C. Defesche, J. Wouter Jukema. (2011) Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin. Atherosclerosis 215:1, 125-129
CrossRef128
Jesús Millán, Juan Pedro-Botet, Anna Muñoz, Emili Corbella, Alipio Mangas, Manuel Zúñiga, Antonio Hernández-Mijares, Xavier Pintó. (2011) Perfil lipídico residual en la cardiopatía isquémica recurrente. Medicina Clínica
CrossRef129
Shobha Ghosh. (2011) Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization. Expert Review of Cardiovascular Therapy 9:3, 329-340
CrossRef130
Leonidas Duntas, Genovefa Kolovou. (2011) Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. Future Cardiology 7:2, 137-144
CrossRef131
Christoph H Saely, Veronika Drexel, Alexander Vonbank, Heinz Drexel. (2011) Lipid management in Type 2 diabetes: the case for combination therapy?. Therapy 8:2, 129-141
CrossRef132
Dean G. Karalis, Raghunandan Dudda Subramanya, Scott E. Hessen, Longjian Liu, Mark F. Victor. (2011) Achieving Optimal Lipid Goals in Patients With Coronary Artery Disease. The American Journal of Cardiology 107:6, 886-890
CrossRef133
Ariel Brautbar, Christie M. Ballantyne. (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology
CrossRef134
A. S. Wierzbicki. (2011) Statin wars: efficacy vs. cost. International Journal of Clinical Practice 65:2, 108-111
CrossRef135
Nkechinyere Ijioma, Jennifer G Robinson. (2011) Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Review of Cardiovascular Therapy 9:2, 131-145
CrossRef136
A. G. Semb, I. Holme, T. K. Kvien, T. R. Pedersen. (2011) Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology 50:2, 324-329
CrossRef137
Howard S. Friedman, Srinivasan Rajagopalan, Jaime P. Barnes, Hal Roseman. (2011) Combination Therapy With Ezetimibe/Simvastatin Versus Statin Monotherapy for Low-Density Lipoprotein Cholesterol Reduction and Goal Attainment in a Real-World Clinical Setting. Clinical Therapeutics 33:2, 212-224
CrossRef138
Bas van den Bogaard, Bert-Jan H. van den Born, Rana Fayyad, David D. Waters, David A. DeMicco, John C. LaRosa, John J. P. Kastelein, Ingar Holme, . (2011) On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study. European Journal of Clinical Investigation 41:2, 134-142
CrossRef139
C. L. Meek, J. D. Reston, T. Ramsbottom, H. Pathmanathan, A. Viljoen. (2011) Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care. International Journal of Clinical Practice 65:2, 120-126
CrossRef140
Paul Frey, David D. Waters, David A. DeMicco, Andrei Breazna, Larry Samuels, Andrew Pipe, Chuan-Chuan Wun, Neal L. Benowitz. (2011) Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials). The American Journal of Cardiology 107:2, 145-150
CrossRef141
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef142
Takahide Kohro, Tsutomu Yamazaki, Tohru Izumi, Hiroyuki Daida, Masahiko Kurabayashi, Katsumi Miyauchi, Taiki Tojo, Ryozo Nagai, JCADII Investigators. (2011) Intensively Lowering Both Low-Density Lipoprotein Cholesterol and Blood Pressure Does Not Reduce Cardiovascular Risk in Japanese Coronary Artery Disease Patients. Circulation Journal 75:9, 2062-2070
CrossRef143
Miyako Kishimoto, Takehiro Sugiyama, Keiichiro Osame, Daisuke Takarabe, Masahide Okamoto, Mitsuhiko Noda. (2011) Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. The Journal of Medical Investigation 58:1,2, 86-94
CrossRef144
Yoshiaki Kawagoe, Yoshiyuki Hattori, Ayuko Nakano, Chie Aoki, Seiichi Tanaka, Satoshi Ohta, Toshie Iijima, Atsuko Tomizawa, Teruo Jojima, Hiroyuki Kase, Kikuo Kasai. (2011) Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocrine Journal 58:3, 171-175
CrossRef145
D. D. Adams. (2011) The great cholesterol myth; unfortunate consequences of Brown and Goldstein's mistake. QJM 104:10, 867
CrossRef146
Tomotaka Dohi, Katsumi Miyauchi, Shinya Okazaki, Takayuki Yokoyama, Naotake Yanagisawa, Hiroshi Tamura, Takahiko Kojima, Ken Yokoyama, Takeshi Kurata, Hiroyuki Daida. (2011) Higher Baseline LDL-C Levels Amplify the Short-Term Benefit of Early Intensive Statin Treatment in Acute Coronary Syndrome. Journal of Atherosclerosis and Thrombosis 18:1, 42-48
CrossRef147
Bernhard Föger, Josef R. Patsch. (2011) LDL-Cholesterin in der Sekundärprävention: Zielwert-Erreichung unter Lipidsenkern in Praxis und Spital in Österreich (ZIEL). Wiener klinische Wochenschrift 123:1-2, 21-27
CrossRef148
Luca Puccetti, Francesca Santilli, Anna Laura Pasqui, Stefano Lattanzio, Rossella Liani, Federica Ciani, Elisabetta Ferrante, Giovanni Ciabattoni, Francesca Scarpini, Anna Ghezzi, Alberto Auteri, Giovanni Davì. (2011) Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214:1, 122-128
CrossRef149
Enrique C. Morales-Villegas, Germano Di Sciascio, Carlo Briguori. (2011) Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins. International Journal of Hypertension 2011, 1-12
CrossRef150
T. A. Jacobson. (2011) ‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. International Journal of Clinical Practice 65:1, 82-101
CrossRef151
Christoph Wanner, Vera Krane. (2011) Recent Advances in the Treatment of Atherogenic Dyslipidemia in Type 2 Diabetes Mellitus. Kidney and Blood Pressure Research 34:4, 209-217
CrossRef152
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Salas, Antonio Hernández Mijares, Vincent J. Carey, Michel P. Hermans, Frank M. Sacks, Jean-Charles Fruchart. (2011) The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinología y Nutrición (English Edition) 58:1, 38-47
CrossRef153
Junichiro Takahashi, Yutaka Wakamatsu, Kouji Ishii, Tsuyoshi Kanaoka, Toshihiro Gohda, Shigeyuki Sasaki, Yoshiro Matsui. (2011) Preoperative HDL-C Predicts Later Cardiovascular Events after Abdominal Aortic Aneurysm Surgery. Annals of Vascular Diseases 4:2, 115-120
CrossRef154
Sei Komatsu, Atsuko Imai, Kazuhisa Kodama. (2011) Multidetector Row Computed Tomography May Accurately Estimate Plaque Vulnerability. Circulation Journal 75:6, 1515-1521
CrossRef155
Antonio García-Ríos, Javier Delgado-Lista, Pablo Pérez Martínez, Francisco Fuentes-Jiménez, Francisco Pérez-Jiménez, José López-Miranda. (2011) Eficacia de las estatinas en el manejo de la dislipemia. Un paso adelante. Revista Española de Cardiología Suplementos 11, 14-20
CrossRef156
D. John Betteridge. (2011) Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology
CrossRef157
Yasuhiko Sakata. (2011) Is "Strict" Conventional Therapy Enough for the Treatment of Coronary Artery Disease?. Circulation Journal 75:9, 2046-2047
CrossRef158
Benoit J. Arsenault, Philip Barter, David A. DeMicco, Weihang Bao, Gregory M. Preston, John C. LaRosa, Scott M. Grundy, Prakash Deedwania, Heiner Greten, Nanette K. Wenger, James Shepherd, David D. Waters, John J.P. Kastelein. (2011) Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers. Journal of the American College of Cardiology 57:1, 63-69
CrossRef159
Kuo-Liong Chien, Hung-Ju Lin, Hsiu-Ching Hsu, Ming-Fong Chen. (2011) Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterol. Lipids in Health and Disease 10:1, 215
CrossRef160
Jun Sasaki, Mitsuhiro Yokoyama, Masunori Matsuzaki, Yasushi Saito, Hideki Origasa, Yuichi Ishikawa, Shinichi Oikawa, Hiroshige Itakura, Hitoshi Hishida, Toru Kita, Akira Kitabatake, Noriaki Nakaya, Toshiie Sakata, Kazuyuki Shimada, Kunio Shirato, Yuji Matsuzawa. (2011) Relationship between Coronary Artery Disease and Non-HDL-C, and Effect of Highly Purified EPA on the Risk of Coronary Artery Disease in Hypercholesterolemic Patients Treated with Statins: Sub-Analysis of the Japan EPA Lipid Intervention Study (JELIS). Journal of Atherosclerosis and Thrombosis
CrossRef161
Kyoichi Mizuno, Noriaki Nakaya, Tamio Teramoto, Shinji Yokoyama, Yasuo Ohashi, Akio Ueki, Soichiro Takahashi, Yukio Kubota, Haruo Nakamura. (2011) Usefulness of LDL-C-Related Parameters to Predict Cardiovascular Risk and Effect of Pravastatin in Mild-to-Moderate Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis
CrossRef162
Finn Akerström, Luis Rodríguez-Padial. (2011) The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe. Clinical Investigation 1:1, 137-144
CrossRef163
P.P. Toth. (2011) Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50mg/dl With Rosuvastatin: The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Yearbook of Endocrinology 2011, 75-78
CrossRef164
Clay F. Semenkovich, Anne C. Goldberg, Ira J. Goldberg. 2011. Disorders of Lipid Metabolism. , 1633-1674.
CrossRef165
Raza H. Orakzai, Chrisandra L. Shufelt, Leslee J. Shaw, C. Noel Bairey Merz. 2011. Prevention of Ischemic Heart Disease in Women. , 398-414.
CrossRef166
Michael H. Davidson, Peter P. Toth. 2011. Low-Density Lipoprotein Cholesterol. , 215-229.
CrossRef167
B.J. Gersh. (2011) Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. Yearbook of Medicine 2011, 355-357
CrossRef168
B.J. Gersh. (2011) Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. Yearbook of Cardiology 2011, 229-231
CrossRef169
Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto, Antonio M. Jr., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, Barter, Philip, . (2010) Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine 363:25, 2406-2415
Full Text170
Michel P Hermans, Jean-Charles Fruchart. (2010) Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. Clinical Lipidology 5:6, 811-826
CrossRef171
Guy De Backer. (2010) Efficacy and benefits of lipid-lowering drug therapy. The new European guidelines for cardiovascular disease prevention. Clínica e Investigación en Arteriosclerosis 22, 48-51
CrossRef172
Marie C. Bradley, Carmel M. Hughes, Marie M. Cantwell, Liam J. Murray. (2010) Statins and pancreatic cancer risk: a nested case–control study. Cancer Causes & Control 21:12, 2093-2100
CrossRef173
Roberto Scarpioni, Marco Ricardi, Luigi Melfa, Luciano Cristinelli. (2010) Dyslipidemia in Chronic Kidney Disease: Are Statins Still Indicated in Reduction Cardiovascular Risk in Patients on Dialysis Treatment?. Cardiovascular Therapeutics 28:6, 361-368
CrossRef174
Terje R. Pedersen. (2010) Pleiotropic Effects of Statins. American Journal Cardiovascular Drugs 10, 10-17
CrossRef175
Philip Greenland, Joseph S. Alpert, George A. Beller, Emelia J. Benjamin, Matthew J. Budoff, Zahi A. Fayad, Elyse Foster, Mark A. Hlatky, John McB. Hodgson, Frederick G. Kushner, Michael S. Lauer, Leslee J. Shaw, Sidney C. Smith, Allen J. Taylor, William S. Weintraub, Nanette K. Wenger. (2010) 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology 56:25, e50-e103
CrossRef176
S. Bangalore, F. H. Messerli, C.-C. Wun, A. L. Zuckerman, D. DeMicco, J. B. Kostis, J. C. LaRosa, . (2010) J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European Heart Journal 31:23, 2897-2908
CrossRef177
Chiara Melloni, Bimal R. Shah, Fang-Shu Ou, Matthew T. Roe, Sidney C. Smith, Charles V. Pollack, Magnus Ohman, W. Brian Gibler, Eric D. Peterson, Karen P. Alexander. (2010) Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. American Heart Journal 160:6, 1121-1129.e1
CrossRef178
L. A. Leiter, H. Bays, S. Conard, J. Lin, M. E. Hanson, A. Shah, A. M. Tershakovec. (2010) Attainment of Canadian and European guidelines’ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. International Journal of Clinical Practice 64:13, 1765-1772
CrossRef179
T M Baye, R A Wilke. (2010) Mapping genes that predict treatment outcome in admixed populations. The Pharmacogenomics Journal 10:6, 465-477
CrossRef180
Jonathan E. Feig, Ines Pineda-Torra, Marie Sanson, Michelle N. Bradley, Yuliya Vengrenyuk, Dusan Bogunovic, Emmanuel L. Gautier, Daniel Rubinstein, Cynthia Hong, Jianhua Liu, Chaowei Wu, Nico van Rooijen, Nina Bhardwaj, Michael J. Garabedian, Peter Tontonoz, Edward A. Fisher. (2010) LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. Journal of Clinical Investigation 120:12, 4415-4424
CrossRef181
Robert S. Rosenson, Michael H. Davidson, Ray Pourfarzib. (2010) Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 213:1, 1-7
CrossRef182
Andrew L Mammen, Anthony A Amato. (2010) Statin myopathy: a review of recent progress. Current Opinion in Rheumatology 22:6, 644-650
CrossRef183
Jamal S Rana, S Matthijs Boekholdt. (2010) Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. Current Opinion in Cardiology 25:6, 622-626
CrossRef184
Natalie D. Muth, Gail A. Laughlin, Denise von Mühlen, Sidney C. Smith, Elizabeth Barrett-Connor. (2010) High-density lipoprotein subclasses are a potential intermediary between alcohol intake and reduced risk of cardiovascular disease: The Rancho Bernardo Study. British Journal of Nutrition 104:07, 1034-1042
CrossRef185
Terry A Jacobson, Peter H Jones, Eli M Roth. (2010) Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. Clinical Lipidology 5:5, 627-649
CrossRef186
Benjamin M. Meador, Kimberly A. Huey. (2010) Statin-associated myopathy and its exacerbation with exercise. Muscle & Nerve 42:4, 469-479
CrossRef187
C.H. Saely, H. Drexel, K. Huber. (2010) Hochdosierte Statintherapie für kardiovaskuläre Risikopatienten. Herz 35:7, 497-502
CrossRef188
Jacek Lewandowski, Maciej Siński, Joanna Bidiuk, Piotr Abramczyk, Anna Dobosiewicz, Agnieszka Ciarka, Zbigniew Gaciong. (2010) Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertension Research 33:10, 1038-1043
CrossRef189
Giuseppe Boriani, Igor Diemberger, Cinzia Valzania, Mauro Biffi, Cristian Martignani, Emanuel Raschi, Valentina Mantovani, Matteo Ziacchi, Matteo Bertini, Fabrizio De Ponti, Angelo Branzi. (2010) Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental & Clinical Pharmacology 24:5, 575-594
CrossRef190
Alan S Go, Robert W Yeh. (2010) Recent epidemiologic trends in the incidence of myocardial infarction: what have we learned?. Interventional Cardiology 2:5, 623-626
CrossRef191
Melvyn Rubenfire, Robert D. Brook, Robert S. Rosenson. (2010) Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events. The American Journal of Medicine 123:10, 892-898
CrossRef192
Duane A. Burnett, Harry R. Davis. 2010. Atherosclerosis I: LDL Cholesterol Lowering. .
CrossRef193
Linda C. Hemphill. (2010) Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresis. Journal of Clinical Lipidology 4:5, 346-349
CrossRef194
Peter P. Toth. (2010) TNT and Recurrent Cardiovascular Events: High-Dose Statin Therapy Offers a Lot of Bang for the Buck. Current Atherosclerosis Reports 12:5, 283-284
CrossRef195
Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, 649-661
CrossRef196
Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P. Mikhailidis. (2010) Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Current Medical Research and Opinion 26:9, 2137-2140
CrossRef197
John Reckless, Glenn Davies, Kaan Tunceli, X. Henry Hu, Philippe Brudi. (2010) Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. Value in Health 13:6, 726-734
CrossRef198
Deeptankar DeMazumder, Rani K. Hasan, Roger S. Blumenthal, Erin D. Michos, Steven Jones. (2010) Should Statin Therapy Be Allocated on the Basis of Global Risk or on the Basis of Randomized Trial Evidence?. The American Journal of Cardiology 106:6, 905-909
CrossRef199
Peter P. Toth, Michael H. Davidson. (2010) High-density lipoproteins: Marker of cardiovascular risk and therapeutic target. Journal of Clinical Lipidology 4:5, 359-364
CrossRef200
Dale A Rublee, Shih-Yin Chen, Jack Mardekian, Ning Wu, Preethi Rao, Luke Boulanger. (2010) Evaluation of Cardiovascular Morbidity Associated with Adherence to Atorvastatin Therapy. American Journal of Therapeutics1
CrossRef201
F. Felices-Abad, J. Latour-Pérez, M.P. Fuset-Cabanes, M. Ruano-Marco, J. Cuñat-de la Hoz, F. del Nogal-Sáez. (2010) Indicadores de calidad en el síndrome coronario agudo para el análisis del proceso asistencial pre e intrahospitalario. Medicina Intensiva 34:6, 397-417
CrossRef202
John R Guyton. (2010) Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. Current Opinion in Lipidology 21:4, 372-377
CrossRef203
Shun Kohsaka, Zhezhen Jin, Tatjana Rundek, Shunichi Homma, Ralph L. Sacco, Marco R. Di Tullio. (2010) Relationship between serum lipid values and atherosclerotic burden in the proximal thoracic aorta. International Journal of Stroke 5:4, 257-263
CrossRef204
Robert A. O'Rourke. (2010) Alternative Strategies for the Management of Chronic Stable Angina. Current Problems in Cardiology 35:8, 384-446
CrossRef205
Kunal N. Bhatt, Bryan J. Wells, Laurence S. Sperling, Jefferson T. Baer. (2010) High-Density Lipoprotein Therapy: Is There Hope?. Current Treatment Options in Cardiovascular Medicine 12:4, 315-328
CrossRef206
Maartje E Visser, John JP Kastelein, Erik SG Stroes. (2010) Apolipoprotein B synthesis inhibition: results from clinical trials. Current Opinion in Lipidology 21:4, 319-323
CrossRef207
Steve E Humphries, H Andrew W Neil. (2010) Developing and applying clinically useful approaches to identify individuals with familial hypercholesterolemia in the UK. Clinical Lipidology 5:4, 497-507
CrossRef208
John S. Millar, Bonnie Ky, Megan L. Wolfe, Leticia Pruscino, Amanda Baer, Daniel J. Rader. (2010) Short-Term Treatment with High-Dose Atorvastatin Reduces LDL Cholesterol but Shows no Anti-Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels. Clinical and Translational Science 3:4, 140-146
CrossRef209
Emily A. Ferenczi, Perviz Asaria, Alun D. Hughes, Nishi Chaturvedi, Darrel P. Francis. (2010) Can a Statin Neutralize the Cardiovascular Risk of Unhealthy Dietary Choices?. The American Journal of Cardiology 106:4, 587-592
CrossRef210
D. H. O'Leary, M. L. Bots. (2010) Imaging of atherosclerosis: carotid intima-media thickness. European Heart Journal 31:14, 1682-1689
CrossRef211
Petter Quist-Paulsen. (2010) Statins and inflammation: an update. Current Opinion in Cardiology 25:4, 399-405
CrossRef212
Ariane Lewis, Alan Segal. (2010) Hyperlipidemia and Primary Prevention of Stroke: Does Risk Factor Identification and Reduction Really Work?. Current Atherosclerosis Reports 12:4, 225-229
CrossRef213
Jesús Millán Núñez-Cortés, Juan Pedro Botet Montoya, Xavier Pintó Sala. (2010) Dislipemia aterogénica: una llamada de atención sobre su papel en el riesgo residual. Clínica e Investigación en Arteriosclerosis 22:4, 162-166
CrossRef214
Derek J Hausenloy, Lionel Opie, Derek M Yellon. (2010) Dissociating HDL cholesterol from cardiovascular risk. The Lancet 376:9738, 305-306
CrossRef215
Jesús Millán Nú˜ez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2010) Riesgo vascular residual: recomendaciones de la Iniciativa Espa˜ola para la Reducción del Riesgo Residual. Medicina Clínica 135:4, 165-171
CrossRef216
Dan-yan Xu, Jun Shu, Quan-yue Huang, Binaya Wasti, Chen Chen, Ling Liu, Shui-ping Zhao. (2010) Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. Atherosclerosis 211:1, 237-241
CrossRef217
Peter P. Toth. (2010) Drug Treatment of Hyperlipidaemia. Drugs 70:11, 1363-1379
CrossRef218
Srikanth Katragadda, Fasi Rai, Rohit Arora. (2010) Dual Inhibition, Newer Paradigms for Cholesterol Lowering. American Journal of Therapeutics 17:4, e88-e99
CrossRef219
Helena Vaverkova, Michel Farnier, Maurizio Averna, Luc Missault, Margus Viigimaa, Qian Dong, Arvind Shah, Amy O. Johnson-Levonas, Philippe Brudi. (2010) Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy. Cardiovascular Therapeuticsno-no
CrossRef220
Yeh, Robert W., Sidney, Stephen, Chandra, Malini, Sorel, Michael, Selby, Joseph V., Go, Alan S., . (2010) Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. New England Journal of Medicine 362:23, 2155-2165
Full Text221
Haseeb Jafri, Alawi A. Alsheikh-Ali, Richard H. Karas. (2010) Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. Journal of the American College of Cardiology 55:25, 2846-2854
CrossRef222
Paul N Hopkins. (2010) Encouraging appropriate treatment for familial hypercholesterolemia. Clinical Lipidology 5:3, 339-354
CrossRef223
Ryan S. Stolcpart, Kari L. Olson, Thomas Delate, Jon Rasmussen, Thomas F. Rehring, John A. Merenich. (2010) The Risk for Significant Creatine Kinase Elevation with Statins. American Journal Cardiovascular Drugs 10:3, 187-192
CrossRef224
Giuseppe Derosa, Pamela Maffioli. (2010) Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Review of Cardiovascular Therapy 8:6, 835-843
CrossRef225
Eddie Vos. (2010) High-Dose Statin, Not So IDEAL?. Journal of the American College of Cardiology 55:22, 2516-2517
CrossRef226
M. John Chapman, Jan S. Redfern, Mark E. McGovern, Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, 314-345
CrossRef227
Abhaya Gupta, Veronique Guyomard, M. Justin S. Zaman, Habib U. Rehman, Phyo Kyaw Myint. (2010) Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. Advances in Therapy 27:6, 348-364
CrossRef228
Eric Bruckert, Julien Labreuche, Pierre Amarenco. (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210:2, 353-361
CrossRef229
T. Sathyapalan, S. L. Atkin, E. S. Kilpatrick. (2010) Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?. Diabetes, Obesity and Metabolism 12:6, 540-544
CrossRef230
Eli M. Roth, James M. McKenney, Maureen T. Kelly, Carolyn M. Setze, Dawn M. Carlson, Alex Gold, James C. Stolzenbach, Laura A. Williams, Peter H. Jones. (2010) Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia. American Journal Cardiovascular Drugs 10:3, 175-186
CrossRef231
James P. Corsetti, Ron T. Gansevoort, Charles E. Sparks, Robin P. F. Dullaart. (2010) Inflammation reduces HDL protection against primary cardiac risk. European Journal of Clinical Investigation 40:6, 483-489
CrossRef232
Lluís Masana, Núria Plana. (2010) Actualización de las tablas de planificación terapéutica de la hipercolesterolemia. Medicina Clínica 135:3, 120-123
CrossRef233
Joel M. Neutel, Michael Eaddy, Orsolya E. Lunacsek, Craig Roberts, Linda Chen, Allison J. Kean, James H. Jackson. (2010) Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Real-World Clinical Practice. The Journal of Clinical Hypertension 12:6, 396-406
CrossRef234
H. B. Sager, P. Linsel-Nitschke, B. Mayer, W. Lieb, B. Franzel, U. Elsasser, H. Schunkert. (2010) Physicians' perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients. European Heart Journal 31:10, 1266-1273
CrossRef235
Amy B. Kauffman, Kari L. Olson, Morgan L. Youngblood, Emily B. Zadvorny, Thomas Delate, John A. Merenich. (2010) Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. Journal of Clinical Lipidology 4:3, 173-180
CrossRef236
Wilbert S. Aronow, William H. Frishman. (2010) Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease. Cardiology in Review 18:3, 132-140
CrossRef237
Francesco Scolari, Pietro Ravani. (2010) Atheroembolic renal disease. The Lancet 375:9726, 1650-1660
CrossRef238
Venkata M. Alla, Manu Kaushik, Aryan Mooss. (2010) Targeting Residual Risk: The Rationale for the Use of Non-HDL Cholesterol. Southern Medical Journal 103:5, 434-439
CrossRef239
Michalis Kalogirou, Vasilis Tsimihodimos, Moses Elisaf. (2010) Pleiotropic effects of ezetimibe: Do they really exist?. European Journal of Pharmacology 633:1-3, 62-70
CrossRef240
Byeong-Keuk Kim, Dong Whan Kim, Seungjin Oh, Se-Jung Yoon, Sungha Park, Dong Woon Jeon, Joo Young Yang. (2010) Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents. Coronary Artery Disease 21:3, 182-188
CrossRef241
George S. Abela. (2010) Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. Journal of Clinical Lipidology 4:3, 156-164
CrossRef242
Neville F. Mistry, Sharon Cresci. (2010) PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure. Heart Failure Reviews 15:3, 197-207
CrossRef243
Jorge R. Kizer, Christopher Madias, Brian Wilner, Carl J. Vaughan, Alvin I. Mushlin, Paula Trushin, Antonio M. Gotto, Richard C. Pasternak. (2010) Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. The American Journal of Cardiology 105:9, 1289-1296
CrossRef244
Juan F. Ascaso. (2010) Avances en el tratamiento de la hipercolesterolemia. Endocrinología y Nutrición 57:5, 210-219
CrossRef245
Rafael Carmena, Juan F. Ascaso. (2010) Tratamiento integral de la dislipidemia diabética: beneficios y nuevas alternativas terapéuticas. Medicina Clínica 134:9, 406-411
CrossRef246
Francisco M. Gomez-Soto, Sotero P. Romero, Jose A. Bernal, Miguel A. Escobar, Jose L. Puerto, Jose L. Andrey, Pedro Ruiz, Francisco Gomez. (2010) Mortality and morbidity of newly diagnosed heart failure treated with statins. International Journal of Cardiology 140:2, 210-218
CrossRef247
John R. Crouse, Michiel L. Bots, Gregory W. Evans, Mike K. Palmer, Daniel H. OʼLeary, Diederick E. Grobbee, Joel S. Raichlen. (2010) Does baseline carotid intima–media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima–media thickness progression? The METEOR study. European Journal of Cardiovascular Prevention & Rehabilitation 17:2, 223-229
CrossRef248
Yuri B Pride, C Michael Gibson. (2010) Intensive statin therapy: a goal worth targeting. Interventional Cardiology 2:2, 103-105
CrossRef249
P. Valensi, E. Cosson. (2010) It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. Diabetes & Metabolism 36:2, 91-96
CrossRef250
Michael Blazing. (2010) Statins-Is There Potential for Uncovering New Benefits (or Detriments)?. Cardiovascular Therapeutics 28:2, 67-69
CrossRef251
Jennifer E. Ho, Vera Bittner, David A. DeMicco, Andrei Breazna, Prakash C. Deedwania, David D. Waters. (2010) Usefulness of Heart Rate at Rest as a Predictor of Mortality, Hospitalization for Heart Failure, Myocardial Infarction, and Stroke in Patients With Stable Coronary Heart Disease (Data from the Treating to New Targets [TNT] Trial). The American Journal of Cardiology 105:7, 905-911
CrossRef252
Nicholas J. Schork, Eric J. Topol. (2010) Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials. Journal of Biopharmaceutical Statistics 20:2, 315-333
CrossRef253
Pradeep Natarajan, Kausik K. Ray, Christopher P. Cannon. (2010) High-Density Lipoprotein and Coronary Heart Disease. Journal of the American College of Cardiology 55:13, 1283-1299
CrossRef254
David J. Maron, William E. Boden, Robert A. O'Rourke, Pamela M. Hartigan, Karen J. Calfas, G.B. John Mancini, John A. Spertus, Marcin Dada, William J. Kostuk, Merril Knudtson, Crystal L. Harris, Steven P. Sedlis, Robert G. Zoble, Lawrence M. Title, Gilbert Gosselin, Shah Nawaz, Gerald T. Gau, Alvin S. Blaustein, Eric R. Bates, Leslee J. Shaw, Daniel S. Berman, Bernard R. Chaitman, William S. Weintraub, Koon K. Teo. (2010) Intensive Multifactorial Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology 55:13, 1348-1358
CrossRef255
Khalid Alwaili, Zuhier Awan, Ali Alshahrani, Jacques Genest. (2010) High-density lipoproteins and cardiovascular disease: 2010 update. Expert Review of Cardiovascular Therapy 8:3, 413-423
CrossRef256
Rosana Gambogi, Marcela Baldizzoni, Henry Albornoz, Carlos Ketzoian, Mariana Cabrera, Gustavo Saona, Abayubá Perna. (2010) Prevención secundaria en pacientes revascularizados coronarios en Uruguay: descripción de un programa, evaluación del control de los factores de riesgo y efecto en la mortalidad. Clínica e Investigación en Arteriosclerosis 22:2, 59-69
CrossRef257
Pranav Dalal, Rohit Arora. (2010) Statin Therapy in South Asians—Facts and Future. American Journal of Therapeutics 17:2, e41-e47
CrossRef258
Jung-Sun Kim, Jaedeok Kim, Donghoon Choi, Chan Joo Lee, Sang Hak Lee, Young-Guk Ko, Myeong-Ki Hong, Byoung-Keuk Kim, Seong Jin Oh, Dong Woon Jeon, Joo-Young Yang, Jung Rae Cho, Nam-Ho Lee, Yun-Hyeong Cho, Deok-Kyu Cho, Yangsoo Jang. (2010) Efficacy of High-Dose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 3:3, 332-339
CrossRef259
L. Nherera, N.W. Calvert, K. DeMott, S.E. Humphries, H.A.W. Neil, R. Minhas, M. Thorogood. (2010) Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Current Medical Research and Opinion 26:3, 529-536
CrossRef260
Carl J. Lavie, Richard V. Milani. (2010) High-Dose Atorvastatin in Acute Coronary and Cerebrovascular Syndromes. JACC: Cardiovascular Interventions 3:3, 340-342
CrossRef261
Yiannis S. Chatzizisis, Konstantinos C. Koskinas, Gesthimani Misirli, Christos Vaklavas, Apostolos Hatzitolios, George D. Giannoglou. (2010) Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy. Drug Safety 33:3, 171-187
CrossRef262
A.H. Pijlman, R. Huijgen, S.N. Verhagen, B.P.M. Imholz, A.H. Liem, J.J.P. Kastelein, E.J. Abbink, A.F.H. Stalenhoef, F.L.J. Visseren. (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209:1, 189-194
CrossRef263
Tjerk Wiersma. (2010) Belangenverstrengeling en NHG-Standaarden. Huisarts en wetenschap 2010:1, 55-58
CrossRef264
Michael S. Kostapanos, Haralampos J. Milionis, Moses S. Elisaf. (2010) Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia. American Journal Cardiovascular Drugs 10:1, 11-28
CrossRef265
Michael J Gonyeau, Dayton W Yuen. (2010) A Clinical Review of Statins and Cancer: Helpful or Harmful?. Pharmacotherapy 30:2, 177-194
CrossRef266
Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
CrossRef267
Scott L. Charland, Daniel C. Malone. (2010) Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current Medical Research and Opinion 26:2, 365-375
CrossRef268
George S Abela. (2010) Role of cholesterol crystals in myocardial infarction and stroke. Clinical Lipidology 5:1, 57-69
CrossRef269
Chin-San Liu, Chong-Kuei Lii, Li-Ling Chang, Chen-Ling Kuo, Wen-Ling Cheng, Shih-Li Su, Chia-Wen Tsai, Haw-Wen Chen. (2010) Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients. Nutrition Research 30:2, 118-124
CrossRef270
Amin Esfahani, David J. A. Jenkins, Cyril W. C. Kendall. (2010) Session 4: CVD, diabetes and cancer A dietary portfolio for management and prevention of heart disease. Proceedings of the Nutrition Society 69:01, 39
CrossRef271
J. J.V. McMurray, K. Swedberg. (2010) HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials. European Journal of Heart Failure 12:2, 99-103
CrossRef272
Ehud Ur, Anatoly Langer, Simon W. Rabkin, Cristina-Dana Calciu, Lawrence A. Leiter. (2010) Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: The CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. Canadian Journal of Cardiology 26:2, 80-86
CrossRef273
Melinda Wenner Moyer. (2010) The search beyond statins. Nature Medicine 16:2, 150-153
CrossRef274
John C. LaRosa, Prakash C. Deedwania, James Shepherd, Nanette K. Wenger, Heiner Greten, David A. DeMicco, Andrei Breazna. (2010) Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial). The American Journal of Cardiology 105:3, 283-287
CrossRef275
Chih-Yuan Wang, Hao-Ai Shui, Tien-Chun Chang. (2010) In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. International Journal of Cancer 126:2, 578-582
CrossRef276
M. J. Chapman, W. Le Goff, M. Guerin, A. Kontush. (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. European Heart Journal 31:2, 149-164
CrossRef277
Derek P. Chew, Robert Carter, Bree Rankin, Andrew Boyden, Helen Egan. (2010) Cost effectiveness of a general practice chronic disease management plan for coronary heart disease in Australia. Australian Health Review 34:2, 162
CrossRef278
Tamio Teramoto, Noriaki Nakaya, Shinji Yokoyama, Yasuo Ohashi, Kyoichi Mizuno, Haruo Nakamura. (2010) Association between Lowering Low-Density Lipoprotein Cholesterol with Pravastatin and Primary Prevention of Cardiovascular Disease in Mild to Moderate Hypercholesterolemic Japanese. Journal of Atherosclerosis and Thrombosis 17:8, 879-887
CrossRef279
Hidenori Arai, Takafumi Hiro, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki. (2010) More Intensive Lipid Lowering is Associated with Regression of Coronary Atherosclerosis in Diabetic Patients with Acute Coronary Syndrome –Sub-Analysis of JAPAN-ACS Study. Journal of Atherosclerosis and Thrombosis 17:10, 1096-1107
CrossRef280
Juan José Badimón, Carlos G. Santos-Gallego, Lina Badimón. (2010) Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?. Revista Española de Cardiología 63, 20-35
CrossRef281
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef282
Paul D. Thompson, Beth A. Parker, Priscilla M. Clarkson, Linda S. Pescatello, C. Michael White, Adam S. Grimaldi, Benjamin D. Levine, Ronald G. Haller, Eric P. Hoffman. (2010) A Randomized Clinical Trial to Assess the Effect of Statins on Skeletal Muscle Function and Performance: Rationale and Study Design. Preventive Cardiology
CrossRef283
Tsuyoshi Nozue, Ichiro Michishita, Ichiro Mizuguchi. (2010) Effects of Ezetimibe on Remnant-Like Particle Cholesterol, Lipoprotein (a), and Oxidized Low-Density Lipoprotein in Patients with Dyslipidemia. Journal of Atherosclerosis and Thrombosis 17:1, 37-44
CrossRef284
Masahiko Kurabayashi, Ichiro Sakuma, Ryuzo Kawamori, Hiroyuki Daida, Tsutomu Yamazaki, Masayuki Yoshida, Mitsumasa Hata, Izuru Masuda, Kohei Kaku, Hiroyoshi Yokoi, Junji Kishimoto, Ryuji Nohara. (2010) Can Intensive Lipid-Lowering Therapy with Statins Ameliorate Atherosclerosis in Japanese Patients?. Journal of Atherosclerosis and Thrombosis 17:4, 416-422
CrossRef285
Kiyoko Uno, Stephen J. Nicholls. (2010) Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. Current Atherosclerosis Reports 12:1, 14-19
CrossRef286
Israel Rabinowitz, Ohad Hochman, Rachel Luzzati, Yelena Haifitz, Yuri Shclar, Natalia Kaykov, Alexander Khemlin, Michael Kaffman, Ada Tamir. (2010) Monitoring and treatment for cardiovascular risk. Primary Health Care Research & Development 11:01, 29
CrossRef287
Christoph H. Saely, Heinz Drexel. (2010) Bedeutung der Lipidtherapie bei Diabetes. Wiener Medizinische Wochenschrift 160:1-2, 25-29
CrossRef288
Liqiang Zheng, Jue Li, Dayi Hu, Yingyi Luo, Xiankai Li, Yuanxi Xu, Zhaoqing Sun, Yingxian Sun. (2010) Association of low ankle-brachial index with mortality in patients with ischemic heart disease. Journal of Atherosclerosis and Thrombosis 17:7, 759-767
CrossRef289
Madhan Shanmugasundaram, Steven J. Rough, Joseph S. Alpert. (2010) Dyslipidemia in the Elderly: Should it Be Treated?. Clinical Cardiology 33:1, 4-9
CrossRef290
Monique P. Curran. (2010) Amlodipine/Atorvastatin. Drugs 70:2, 191-213
CrossRef291
Katsumi Miyauchi, Hiroyuki Daida. (2010) Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease. Circulation Journal 74:8, 1718-1730
CrossRef292
Iwona Szadkowska, Adam Stanczyk, Wilbert S. Aronow, Jan Kowalski, Lucjan Pawlicki, Ali Ahmed, Maciej Banach. (2010) Statin therapy in the elderly: A review. Archives of Gerontology and Geriatrics 50:1, 114-118
CrossRef293
Vincent J. Willey, Michael F. Bullano, Nze N. Shoetan, Sanjay K. Gandhi. (2010) Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Current Medical Research and Opinion 26:1, 121-128
CrossRef294
Kazuhisa Kodama, Sei Komatsu, Yasunori Ueda, Tadateru Takayama, Jyunji Yajima, Shinsuke Nanto, Hiroshi Matsuoka, Satoshi Saito, Atsushi Hirayama. (2010) Stabilization and Regression of Coronary Plaques Treated With Pitavastatin Proven by Angioscopy and Intravascular Ultrasound. Circulation Journal 74:9, 1922-1928
CrossRef295
Takumi Kimura, Tomonori Itoh, Tetsuya Fusazaki, Hiroki Matsui, Shoma Sugawara, Yoshinobu Ogino, Hiroshi Endo, Ken Kobayashi, Motoyuki Nakamura. (2010) Low-Density Lipoprotein-Cholesterol/High-Density Lipoprotein-Cholesterol Ratio Predicts Lipid-Rich Coronary Plaque in Patients With Coronary Artery Disease. Circulation Journal 74:7, 1392-1398
CrossRef296
N. K. Wenger, S. J. Lewis. (2010) Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients. Current Gerontology and Geriatrics Research 2010, 1-9
CrossRef297
Tomohiro Sakamoto, Hisao Ogawa. (2010) "Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients. Circulation Journal 74:8, 1731-1741
CrossRef298
Virginia M. Rosen, Douglas C.A. Taylor, Hemangi Parekh, Ankur Pandya, David Thompson, Andreas Kuznik, David D. Waters, Michael Drummond, Milton C. Weinstein. (2010) Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US. PharmacoEconomics 28:1, 47-60
CrossRef299
Ross J. Simpson, Sidney C. Smith. 2010. Treatment of Lipid Abnormalities. , 619-625.
CrossRef300
John R. Guyton. 2010. The Coronary Circulation. , 903-917.
CrossRef301
Stephen J. Nicholls, Gunnar Brandrup-Wognsen, Mike Palmer, Philip J. Barter. (2010) Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). The American Journal of Cardiology 105:1, 69-76
CrossRef302
P.P. Toth. (2010) Comparison of 80 versus 10mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial). Yearbook of Endocrinology 2010, 47-49
CrossRef303
Sabina A. Murphy, Christopher P. Cannon, Stephen D. Wiviott, Carolyn H. McCabe, Eugene Braunwald. (2009) Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes. Journal of the American College of Cardiology 54:25, 2358-2362
CrossRef304
Ngan N Lam, Arsh K Jain, Dan G Hackam, Meaghan S Cuerden, Rita S Suri, Cindy Y Huo, Ping Li, William F Clark, Amit X Garg. (2009) Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Kidney International 76:11, 1172-1179
CrossRef305
Naresh Ranjith, Rosemary J. Pegoraro, Lee Rom. (2009) Lipid Profiles and Associated Gene Polymorphisms in Young Asian Indian Patients With Acute Myocardial Infarction and the Metabolic Syndrome. Metabolic Syndrome and Related Disorders 7:6, 571-578
CrossRef306
Adam B. Polis, Nicola Abate, Alberico L. Catapano, Christie M. Ballantyne, Michael H. Davidson, Steven S. Smugar, Andrew M. Tershakovec. (2009) Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. Metabolic Syndrome and Related Disorders 7:6, 601-610
CrossRef307
Peter Henke. (2009) What is the Optimum Perioperative Drug Therapy Following Lower-Extremity Vein Bypass Surgery?. Seminars in Vascular Surgery 22:4, 245-251
CrossRef308
S. Lüders, J. Schrader. (2009) Prävention des Schlaganfalls. Der Internist 50:12, 1337-1344
CrossRef309
Helene Glassberg. (2009) Statins in the prevention of heart failure after myocardial infarction. Current Heart Failure Reports 6:4, 215-219
CrossRef310
Stephen P. Motsko, Stefan Russmann, Eileen E. Ming, Varinder P. Singh, Ruby M. Vendiola, Judith K. Jones. (2009) Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular eventsâa cohort study in 395â039 patients from clinical practice. Pharmacoepidemiology and Drug Safety 18:12, 1214-1222
CrossRef311
Heinz Drexel. (2009) Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?. Fundamental & Clinical Pharmacology 23:6, 687-692
CrossRef312
Michael J. Lipinski, Clay A. Cauthen, Giuseppe G.L. Biondi-Zoccai, Antonio Abbate, Bojan Vrtovec, Bobby V. Khan, George W. Vetrovec. (2009) Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure. The American Journal of Cardiology 104:12, 1708-1716
CrossRef313
Andrew Cassar, David R. Holmes, Charanjit S. Rihal, Bernard J. Gersh. (2009) Chronic Coronary Artery Disease: Diagnosis and Management. Mayo Clinic Proceedings 84:12, 1130-1146
CrossRef314
D. Sander, T. Etgen. (2009) Sekundärprophylaxe des Schlaganfalls nach PRoFESS und SPARCL. Der Internist 50:11, 1227-1238
CrossRef315
Raul D. Santos, David D. Waters, Lisa Tarasenko, Michael Messig, J. Wouter Jukema, Jean Ferrières, Juan Verdejo, Cheng-Wen Chiang. (2009) Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. American Heart Journal 158:5, 860-866
CrossRef316
Christine T. Cigolle, Caroline S. Blaum, Jeffrey B. Halter. (2009) Diabetes and Cardiovascular Disease Prevention in Older Adults. Clinics in Geriatric Medicine 25:4, 607-641
CrossRef317
Jennifer G. Robinson. (2009) Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly. Drugs & Aging 26:11, 917-931
CrossRef318
Jörg Slany. (2009) Zielwerterreichung unter lipidsenkender Therapie mit Ezetimib/Simvastatin bei Patienten mit Atherosklerose und/oder Diabetes mellitus – eine österreichische Anwendungsbeobachtung. Wiener Medizinische Wochenschrift 159:21-22, 558-564
CrossRef319
Prakash Deedwania, Vibhuti Singh, Michael H. Davidson. (2009) Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials. The American Journal of Cardiology 104:10, 3E-9E
CrossRef320
David D. Waters, Ivy Ku. (2009) Early Statin Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:15, 1434-1437
CrossRef321
Richard H. Chapman, Allison A. Petrilla, Lance Berman, Joshua S. Benner, Simon S.K. Tang. (2009) Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?. American Journal Cardiovascular Drugs 9:5, 299-308
CrossRef322
Keith C. Ferdinand, John M. Flack, Elijah Saunders, Ronald Victor, Karol Watson, Attila Kursun, Michael J. Jamieson, Harry Shi. (2009) Amlodipine/Atorvastatin Single-Pill Therapy for Blood Pressure and Lipid Goals in African Americans: Influence of the Metabolic Syndrome and Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 11:10, 585-593
CrossRef323
Mark J Evans, Stephen J Gardell. (2009) Farnesoid X receptor as a therapeutic target for dyslipidemia. Clinical Lipidology 4:5, 587-594
CrossRef324
Ryan P. Morrissey, George A. Diamond, Sanjay Kaul. (2009) Statins in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:15, 1425-1433
CrossRef325
Joshua Devine, Andrea Linton, Harsha Mistry, Josh Napier, Shana Trice, Thomas Bacon. (2009) Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study. Pharmacoepidemiology and Drug Safety 18:10, 891-899
CrossRef326
Shui-ping Zhao, Dao-quan Peng, Bi-lian Yu, Yong Huo. (2009) Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study. American Heart Journal 158:4, 509-512.e1
CrossRef327
Jacques Genest, Ruth McPherson, Jiri Frohlich, Todd Anderson, Norm Campbell, André Carpentier, Patrick Couture, Robert Dufour, George Fodor, Gordon A. Francis, Steven Grover, Milan Gupta, Robert A. Hegele, David C. Lau, Lawrence Leiter, Gary F. Lewis, Eva Lonn, G.B. John Mancini, Dominic Ng, Glen J. Pearson, Allan Sniderman, James A. Stone, Ehud Ur. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology 25:10, 567-579
CrossRef328
Roberta Ara, Rachid Rafia, Sue E Ward, Anthony S Wierzbicki, Tim M Reynolds, Angie Rees, Abdullah Pandor. (2009) Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Review of Pharmacoeconomics & Outcomes Research 9:5, 423-433
CrossRef329
Alexandre Ouattara, Hamina Benhaoua, Yannick Le Manach, Nejma Mabrouk-Zerguini, Omar Itani, Amer Osman, Marc Landi, Bruno Riou, Pierre Coriat. (2009) Perioperative Statin Therapy Is Associated With a Significant and Dose-Dependent Reduction of Adverse Cardiovascular Outcomes After Coronary Artery Bypass Graft Surgery. Journal of Cardiothoracic and Vascular Anesthesia 23:5, 633-638
CrossRef330
Maurizio Paciaroni, Julien Bogousslavsky. (2009) Statins and stroke prevention. Expert Review of Cardiovascular Therapy 7:10, 1231-1243
CrossRef331
Christopher P. Cannon, Hayes M. Dansky, Michael Davidson, Antonio M. Gotto, Eliot A. Brinton, A. Lawrence Gould, Michael Stepanavage, Sherry Xueyu Liu, Sukrut Shah, Joseph Rubino, Patrice Gibbons, Anne Hermanowski-Vosatka, Bruce Binkowitz, Yale Mitchel, Philip Barter. (2009) Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib. American Heart Journal 158:4, 513-519.e3
CrossRef332
Thitima Kongnakorn, Alexandra Ward, Craig S. Roberts, Judith A. O'Brien, Irina Proskorovsky, J. Jaime Caro. (2009) Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial. Value in Health 12:6, 880-887
CrossRef333
Derek J Hausenloy, Derek M Yellon. (2009) Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Current Opinion in Cardiology 24:5, 473-482
CrossRef334
Xinwei Jia, Meng Wei, Xianghua Fu, Xinshun Gu, Weize Fan, Jing Zhang, Ling Xue. (2009) Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients. Heart and Vessels 24:5, 340-346
CrossRef335
John Farmer. (2009) The Vytorin on Carotid–Media Thickness and Overall Arterial Rigidity (VYCTOR) study. Expert Review of Cardiovascular Therapy 7:9, 1057-1060
CrossRef336
M. Miller. (2009) Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 102:9, 657-667
CrossRef337
Henry N. Ginsberg, Paul R. MacCallum. (2009) The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia. The Journal of Clinical Hypertension 11:9, 520-527
CrossRef338
Shinichiro Uchiyama, Noriaki Nakaya, Kyoichi Mizuno, Yasuo Ohashi, Naoko Tajima, Toshio Kushiro, Tamio Teramoto, Haruo Nakamura. (2009) Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: Analysis of data from the MEGA Study, a large randomized controlled trial. Journal of the Neurological Sciences 284:1-2, 72-76
CrossRef339
Lawrence A. Notaro, Mohammed H. Usman, James F. Burke, Aqeel Siddiqui, Keith R. Superdock, Michael D. Ezekowitz. (2009) Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics 27:3, 199-215
CrossRef340
Eli M Roth, Harold E Bays, Alan D Forker, Kevin C Maki, Roderick Carter, Ralph T Doyle, Evan A Stein. (2009) Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects. Journal of Cardiovascular Pharmacology 54:3, 196-203
CrossRef341
Terje R. Pedersen. (2009) Lipid-lowering drugs and risk for cancer. Current Atherosclerosis Reports 11:5, 350-357
CrossRef342
Anselm K. Gitt, Claus Juenger, Christina Jannowitz, Barbara Karmann, Juergen Senges, Kurt Bestehorn. (2009) Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. European Journal of Cardiovascular Prevention & Rehabilitation 16:4, 438-444
CrossRef343
(2009) Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities. Kidney International 76, S22-S49
CrossRef344
Ole Faergeman, Ingar Holme, Rana Fayyad, Sonal Bhatia, Scott M. Grundy, John J.P. Kastelein, John C. LaRosa, Mogens Lytken Larsen, Christina Lindahl, Anders G. Olsson, Matti J. Tikkanen, David D. Waters, Terje R. Pedersen. (2009) Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease. The American Journal of Cardiology 104:4, 459-463
CrossRef345
Karen J McConnell, Kari L Olson, Thomas Delate, John A Merenich. (2009) Factors Associated with Recurrent Coronary Events Among Patients with Cardiovascular Disease. Pharmacotherapy 29:8, 906-913
CrossRef346
P. G. Steg. (2009) Heart rate management in coronary artery disease: the CLARIFY registry. European Heart Journal Supplements 11:Suppl D, D13-D18
CrossRef347
James H. O'Keefe, Maia D. Carter, Carl J. Lavie. (2009) Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. Mayo Clinic Proceedings 84:8, 741-757
CrossRef348
Douglas C. A. Taylor, Ankur Pandya, David Thompson, Paula Chu, Jennifer Graff, James Shepherd, Nanette Wenger, Heiner Greten, Rafael Carmena, Michael Drummond, Milton C. Weinstein. (2009) Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. The European Journal of Health Economics 10:3, 255-265
CrossRef349
Stephen D. Wiviott, Satishkumar Mohanavelu, Joel S. Raichlen, Valerie A. Cain, Steven E. Nissen, Peter Libby. (2009) Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study). The American Journal of Cardiology 104:1, 29-35
CrossRef350
Sylvie Perreault, Laura Ellia, Alice Dragomir, Robert Côté, Lucie Blais, Anick Bérard, Lyne Lalonde. (2009) Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention. The American Journal of Medicine 122:7, 647-655
CrossRef351
Jean Ferrières, Vincent Bataille, Florence Leclercq, Philippe Geslin, Jean-Bernard Ruidavets, Gilles Grollier, Paul Bernard, Jean-Pierre Cambou, Tabassome Simon, Nicolas Danchin. (2009) Patterns of statin prescription in acute myocardial infarction. Atherosclerosis 204:2, 491-496
CrossRef352
Fabrizio Montecucco, François Mach. (2009) Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 389-400
CrossRef353
Yosuke Takamiya, Shin-Ichiro Miura, Akira Kawamura, Hiroyuki Tanigawa, Bo Zhang, Atsushi Iwata, Hiroaki Nishikawa, Kunihiro Matsuo, Kazuyuki Shirai, Keijiro Saku. (2009) Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease. Coronary Artery Disease 20:4, 288-294
CrossRef354
Ingar Holme, Michael Szarek, Nilo B. Cater, Ole Faergeman, John J.P. Kastelein, Anders G. Olsson, Matti J. Tikkanen, Mogens Lytken Larsen, Christina Lindahl, Terje R. Pedersen. (2009) Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. European Journal of Cardiovascular Prevention & Rehabilitation 16:3, 315-320
CrossRef355
Fabrizio Montecucco, François Mach. (2009) Update on statin-mediated anti-inflammatory activities in atherosclerosis. Seminars in Immunopathology 31:1, 127-142
CrossRef356
Xiankai Li, Yawei Xu, Jue Li, Dayi Hu. (2009) The Gender Differences in Baseline Characteristics and Statin Intervention Among Outpatients with Coronary Heart Disease in China: The China Cholesterol Education Program. Clinical Cardiology 32:6, 308-314
CrossRef357
Martin B. Leon, Dominic J. Allocco, Keith D. Dawkins, Donald S. Baim. (2009) Late Clinical Events After Drug-Eluting Stents. JACC: Cardiovascular Interventions 2:6, 504-512
CrossRef358
Joseph P. Vande Griend, Joseph J. Saseen. (2009) Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients. Journal of Clinical Lipidology 3:3, 195-200
CrossRef359
David D. Waters. (2009) Clinical Insights From the Treating to New Targets Trial. Progress in Cardiovascular Diseases 51:6, 487-502
CrossRef360
Gianna Fabbri, Aldo Pietro Maggioni. (2009) Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. Advances in Therapy 26:5, 469-487
CrossRef361
Ralph AH Stewart. (2009) Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Future Cardiology 5:3, 231-236
CrossRef362
H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, J. Armbrecht, M. A. Pfeffer. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation 24:5, 1663-1671
CrossRef363
Pierre Amarenco, Julien Labreuche. (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. The Lancet Neurology 8:5, 453-463
CrossRef364
Clodagh S. O’Gorman, Mary F. Higgins, Michael B. O’Neill. (2009) Systematic Review and Metaanalysis of Statins for Heterozygous Familial Hypercholesterolemia in Children: Evaluation of Cholesterol Changes and Side Effects. Pediatric Cardiology 30:4, 482-489
CrossRef365
Suguru Yamamoto, Valentina Kon. (2009) Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Current Opinion in Nephrology and Hypertension 18:3, 181-188
CrossRef366
J. P. Burke, R. W. G. Watson, M. Murphy, N. G. Docherty, J. C. Coffey, P. R. O'Connell. (2009) Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor β1-mediated activation of intestinal fibroblasts. British Journal of Surgery 96:5, 541-551
CrossRef367
A. S. Wierzbicki. (2009) SEARCHing for JUPITER: starry-eyed optimism is not warranted. International Journal of Clinical Practice 63:5, 685-688
CrossRef368
William Clifford Roberts. (2009) Evaluating Lipid-Lowering Trials in the Twenty-First Century. The American Journal of Cardiology 103:9, 1325-1328
CrossRef369
Ewa Dembowski, Michael H Davidson. (2009) Statin and ezetimibe combination therapy in cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity 16:2, 183-188
CrossRef370
M. Farnier, M. Averna, L. Missault, H. Vaverkova, M. Viigimaa, R. Massaad, K. Vandormael, A. O. Johnson-Levonas, P. Brudi. (2009) Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. International Journal of Clinical Practice 63:4, 547-559
CrossRef371
Khalid Alwaili, Khalid Alrasadi, Zuhier Awan, Jacques Genest. (2009) Approach to the diagnosis and management of lipoprotein disorders. Current Opinion in Endocrinology, Diabetes and Obesity 16:2, 132-140
CrossRef372
A. Blum, R. Shamburek. (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203:2, 325-330
CrossRef373
Paul M Ridker, Eleanor Danielson, Francisco AH Fonseca, Jacques Genest, Antonio M Gotto, John JP Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 373:9670, 1175-1182
CrossRef374
Peter S. Kruger, Noelle M. Freir, Bala Venkatesh, Thomas A. Robertson, Michael S. Roberts, Mark Jones. (2009) A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Medicine 35:4, 717-721
CrossRef375
Stefan N. Willich, Heike Englert, Frank Sonntag, Heinz Völler, Wolfgang Meyer-Sabellek, Karl Wegscheider, Eberhard Windler, Hugo Katus, Jacqueline Müller-Nordhorn. (2009) Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention & Rehabilitation 16:2, 180-187
CrossRef376
Paul Hamilton. (2009) Role of ezetimibe in the management of patients with atherosclerosis. Coronary Artery Disease 20:2, 169-174
CrossRef377
Runhua Hou, Anne Carol Goldberg. (2009) Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety. Endocrinology & Metabolism Clinics of North America 38:1, 79-97
CrossRef378
S Erdine, Y M Ro, H-F Tse, L G Howes, C A Aguilar-Salinas, H Chaves, R Guindy, P Chopra, R A Moller, I M Schou. (2009) Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). Journal of Human Hypertension 23:3, 196-210
CrossRef379
Sreenivasa RK Seshasai, Kausik K Ray. (2009) Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe?. Future Cardiology 5:2, 129-139
CrossRef380
Joe F. Lau, Donald A. Smith. (2009) Advanced Lipoprotein Testing: Recommendations Based on Current Evidence. Endocrinology & Metabolism Clinics of North America 38:1, 1-31
CrossRef381
D. N. Orken, G. Kenangil, M. Celik, Z. Mail, H. Kayaalp, E. Erginoz, H. Forta. (2009) Association of low cholesterol with primary intracerebral haemorrhage: a case control study. Acta Neurologica Scandinavica 119:3, 151-154
CrossRef382
Evan A. Stein. (2009) Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development. Endocrinology & Metabolism Clinics of North America 38:1, 99-119
CrossRef383
Matti J. Tikkanen, Ingar Holme, Nilo B. Cater, Michael Szarek, Ole Faergeman, John J.P. Kastelein, Anders G. Olsson, Mogens Lytken Larsen, Christina Lindahl, Terje R. Pedersen. (2009) Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study). The American Journal of Cardiology 103:5, 577-582
CrossRef384
Ajith P. Nair, Bruce Darrow. (2009) Lipid Management in the Geriatric Patient. Endocrinology & Metabolism Clinics of North America 38:1, 185-206
CrossRef385
Suzanne Hughes. (2009) On the road to better dyslipidemia outcomes. The Nurse Practitioner 34:2, 14-21
CrossRef386
Daisy Dulay, Stephen A. LaHaye, Karen A. Lahey, Andrew G. Day. (2009) Efficacy of alternate day versus daily dosing of rosuvastatin. Canadian Journal of Cardiology 25:2, e28-e31
CrossRef387
Jay N. Cohn, Daniel J. Wilson, Joel Neutel, Mark Houston, Myron H. Weinberger, Richard Grimm, David H.G. Smith, William Sun. (2009) Coadministered Amlodipine and Atorvastatin Produces Early Improvements in Arterial Wall Compliance in Hypertensive Patients With Dyslipidemia. American Journal of Hypertension 22:2, 137-144
CrossRef388
K. Graf. (2009) Die JUPITER-Studie: Primärprävention bei erhöhtem C-reaktivem Protein. Der Kardiologe 3:1, 35-36
CrossRef389
Helene M. Devold, Espen Molden, Svetlana Skurtveit, Kari Furu. (2009) Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. British Journal of Clinical Pharmacology 67:2, 234-241
CrossRef390
Annapoorna S. Kini, Paul Muntner, Pedro R. Moreno, Devin Mann, Prakash Krishnan, Michael C. Kim, Oana C. Rafael, Michael E. Farkouh, Samin K. Sharma. (2009) Relation of High-Density Lipoprotein Cholesterol to Mortality After Percutaneous Coronary Interventions in Patients With Low-Density Lipoprotein <70 mg/dl. The American Journal of Cardiology 103:3, 350-354
CrossRef391
Craig D. Williams. (2009) Not so choppy SEAS. Journal of Clinical Lipidology 3:1, 11-13
CrossRef392
Robert A. Vogel, Michael Miller. (2009) Cholesterol Goals: Moving from Numbers to Treatment. Clinical Cardiology 32:2, 106-108
CrossRef393
Hemanth Neeli, Ram Gadi, Daniel J. Rader. (2009) Managing diabetic dyslipidemia: Beyond statin therapy. Current Diabetes Reports 9:1, 11-17
CrossRef394
Virginie Gardette, Vanina Bongard, Jean Dallongeville, Dominique Arveiler, Annie Bingham, Jean-Bernard Ruidavets, Philippe Amouyel, Bernadette Haas, Pierre Ducimetière, Jean Ferrières. (2009) Ten-Year All-Cause Mortality in Presumably Healthy Subjects on Lipid-Lowering Drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). The American Journal of Cardiology 103:3, 381-386
CrossRef395
Tsutomu Yamazaki, Masahiko Kurabayashi. (2009) A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5mg and Atorvastatin10mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). Annals of Vascular Diseases 2:3, 159-173
CrossRef396
Babak B. Navi, Alan Z. Segal. (2009) The role of cholesterol and statins in stroke. Current Cardiology Reports 11:1, 4-11
CrossRef397
Tomohito Hamazaki. (2009) Are the upper limits for serum cholesterol levels necessary?. Journal of Lipid Nutrition 18:1, 33-50
CrossRef398
Takahide Kohro, Tsutomu Yamazaki. (2009) Mechanism of Statin-Induced Myopathy Investigated Using Microarray Technology. Journal of Atherosclerosis and Thrombosis 16:1, 30-32
CrossRef399
Toru Toi, Isao Taguchi, Shuichi Yoneda, Michiya Kageyama, Akiko Kikuchi, Michiaki Tokura, Tomoaki Kanaya, Shichiro Abe, Ryuko Matsuda, Noboru Kaneko. (2009) Early Effect of Lipid-Lowering Therapy With Pitavastatin on Regression of Coronary Atherosclerotic Plaque. Circulation Journal 73:8, 1466-1472
CrossRef400
Peter Baginsky. (2009) Should we treat all patients with coronary heart disease or the equivalent with statins?. Current Atherosclerosis Reports 11:1, 28-35
CrossRef401
Herbert D. Aronow, Michael P. Dutro, Andreas Kuznik, James Cwengros. (2009) Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan*. Current Medical Research and Opinion 25:1, 205-213
CrossRef402
Jennifer G. Robinson, Songfeng Wang, Brian J. Smith, Terry A. Jacobson. (2009) Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk. Journal of the American College of Cardiology 53:4, 316-322
CrossRef403
James E. Novak, Lynda A. Szczech. (2009) Phosphate Binders in Chronic Kidney Disease and End-Stage Renal Disease: A Patient-Centered Approach. Seminars in Dialysis 22:1, 56-63
CrossRef404
Atsushi Hirayama, Satoshi Saito, Yasunori Ueda, Tadateru Takayama, Junko Honye, Sei Komatsu, Osamu Yamaguchi, Yuxin Li, Junji Yajima, Shinsuke Nanto, Kenji Takazawa, Kazuhisa Kodama. (2009) Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy. Circulation Journal 73:4, 718-725
CrossRef405
Katsunori Ikewaki, Yoshio Terao, Hideki Ozasa, Yoshinobu Nakada, Jun-ichiro Tohyama, Yae Inoue, Michihiro Yoshimura. (2009) Effects of Atorvastatin on Nuclear Magnetic Resonance-Defined Lipoprotein Subclasses and Inflammatory Markers in Patients with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 16:1, 51-56
CrossRef406
Jennifer G. Robinson. (2009) Is a statin as part of a polypill the answer?. Current Atherosclerosis Reports 11:1, 15-22
CrossRef407
Iveta Mintāle, Inga Narbute, Sanda Jēgere, Milāna Zabunova, Dace Lūriņa, Iļja Zakke, Vilnis Taluts Dzērve, Andrejs Ērglis. (2009) Importance of the Exercise Test Follow-up Programme for Patients with Coronary Artery Disease who Underwent Percutaneous Coronary Intervention. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 63:4, 151-155
CrossRef408
Michael T. McDermott. 2009. Lipid Disorders. , 65-75.
CrossRef409
Carol M. Mason. (2009) Preventing coronary heart disease and stroke with aggressive statin therapy in older adults using a team management model. Journal of the American Academy of Nurse Practitioners 21:1, 47-53
CrossRef410
Martin Sénécal, George Fodor, Claude Gagné, Jacques Genest, Marc-André Lavoie, Ruth McPherson, Michael Marentette, Rolf J. Sebaldt. (2009) Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study – observational. Current Medical Research and Opinion 25:1, 47-55
CrossRef411
Tsuyoshi Nozue, Shingo Yamamoto, Shinichi Tohyama, Shigeo Umezawa, Tomoyuki Kunishima, Akira Sato, Shogo Miyake, Youichi Takeyama, Yoshihiro Morino, Takao Yamauchi, Toshiya Muramatsu, Kiyoshi Hibi, Takashi Sozu, Ichiro Michishita, Kanagawa PTCA Conference Study Grou. (2009) Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology (TRUTH Study). Circulation Journal 73:2, 352-355
CrossRef412
John F. Thompson, Jennifer M. Reynolds, Suzanne P. Williams, Linda S. Wood, Sara A. Paciga, David B. Lloyd. (2009) Frequency and function of CETP variants among individuals of Asian ancestry. Atherosclerosis 202:1, 241-247
CrossRef413
Takatoshi Kasai, Katsumi Miyauchi, Kan Kajimoto, Naozumi Kubota, Takeshi Kurata, Atsushi Amano, Hiroyuki Daida. (2009) The Impact of Pravastatin Therapy on Long-Term Outcome in Patients With Metabolic Syndrome Undergoing Complete Coronary Revascularization. Circulation Journal 73:11, 2104-2109
CrossRef414
2009. LIPID – REGULATING DRUGS. , 527-570.
CrossRef415
ANTONIO M. GOTTO, LIONEL H. OPIE. 2009. Lipid-Modifying and Antiatherosclerotic Drugs. , 341-372.
CrossRef416
B.J. Gersh. (2009) Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Yearbook of Medicine 2009, 402-404
CrossRef417
B.J. Gersh. (2009) Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After coronary Artery Bypass Surgery. Yearbook of Cardiology 2009, 312-313
CrossRef418
H. Almroth, N. Hoglund, K. Boman, A. Englund, S. Jensen, B. Kjellman, P. Tornvall, M. Rosenqvist. (2008) Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. European Heart Journal 30:7, 827-833
CrossRef419
Eileen E. Ming, Michael H. Davidson, Sanjay K. Gandhi, Marcelo Marotti, Carolyn G. Miles, Xiongkan Ke, James M. McKenney. (2008) Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. Journal of Clinical Lipidology 2:6, 453-463
CrossRef420
Jacques Bonnet, R. McPherson, A. Tedgui, D. Simoneau, A. Nozza, P. Martineau, Jean Davignon. (2008) Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clinical Therapeutics 30:12, 2298-2313
CrossRef421
Wei Zhao, Rong Xue, Zhen-Xian Zhou, Wei-Jia Kong, Jian-Dong Jiang. (2008) Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomedicine & Pharmacotherapy 62:10, 730-731
CrossRef422
Michael H. Davidson, Nicola Abate, Christie M. Ballantyne, Alberico L. Catapano, Xia Xu, Jianxin Lin, Elizabeth Rosenberg, Andrew M. Tershakovec. (2008) Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non–HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. Journal of Clinical Lipidology 2:6, 436-446
CrossRef423
Luis Castilla Guerra, María Dolores Jiménez Hernández, María del Carmen Fernández Moreno. (2008) Ictus y estatinas: más allá de la reducción de los valores de colesterol. Clínica e Investigación en Arteriosclerosis 20:6, 239-246
CrossRef424
Seung-Hoon Lee, Yoon-Hee Kim, Young-Ju Kim, Byung-Woo Yoon. (2008) Atorvastatin enhances hypothermia-induced neuroprotection after stroke. Journal of the Neurological Sciences 275:1-2, 64-68
CrossRef425
Richard A. Krasuski. (2008) Primary Prevention and Statins: Is It Just About Going to Class?. Mayo Clinic Proceedings 83:12, 1313-1315
CrossRef426
Peter H. Jones. (2008) Expert Perspective: Reducing Cardiovascular Risk in Metabolic Syndrome and Type 2 Diabetes Mellitus Beyond Low-Density Lipoprotein Cholesterol Lowering. The American Journal of Cardiology 102:12, 41L-47L
CrossRef427
Terry A. Jacobson, Debra A. Wertz, Tracey Hoy, Andreas Kuznik, Daniel Grochulski, Mark Cziraky. (2008) Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. Mayo Clinic Proceedings 83:12, 1316-1325
CrossRef428
Terje R. Pedersen. (2008) Intensive Lipid-Lowering Therapy for Patients With Aortic Stenosis. The American Journal of Cardiology 102:11, 1571-1576
CrossRef429
José M. Mostaza, Luis Manzano, Carmen Suárez, Marc Cairols, Eva María Ferreira, Eduardo Rovira, Aquilino Sánchez, Manuel A. Suárez-Tembra, Eva Estirado, Juan de Dios Estrella, Francisco Vega, Miguel Ángel Sánchez-Zamorano. (2008) Prevalencia de enfermedad arterial periférica asintomática, estimada mediante el índice tobillo-brazo, en pacientes con enfermedad vascular. Estudio MERITO II. Medicina Clínica 131:15, 561-565
CrossRef430
Michael H. Davidson, Ewa Dembowski. (2008) Atherosclerosis surrogate imaging trials come of age: For better or for worse?. Current Cardiology Reports 10:6, 521-525
CrossRef431
Tatjana Rundek, Ralph L. Sacco. (2008) Risk Factor Management to Prevent First Stroke. Neurologic Clinics 26:4, 1007-1045
CrossRef432
Jennifer G. Robinson. (2008) LDL reduction: How low should we go and is it safe?. Current Cardiology Reports 10:6, 481-487
CrossRef433
Brian G. Choi, Gemma Vilahur, M. Urooj Zafar, Luis Cardoso, Daniel Yadegar, Borja Ibanez, James Tunstead, Juan F. Viles-Gonzalez, Mitchell B. Schaffler, Valentin Fuster, Juan J. Badimon. (2008) Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis 201:1, 76-84
CrossRef434
Evangelos N Liberopoulos, Matilda Florentin, Dimitri P Mikhailidis, Moses S Elisaf. (2008) Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opinion on Drug Safety 7:6, 717-725
CrossRef435
Melinda J Carrington, Claudia Retegan, Colin I Johnston, Garry L Jennings, Simon Stewart. (2008) Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention. Journal of Clinical Nursing
CrossRef436
Robert S Rosenson. (2008) Fenofibrate: treatment of hyperlipidemia and beyond. Expert Review of Cardiovascular Therapy 6:10, 1319-1330
CrossRef437
Jean-Charles Fruchart, Frank Sacks, Michel P. Hermans, Gerd Assmann, W. Virgil Brown, Richard Ceska, M. John Chapman, Paul M. Dodson, Paola Fioretto, Henry N. Ginsberg, Takashi Kadowaki, Jean-Marc Lablanche, Nikolaus Marx, Jorge Plutzky, Željko Reiner, Robert S. Rosenson, Bart Staels, Jane K. Stock, Rody Sy, Christoph Wanner, Alberto Zambon, Paul Zimmet. (2008) The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. The American Journal of Cardiology 102:10, 1K-34K
CrossRef438
Colleen Johnson, David D. Waters, David A. DeMicco, Andrei Breazna, Vera Bittner, Heiner Greten, Scott M. Grundy, John C. LaRosa. (2008) Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study). The American Journal of Cardiology 102:10, 1312-1317
CrossRef439
T. Mantilla Morató. (2008) Manejo terapéutico general y extrahospitalario del paciente con hiperlipidemia. Medidas generales y farmacológicas. Criterios clínicos y analíticos de seguimiento. Modificaciones posológicas y farmacológicas. Cumplimiento terapéutico. Medicine - Programa de Formación Médica Continuada Acreditado 10:19, 1272-1278
CrossRef440
Richard J. Willke, Steve Zhou, Robert A. Vogel. (2008) Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Current Medical Research and Opinion 24:10, 2873-2882
CrossRef441
Francisco José Fernández Fernández, Tamara Caínzos Romero, Gonzalo Pía Iglesias, Pascual Sesma. (2008) Estatinas y accidente cerebrovascular. Medicina Clínica 131:14, 559
CrossRef442
J. S. Benner, L. Erhardt, M. Flammer, R. A. Moller, N. Rajicic, K. Changela, C. Yunis, S. B. Cherry, Z. Gaciong, E. S. Johnson, M. C. J. M. Sturkenboom, J. García-Puig, X. Girerd, . (2008) A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients’ modifiable risk factor profile. International Journal of Clinical Practice 62:10, 1484-1498
CrossRef443
Daniel B. Mark, J. David Knight, Patricia A. Cowper, Linda Davidson-Ray, Kevin J. Anstrom. (2008) Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: Results from the Treating to New Targets (TNT) Trial. American Heart Journal 156:4, 698-705
CrossRef444
Russell A. Wilke, Richard L. Berg, James G. Linneman, Chengfeng Zhao, Catherine A. McCarty, Ronald M. Krauss. (2008) Characterization of Low-Density Lipoprotein Cholesterol-Lowering Efficacy for Atorvastatin in a Population-Based DNA Biorepository. Basic & Clinical Pharmacology & Toxicology 103:4, 354-359
CrossRef445
Michael Domanski, Xin Tian, Jerome Fleg, Sean Coady, Christine Gosen, Ruth Kirby, Vandana Sachdev, Genell Knatterud, Eugene Braunwald. (2008) Pleiotropic Effect of Lovastatin, With and Without Cholestyramine, in the Post Coronary Artery Bypass Graft (Post CABG) Trial. The American Journal of Cardiology 102:8, 1023-1027
CrossRef446
John C. LaRosa, Scott M. Grundy, David D. Waters. 2008. TNT Trial. .
CrossRef447
Roberto R. Giraldez, Robert P. Giugliano, Satishkumar Mohanavelu, Sabina A. Murphy, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald. (2008) Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. Journal of the American College of Cardiology 52:11, 914-920
CrossRef448
Barry A Franklin, Justin E Trivax, Thomas E Vanhecke. (2008) New insights in preventive cardiology and cardiac rehabilitation. Current Opinion in Cardiology 23:5, 477-486
CrossRef449
Claudio Rapezzi, Elena Biagini, Paolo Bellis, Massimo Cafiero, Mario Velussi, Antonio Ceriello, Robin MT Cooke, Carlo Schweiger. (2008) Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. Journal of Cardiovascular Medicine 9:9, 878-887
CrossRef450
Barbara J. Messinger-Rapport, David R. Thomas, Julie K. Gammack, John E. Morley. (2008) Clinical Update on Nursing Home Medicine: 2008. Journal of the American Medical Directors Association 9:7, 460-475
CrossRef451
&NA;. (2008) Which Statin?. Obstetrics & Gynecology 112:3, 696-698
CrossRef452
Ori Ben-Yehuda, Anthony N. DeMaria. (2008) Low LDL-C Levels and Cancer. Journal of the American College of Cardiology 52:14, 1150-1151
CrossRef453
William T. Cefalu. (2008) Diabetic dyslipidemia and the metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2:3, 208-222
CrossRef454
Dakshinamoorty Kandasamy Arulmozhi, Rubin Kurian, Subodh L. Bodhankar, Addepalli Veeranjaneyulu. (2008) Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. Journal of Pharmacy and Pharmacology 60:9, 1167-1173
CrossRef455
Amy K. Kearns, Cherie L. Bilbie, Priscilla M. Clarkson, C. Michael White, Kim A. Sewright, Kevin S. O’Fallon, Mamatha Gadarla, Paul D. Thompson. (2008) The creatine kinase response to eccentric exercise with atorvastatin 10mg or 80mg. Atherosclerosis 200:1, 121-125
CrossRef456
Zlatko Fras, Dimitri P Mikhailidis. (2008) Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Current Medical Research and Opinion 24:9, 2467-2476
CrossRef457
Philippe Couvert, Philippe Giral, Sylvie Dejager, Jessie Gu, Thierry Huby, M John Chapman, Eric Bruckert, Alain Carrié. (2008) Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9:9, 1217-1227
CrossRef458
Michael Roden, Kurt Huber. (2008) Lipidprofil und Therapiestatus in der Sekundärprävention bei Hochrisiko-Patienten mit klinisch manifester Arteriosklerose und/oder Diabetes mellitus: Das Hospital Screening Projekt (HSP) in Österreich. Wiener klinische Wochenschrift 120:17-18, 558-565
CrossRef459
Niels Engberding, Nanette K Wenger. (2008) Cardiovascular disease prevention tailored for women. Expert Review of Cardiovascular Therapy 6:8, 1123-1134
CrossRef460
The SEARCH Collaborative Group. (2008) SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. New England Journal of Medicine 359:8, 789-799
Full Text461
A. S. Wierzbicki. (2008) A fishy business: omega-3 fatty acids and cardiovascular disease. International Journal of Clinical Practice 62:8, 1142-1146
CrossRef462
Handrean Soran, Paul Durrington. (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opinion on Pharmacotherapy 9:12, 2145-2160
CrossRef463
Goran Gajski, Vera Garaj-Vrhovac, Višnja Oreščanin. (2008) Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: Standard and Fpg-modified comet assay. Toxicology and Applied Pharmacology 231:1, 85-93
CrossRef464
Zuhier Awan, Khalid Al. Waili, Khalid Alrasadi, Jacques Genest. (2008) Treatment of low high-density lipoprotein cholesterol. Canadian Journal of Cardiology 24, 27C-31C
CrossRef465
Stephen J Nicholls. (2008) Rosuvastatin and progression of atherosclerosis. Expert Review of Cardiovascular Therapy 6:7, 925-933
CrossRef466
Michael A. Pacanowski, Reginald F. Frye, Osatohanmen Enogieru, Richard S. Schofield, Issam Zineh. (2008) Plasma coenzyme Q10 predicts lipid-lowering response to high-dose atorvastatin. Journal of Clinical Lipidology 2:4, 289-297
CrossRef467
Gilbert J. Zoghbi, Todd A. Dorfman, Ami E. Iskandrian. (2008) The Effects of Medications on Myocardial Perfusion. Journal of the American College of Cardiology 52:6, 401-416
CrossRef468
P. P. Toth. (2008) Subclinical atherosclerosis: what it is, what it means and what we can do about it. International Journal of Clinical Practice 62:8, 1246-1254
CrossRef469
Fergus McTaggart, Peter Jones. (2008) Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. Cardiovascular Drugs and Therapy 22:4, 321-338
CrossRef470
Gerald F Watts, P Hugh R Barrett, Dick C Chan. (2008) HDL metabolism in context: looking on the bright side. Current Opinion in Lipidology 19:4, 395-404
CrossRef471
James Shepherd, John J.P. Kastelein, Vera A. Bittner, Rafael Carmena, Prakash C. Deedwania, Andrei Breazna, Stephen Dobson, Daniel J. Wilson, Andrea L. Zuckerman, Nanette K. Wenger. (2008) Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease. Mayo Clinic Proceedings 83:8, 870-879
CrossRef472
James Shepherd, John J.P. Kastelein, Vera A. Bittner, Rafael Carmena, Prakash C. Deedwania, Andrei Breazna, Stephen Dobson, Daniel J. Wilson, Andrea L. Zuckerman, Nanette K. Wenger. (2008) Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease. Mayo Clinic Proceedings 83:8, 870-879
CrossRef473
T. R. Pedersen. (2008) Overview of clinical trials on calcific aortic stenosis. European Heart Journal Supplements 10:Suppl E, E31-E40
CrossRef474
William H. Frishman, John Horn. (2008) Statin???Drug Interactions. Cardiology in Review 16:4, 205-212
CrossRef475
Suresh Krishnamoorthy, Gregory YH Lip. (2008) Beyond lipid-lowering therapy: does ezetimibe enhance the effects of statins on atherosclerosis?. Therapy 5:4, 487-489
CrossRef476
JoAnne M. Foody, Amie T. Joyce, Amy E. Rudolph, Larry Z. Liu, Joshua S. Benner. (2008) Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Current Medical Research and Opinion 24:7, 1987-2000
CrossRef477
Gregg O. Coodley, Maryclair Jorgensen, Jack Kirschenbaum, Chieko Sparks, Lisa Zeigler, Barry D. Albertson. (2008) Lowering LDL Cholesterol in Adults: A Prospective, Community-Based Practice Initiative. The American Journal of Medicine 121:7, 604-610
CrossRef478
Peter F. Wilson. 2008. Statins. .
CrossRef479
M. Settergren, F. Bohm, L. Ryden, J. Pernow. (2008) Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. European Heart Journal 29:14, 1753-1760
CrossRef480
Pierre Amarenco, Philippa C Lavallée, Mikael Mazighi, Julien Labreuche. (2008) Statins in stroke prevention. Future Lipidology 3:3, 319-325
CrossRef481
Alejandro de la Sierra, Manuel Gorostidi, Rafael Marín, Josep Redón, José R. Banegas, Pedro Armario, Juan García Puig, Julio Zarco, José L. Llisterri, Carlos Sanchís, Benjamín Abarca, Vicente Palomo, Ramón Gomis, Alfonso Otero, Fernando Villar, Jesús Honorato, Juan Tamargo, José M. Lobos, Juan Macías-Núñez, Antonio Sarría, Pedro Aranda, Luis M. Ruilope. (2008) Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso. Medicina Clínica 131:3, 104-116
CrossRef482
Dean G. Karalis. (2008) The Role of Lipid-lowering Therapy in Preventing Coronary Heart Disease in Patients with Type 2 Diabetes. Clinical Cardiology 31:6, 241-248
CrossRef483
Piia Peura, Janne Martikainen, Erkki Soini, Taru Hallinen, Leo Niskanen. (2008) Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Current Medical Research and Opinion 24:6, 1823-1832
CrossRef484
Michele Mietus-Snyder, Ronald M. Krauss. (2008) Lipid metabolism in children and adolescents: Impact on vascular biology. Journal of Clinical Lipidology 2:3, 127-137
CrossRef485
Shahar Lavi, Joerg Herrmann, Ronit Lavi, Joseph P. McConnell, Lilach O. Lerman, Amir Lerman. (2008) Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Current Atherosclerosis Reports 10:3, 230-235
CrossRef486
Sofia G. Tsouli, Evangelos N. Liberopoulos, John A. Goudevenos, Dimitri P. Mikhailidis, Moses S. Elisaf. (2008) Should a statin be prescribed to every patient with heart failure?. Heart Failure Reviews 13:2, 211-225
CrossRef487
Rebecca L Pollex, Tisha R Joy, Robert A Hegele. (2008) Emerging antidyslipidemic drugs. Expert Opinion on Emerging Drugs 13:2, 363-381
CrossRef488
Michael H. Davidson, Marshall A. Corson, Mark J. Alberts, Jeffrey L. Anderson, Philip B. Gorelick, Peter H. Jones, Amir Lerman, Joseph P. McConnell, Howard S. Weintraub. (2008) Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines. The American Journal of Cardiology 101:12, S51-S57
CrossRef489
D BHATT. (2008) Anti-Inflammatory Agents and Antioxidants as a Possible “Third Great Wave” in Cardiovascular Secondary Prevention. The American Journal of Cardiology 101:10, S4-S13
CrossRef490
Amy E Miller, Laura B Hansen, Joseph J Saseen. (2008) Switching Statin Therapy Using a Pharmacist-Managed Therapeutic Conversion Program versus Usual Care Conversion Among Indigent Patients. Pharmacotherapy 28:5, 553-561
CrossRef491
M-a Kawashiri, A Nohara, H Tada, M Mori, M Tsuchida, S Katsuda, A Inazu, J Kobayashi, J Koizumi, H Mabuchi, M Yamagishi. (2008) Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study. Clinical Pharmacology & Therapeutics 83:5, 731-739
CrossRef492
John B. Kostis, Andrei Breazna, Prakash C. Deedwania, John C. LaRosa. (2008) The Benefits of Intensive Lipid Lowering in Patients With Stable Coronary Heart Disease With Normal or High Systolic Blood Pressure: An Analysis of the Treating to New Targets (TNT) Study. The Journal of Clinical Hypertension 10:5, 367-376
CrossRef493
Sanjiv J. Shah, David D. Waters, Philip Barter, John J.P. Kastelein, James Shepherd, Nanette K. Wenger, David A. DeMicco, Andrei Breazna, John C. LaRosa. (2008) Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 51:20, 1938-1943
CrossRef494
JB Warren. (2008) Cholesterol—When Is Lower Better?. Clinical Pharmacology & Therapeutics 83:5, 777-780
CrossRef495
Brian J. Adams, John G. Carr, Al Ozonoff, Michael S. Lauer, Gary J. Balady. (2008) Effect of Exercise Training in Supervised Cardiac Rehabilitation Programs on Prognostic Variables From the Exercise Tolerance Test. The American Journal of Cardiology 101:10, 1403-1407
CrossRef496
Kastelein, John J.P., Akdim, Fatima, Stroes, Erik S.G., Zwinderman, Aeilko H., Bots, Michiel L., Stalenhoef, Anton F.H., Visseren, Frank L.J., Sijbrands, Eric J.G., Trip, Mieke D., Stein, Evan A., Gaudet, Daniel, Duivenvoorden, Raphael, Veltri, Enrico P., Marais, A. David, de Groot, Eric, . (2008) Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. New England Journal of Medicine 358:14, 1431-1443
Full Text497
Bonnie Ky, Anne Burke, Sotirios Tsimikas, Megan L. Wolfe, Mahlet G. Tadesse, Philippe O. Szapary, Joseph L. Witztum, Garret A. FitzGerald, Daniel J. Rader. (2008) The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. Journal of the American College of Cardiology 51:17, 1653-1662
CrossRef498
Chirag M. Sandesara, Hamid Roodneshin, Salam Sbaity, Brian Olshansky. (2008) Antiarrhythmic Effects of Statins in Heart Failure. Heart Failure Clinics 4:2, 187-200
CrossRef499
John A. Ambrose. (2008) In Search of the “Vulnerable Plaque”. Journal of the American College of Cardiology 51:16, 1539-1542
CrossRef500
Yasmine S Ali, MacRae F Linton, Sergio Fazio. (2008) Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Current Opinion in Endocrinology, Diabetes and Obesity 15:2, 142-146
CrossRef501
F. Paillard, M. Mosnier. (2008) Étude d’utilisation de l’acide nicotinique a libération prolongée en France chez des patients en prévention secondaire sous statine avec persistance d’un taux bas de HDL-c. Annales de Cardiologie et d'Angéiologie 57:2, 121-126
CrossRef502
B. G. Choi, G. Vilahur, L. Cardoso, J. C. Fritton, B. Ibanez, M. U. Zafar, D. Yadegar, W. S. Speidl, M. B. Schaffler, V. Fuster, J. J. Badimon. (2008) Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway. European Journal of Clinical Investigation 38:4, 211-217
CrossRef503
M. Florentin, E. N. Liberopoulos, D. P. Mikhailidis, M. S. Elisaf. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion 24:4, 995-1009
CrossRef504
Amit Kumar, Christopher P. Cannon. (2008) The Role of Statins in the Prevention of Heart Failure After Acute Coronary Syndrome. Heart Failure Clinics 4:2, 129-139
CrossRef505
James Shepherd, John J.P. Kastelein, Vera Bittner, Prakash Deedwania, Andrei Breazna, Stephen Dobson, Daniel J. Wilson, Andrea Zuckerman, Nanette K. Wenger. (2008) Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease. Journal of the American College of Cardiology 51:15, 1448-1454
CrossRef506
Rodrigo Alonso, Jaime Fernández de Bobadilla, Ignacio Méndez, Pablo Lázaro, Nelva Mata, Pedro Mata. (2008) Coste-efectividad del manejo de la hipercolesterolemia familiar con estrategias de tratamiento preventivo basadas en atorvastatina. Revista Española de Cardiología 61:4, 382-393
CrossRef507
Kevin A. Bybee, John H. Lee, James H. O'Keefe. (2008) Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Current Medical Research and Opinion 24:4, 1217-1229
CrossRef508
MT Bennett, KW Johns, GP Bondy. (2008) Current and future treatments of HIV-associated dyslipidemia. Future Lipidology 3:2, 175-188
CrossRef509
M. Anselmino, K. Malmberg, J. Ohrvik, L. Ryden, . (2008) Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. European Journal of Cardiovascular Prevention & Rehabilitation 15:2, 216-223
CrossRef510
Madiha Abdel-Maksoud, Vasilisa Sazonov, Stephen W Gutkin, John E Hokanson. (2008) Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes. Journal of Cardiovascular Pharmacology 51:4, 331-351
CrossRef511
J. P. D. Reckless, P. Henry, T. Pomykaj, S. T. Lim, R. Massaad, K. Vandormael, A. O. Johnson-Levonas, K. Lis, P. Brudi, C. Allen. (2008) Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. International Journal of Clinical Practice 62:4, 539-554
CrossRef512
Kumar Rajamani, Seemant Chaturvedi. (2008) New strategies in the medical treatment of carotid artery disease. Current Treatment Options in Cardiovascular Medicine 10:2, 156-163
CrossRef513
C. P. Cannon. (2008) Combination therapy in the management of mixed dyslipidaemia. Journal of Internal Medicine 263:4, 353-365
CrossRef514
B. Greg Brown, Xue-Qiao Zhao. (2008) Nicotinic Acid, Alone and in Combinations, for Reduction of Cardiovascular Risk. The American Journal of Cardiology 101:8, S58-S62
CrossRef515
Robert H. Knopp, Pathmaja Paramsothy, Benjamin Atkinson, Alice Dowdy. (2008) Comprehensive Lipid Management Versus Aggressive Low-Density Lipoprotein Lowering to Reduce Cardiovascular Risk. The American Journal of Cardiology 101:8, S48-S57
CrossRef516
Tamar S. Polonsky, Michael H. Davidson. (2008) Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy. The American Journal of Cardiology 101:8, S27-S35
CrossRef517
Susanne H Meeuwisse-Pasterkamp, Melanie M van der Klauw, Bruce HR Wolffenbuttel. (2008) Type 2 diabetes mellitus: prevention of macrovascular complications. Expert Review of Cardiovascular Therapy 6:3, 323-341
CrossRef518
Binita Shah, Nidhi Kumar, Parveen Garg, Eunice Kang, Eugene Grossi, Jeffrey D. Lorin, Arthur Z. Schwartzbard, Howard Mass, Ann Danoff, Steven P. Sedlis. (2008) Metabolic syndrome does not impact survival in patients treated for coronary artery disease. Coronary Artery Disease 19:2, 71-77
CrossRef519
François Charbonneau, Todd J. Anderson, Lawrence Title, Jean Jobin, Paul Poirier, Thao Huyhn, Sammy Chan, Ann Walling, Stuart Hutchison, Thang Tran, Eva Lonn, Jean Buithieu, Jacques Genest. (2008) Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 197:1, 420-427
CrossRef520
Marc A. Pfeffer. (2008) Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo. American Journal of Kidney Diseases 51:3, 366-369
CrossRef521
Roy W. Jones, Miia Kivipelto, Howard Feldman, Larry Sparks, Rachelle Doody, David D. Waters, Judith Hey-Hadavi, Andrei Breazna, Rachel J. Schindler, Harry Ramos. (2008) The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics
Roy W. Jones and Miia Kivipelto contributed equally to the content of the manuscript.. Alzheimer's and Dementia 4:2, 145-153
CrossRef522
Lisa R Tannock. (2008) Advances in the management of hyperlipidemia-induced atherosclerosis. Expert Review of Cardiovascular Therapy 6:3, 369-383
CrossRef523
Thomas F. Whayne. (2008) Nonprescription Statins: Not Ready for Prime Time. The American Journal of Cardiology 101:5, 745-746
CrossRef524
M Skamagas, TL Breen, D LeRoith. (2008) Update on diabetes mellitus: prevention, treatment, and association with oral diseases. Oral Diseases 14:2, 105-114
CrossRef525
Kosmas I. Paraskevas. (2008) Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering. International Urology and Nephrology 40:1, 165-170
CrossRef526
Peter Wenaweser, Jean-François Surmely, Stephan Windecker, Marco Roffi, Mario Togni, Michael Billinger, Stephane Cook, Rolf Vogel, Christian Seiler, Otto M. Hess, Bernhard Meier. (2008) Prognostic Value of Early Exercise Testing After Coronary Stent Implantation. The American Journal of Cardiology 101:6, 807-811
CrossRef527
Kenneth K.C. Lee, Vivian W.Y. Lee, Wai Kwong Chan, Benjamin S.C. Lee, Agnes C.Y. Chong, Jasper C.L. Wong, Don Yin, Evo Alemao, Brian Tomlinson. (2008) Cholesterol Goal Attainment in Patients with Coronary Heart Disease and Elevated Coronary Risk: Results of the Hong Kong Hospital Audit Study. Value in Health 11, S91-S98
CrossRef528
John R Crouse. (2008) An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. Expert Opinion on Drug Metabolism & Toxicology 4:3, 287-304
CrossRef529
Wilbert S Aronow. (2008) Treatment of High-Risk Older Persons With Lipid-Lowering Drug Therapy. American Journal of Therapeutics 15:2, 102-107
CrossRef530
Wilbert S. Aronow, William H. Frishman. 2008. Angina in the Elderly. , 269-292.
CrossRef531
Doris T. Chan, Ashley B. Irish, Gursharan K. Dogra, Gerald F. Watts. (2008) Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 196:2, 823-834
CrossRef532
J. Ferrières. (2008) Statines chez le coronarien : un problème résolu ?. Annales de Cardiologie et d'Angéiologie 57, 16-23
CrossRef533
H. Sillesen. (2008) What Does ‘Best Medical Therapy’ Really Mean?. European Journal of Vascular and Endovascular Surgery 35:2, 139-144
CrossRef534
Helene Glassberg, Daniel J. Rader. (2008) Management of Lipids in the Prevention of Cardiovascular Events. Annual Review of Medicine 59:1, 79-94
CrossRef535
Wilbert S. Aronow. 2008. Management of the Older Patient After Myocardial Infarction. , 327-350.
CrossRef536
JH Choi, MG Lee, J-Y Cho, J-E Lee, KH Kim, K Park. (2008) Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans. Clinical Pharmacology & Therapeutics 83:2, 251-257
CrossRef537
J Chung, EP Brass, RG Ulrich, WR Hiatt. (2008) Effect of Atorvastatin on Energy Expenditure and Skeletal Muscle Oxidative Metabolism at Rest and During Exercise. Clinical Pharmacology & Therapeutics 83:2, 243-250
CrossRef538
Jaspal S Kooner, John C Chambers, Carlos A Aguilar-Salinas, David A Hinds, Craig L Hyde, Gregory R Warnes, Francisco J Gómez Pérez, Kelly A Frazer, Paul Elliott, James Scott, Patrice M Milos, David R Cox, John F Thompson. (2008) Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nature Genetics 40:2, 149-151
CrossRef539
William H Frishman, Wilbert S Aronow, Angela Cheng-Lai. 2008. Cardiovascular Drug Therapy in the Elderly. , 99-136.
CrossRef540
John A. Farmer. (2008) Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Current Diabetes Reports 8:1, 71-77
CrossRef541
Joseph E. Thomas, JoAnne M. Foody. 2008. Disorders of Lipid Metabolism. , 159-178.
CrossRef542
Fernando Fabiani, Teresa Arrobas, Reyes de la Iglesia, Juan Manuel de la Vega, Teresa Holgado, Patricia Fernández-Riejos, Miguel Ángel Rico, Antonio Barco, Salomé Hijano, Eva Martínez, Ana I. Oribe, Carmen Cruz. (2008) Cumplimiento de objetivos terapéuticos en pacientes con revascularización miocárdica en el Área Virgen Macarena de Sevilla. Clínica e Investigación en Arteriosclerosis 20:1, 1-7
CrossRef543
Antonella Sassano, Leonidas C. Platanias. (2008) Statins in tumor suppression. Cancer Letters 260:1-2, 11-19
CrossRef544
Sergio Fazio. (2008) Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. Clinical Therapeutics 30:2, 294-306
CrossRef545
S. M. Grundy. (2008) Thyroid mimetic as an option for lowering low-density lipoprotein. Proceedings of the National Academy of Sciences 105:2, 409-410
CrossRef546
Joshua S. Benner, Timothy W. Smith, Allison A. Petrilla, David Klingman, Sangeeta Goel, Simon S.K. Tang, Nathan D. Wong. (2008) Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States. Journal of the American Society of Hypertension 2:1, 44-53
CrossRef547
Tamio Teramoto, Jun Sasaki, Hirotsugu Ueshima, Genshi Egusa, Makoto Kinoshita, Kazuaki Shimamoto, Hiroyuki Daida, Sadatoshi Biro, Kazuhiko Hirobe, Tohru Funahashi, Koutaro Yokote, Masayuki Yokode. (2008) Treatment - Drug Therapy. Journal of Atherosclerosis and Thrombosis 15:4, 167-178
CrossRef548
Leif R. Erhardt, Lawrence A. Leiter, F.D. Richard Hobbs. (2008) Lipid management in cardiovascular disease prevention guidelines: Strategies and tactics for implementation. Atherosclerosis 196:2, 532
CrossRef549
Michel De Lorgeril, Patricia Salen. (2008) Cholesterol lowering, sudden cardiac death and mortality. Scandinavian Cardiovascular Journal 42:4, 264-267
CrossRef550
Karol E. Watson. (2008) What is the evidence in favor of low-dose statin therapy in 2008?. Current Atherosclerosis Reports 10:1, 33-38
CrossRef551
William E. Braun. 2008. Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 1009-1033.
CrossRef552
U. Sechtem. (2008) Therapie der stabilen Angina pectoris. Der Internist 49:1, 57-68
CrossRef553
Daisuke Uematsu. (2008) New assessment for the risk of ischemic stroke or carotid artery stenosis: Prognostic factor analysis in hypercholesterolemia patients. Nosotchu 30:4, 562-569
CrossRef554
Charles H Hennekens, Wendy R Schneider. (2008) The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Review of Cardiovascular Therapy 6:1, 95-107
CrossRef555
Robert D. Toto, Gloria Lena Vega, Scott M. Grundy. 2008. Cholesterol Management in Patients with Chronic Kidney Disease. , 715-724.
CrossRef556
Dayi Hu, Jue Li, Xiankai Li, for the China Cholesterol Education. (2008) Investigation of Blood Lipid Levels and Statin Interventions in Outpatients With Coronary Heart Disease in China. Circulation Journal 72:12, 2040-2045
CrossRef557
Olga A. Iakoubova, Marc S. Sabatine, Charles M. Rowland, Carmen H. Tong, Joseph J. Catanese, Koustubh Ranade, Katy L. Simonsen, Todd G. Kirchgessner, Christopher P. Cannon, James J. Devlin, Eugene Braunwald. (2008) Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes. Journal of the American College of Cardiology 51:4, 449-455
CrossRef558
B. M. Biccard. (2008) A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients. Anaesthesia 63:1, 52-64
CrossRef559
Karim El Harchaoui, Fatima Akdim, Erik S G Stroes, Mieke D Trip, John J P Kastelein. (2008) Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins. American Journal of Cardiovascular Drugs 8:4, 233-242
CrossRef560
Jeffrey A. Pfefferkorn, Scott D. Larsen, Chad Van Huis, Roderick Sorenson, Tom Barton, Thomas Winters, Bruce Auerbach, Chenyan Wu, Thaddeus J. Wolfram, Hongliang Cai, Kathleen Welch, Nadia Esmaiel, JoAnn Davis, Richard Bousley, Karl Olsen, Sandra Bak Mueller, Thomas Mertz. (2008) Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption. Bioorganic & Medicinal Chemistry Letters 18:2, 546-553
CrossRef561
Ilke Sipahi, E Murat Tuzcu. (2008) Candidate Mechanisms for Regression of Coronary Atherosclerosis with High-Dose Statins. American Journal of Cardiovascular Drugs 8:6, 365-371
CrossRef562
Chao-Yung Wang, Ping-Yen Liu, James K. Liao. (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine 14:1, 37-44
CrossRef563
Mikael Mazighi, Philippa C Lavallée, Julien Labreuche, Pierre Amarenco. (2007) Statin therapy and stroke prevention: what was known, what is new and what is next?. Current Opinion in Lipidology 18:6, 622-625
CrossRef564
Todd M. Brown, Vera Bittner. (2007) Management of stable patients with coronary heart disease: Clinical implications of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. Journal of Clinical Lipidology 1:6, 564-574
CrossRef565
David J. A. Jenkins, Andrea R. Josse, Julia M. W. Wong, Tri H. Nguyen, Cyril W. C. Kendall. (2007) The portfolio diet for cardiovascular risk reduction. Current Atherosclerosis Reports 9:6, 501-507
CrossRef566
Dursun Duman, Refik Demirtunc, Sinan Sahin, Kenan Esertas. (2007) The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study. Journal of Cardiovascular Medicine 8:12, 1007-1011
CrossRef567
AMIT KUMAR, CHRISTOPHER P. CANNON. (2007) Importance of Intensive Lipid Lowering in Acute Coronary Syndrome and Percutaneous Coronary Intervention. Journal of Interventional Cardiology 20:6, 447-457
CrossRef568
V. Schächinger. (2007) Betreuung von Patienten nach Koronarstentimplantation. Der Internist 48:12, 1365-1375
CrossRef569
Andrew Moore, Binh An P. Phan, Catherine Challender, Jayne Williamson, Santica Marcovina, Xue-Qiao Zhao. (2007) Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. Journal of Clinical Lipidology 1:6, 620-625
CrossRef570
Dhakshinamurthy Vijay Anand, Eric Lim, Daniel Darko, Paul Bassett, David Hopkins, David Lipkin, Roger Corder, Avijit Lahiri. (2007) Determinants of Progression of Coronary Artery Calcification in Type 2 Diabetes. Journal of the American College of Cardiology 50:23, 2218-2225
CrossRef571
Martin Duerden. (2007) Absence of policy on how to use statins in England and Wales: do not let JBS2 fill the void. International Journal of Clinical Practice 61:12, 1967-1970
CrossRef572
Alipio Mangas Rojas, Francisco Gómez Rodríguez. (2007) Tratamiento multifactorial de la arteriosclerosis. Medicina Clínica 129:20, 785-796
CrossRef573
Jennifer G Robinson, Michael H Davidson, Arvind Shah, Jianxin Lin, David Neff, Paul T DeLucca, Joanne E Tomassini, Enrico Veltri, Andrew M Tershakovec. (2007) Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65–74 and 75 years and older. Aging Health 3:6, 691-705
CrossRef574
John M Galla, Stephen J Nicholls. (2007) Impact of statin therapy on the artery wall in the low-risk patient: implications from the METEOR study. Future Lipidology 2:6, 595-601
CrossRef575
Joanna M. Young, Christopher M. Florkowski, Sarah L. Molyneux, Roberta G. McEwan, Christopher M. Frampton, Peter M. George, Russell S. Scott. (2007) Effect of Coenzyme Q10 Supplementation on Simvastatin-Induced Myalgia. The American Journal of Cardiology 100:9, 1400-1403
CrossRef576
Sharon Cresci. (2007) Pharmacogenetics of the PPAR genes and cardiovascular disease. Pharmacogenomics 8:11, 1581-1595
CrossRef577
Pierre Amarenco. (2007) Atorvastatin in prevention of stroke and transient ischaemic attack. Expert Opinion on Pharmacotherapy 8:16, 2789-2797
CrossRef578
Christopher M. Rembold. (2007) To statin or to non-statin in coronary disease—considering absolute risk is the answer. Atherosclerosis 195:1, 1-6
CrossRef579
Catherine Y. Campbell, Juan J. Rivera, Roger S. Blumenthal. (2007) Residual risk in statin-treated patients: Future therapeutic options. Current Cardiology Reports 9:6, 499-505
CrossRef580
A. Vogt, U. Kassner, U. Hostalek, E. Steinhagen-Thiessen. (2007) Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan®). International Journal of Clinical Practice 61:11, 1914-1921
CrossRef581
Donald A. Smith. (2007) Treatment of the Dyslipidemia of Insulin Resistance. Medical Clinics of North America 91:6, 1185-1210
CrossRef582
Annemarie Armani, Peter P. Toth. (2007) SPARCL: The glimmer of statins for stroke risk reduction. Current Atherosclerosis Reports 9:5, 347-351
CrossRef583
Dennis L. DeSilvey. (2007) Outcomes for the Elderly Cohort in the Treating to New Targets Trial. The American Journal of Geriatric Cardiology 16:6, 386-387
CrossRef584
Loukianos S. Rallidis, John Lekakis, Dimitrios T. Kremastinos. (2007) Current questions regarding the use of statins in patients with coronary heart disease. International Journal of Cardiology 122:3, 188-194
CrossRef585
Madhavi Koka, Julie Joseph, Wilbert S. Aronow. (2007) Prevalence of Adequate and of Optimal Control of Serum Low-Density Lipoprotein Cholesterol in an Academic Nursing Home. Journal of the American Medical Directors Association 8:9, 604-606
CrossRef586
Stanley G. Rockson, Emil M. deGoma, Gregg C. Fonarow. (2007) Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 21:5, 375-388
CrossRef587
Scott D. Larsen, Toni-Jo Poel, Kevin J. Filipski, Jeffrey T. Kohrt, Jeffrey A. Pfefferkorn, Roderick J. Sorenson, Bradley D. Tait, Valerie Askew, Lisa Dillon, Jeffrey C. Hanselman, Gina H. Lu, Andrew Robertson, Catherine Sekerke, Mark C. Kowala, Bruce J. Auerbach. (2007) Pyrazole inhibitors of HMG-CoA reductase: An attempt to dramatically reduce synthetic complexity through minimal analog re-design. Bioorganic & Medicinal Chemistry Letters 17:20, 5567-5572
CrossRef588
Sabina A. Murphy, Christopher P. Cannon, Stephen D. Wiviott, James A. de Lemos, Michael A. Blazing, Carolyn H. McCabe, Robert M. Califf, Eugene Braunwald. (2007) Effect of Intensive Lipid-Lowering Therapy on Mortality After Acute Coronary Syndrome (a Patient-Level Analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 Trials). The American Journal of Cardiology 100:7, 1047-1051
CrossRef589
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef590
Lawrence A. Leiter, Robert S. Rosenson, Evan Stein, John P.D. Reckless, Karl-Ludwig Schulte, Margo Schleman, Paul Miller, Michael Palmer, Froukje Sosef. (2007) Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 194:2, e154-e164
CrossRef591
Juan Ascaso, Pedro Gonzalez Santos, Antonio Hernández Mijares, Alipio Mangas Rojas, Luis Masana Marín, Jesús Millan Nuñez-Cortés, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco Pérez Jimenez, Xavier Pintó, Ignacio Plaza, Juan Rubiés, Manuel Zúñiga. (2007) Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL. Clínica e Investigación en Arteriosclerosis 19:5, 252-263
CrossRef592
James O. Mudd, Barry A. Borlaug, Peter V. Johnston, Brian G. Kral, Rosanne Rouf, Roger S. Blumenthal, Peter O. Kwiterovich. (2007) Beyond Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 50:18, 1735-1741
CrossRef593
Lizzy M. Brewster, Gideon Mairuhu, August Sturk, Gert A. van Montfrans. (2007) Distribution of creatine kinase in the general population: Implications for statin therapy. American Heart Journal 154:4, 655-661
CrossRef594
Barter, Philip, Gotto, Antonio M., LaRosa, John C., Maroni, Jaman, Szarek, Michael, Grundy, Scott M., Kastelein, John J.P., Bittner, Vera, Fruchart, Jean-Charles, . (2007) HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine 357:13, 1301-1310
Full Text595
Wilbert S. Aronow. (2007) Treatment After Myocardial Infarction. Comprehensive Therapy 33:1, 39-47
CrossRef596
John B. Kostis. (2007) The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease. Cardiovascular Drugs and Therapy 21:4, 297-309
CrossRef597
Uwe Fuhr. (2007) What is the true risk of a pharmacokinetic drug–drug interaction?. European Journal of Clinical Pharmacology 63:10, 897-899
CrossRef598
L. Andrén, Å Andreasson, R. Eggertsen. (2007) Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia. European Journal of Clinical Pharmacology 63:10, 913-916
CrossRef599
Pamela R. Kushner. (2007) Can Intensive Statin Therapy Halt the Progression of Atherosclerosis? Recent Evidence and Potential Implications for Patient Management. Progress in Cardiovascular Nursing 22:4, 207-213
CrossRef600
Michael H. Davidson. (2007) Targeting High-Density Lipoprotein Cholesterol in the Management of Cardiovascular Disease. The American Heart Hospital Journal 5:4, 210-216
CrossRef601
J. Shepherd. (2007) Dyslipidaemia in diabetic patients: time for a rethink. Diabetes, Obesity and Metabolism 9:5, 609-616
CrossRef602
John C. LaRosa, Scott M. Grundy, John J.P. Kastelein, John B. Kostis, Heiner Greten. (2007) Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT] Study). The American Journal of Cardiology 100:5, 747-752
CrossRef603
Peale Chuang, Anthony J Langone. (2007) Ezetimibe Reduces Low-Density Lipoprotein Cholesterol (LDL-C) in Renal Transplant Patients Resistant to HMG-CoA Reductase Inhibitors. American Journal of Therapeutics 14:5, 438-441
CrossRef604
Stephen J. Nicholls, Srinivasa Kalidindi, Steven E. Nissen. (2007) Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. Current Cardiovascular Risk Reports 1:4, 290-295
CrossRef605
Robert M Guthrie, Daniel R Martin. (2007) The safety of rosuvastatin: effects on renal and hepatic function. Expert Opinion on Drug Safety 6:5, 573-581
CrossRef606
Maurizio Trevisan, Saverio Stranges. (2007) Reply to Drs Vos, Ravnskov, Mascitelli and Pezzetta. Nutrition, Metabolism and Cardiovascular Diseases 17:7, e21-e23
CrossRef607
Irene F. Gazi, Stella S. Daskalopoulou, Devaki R. Nair, Dimitri P. Mikhailidis. (2007) Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current Medical Research and Opinion 23:9, 2183-2192
CrossRef608
&NA;. (2007) FULL TEXT Chapter 1: Introduction. European Journal of Cardiovascular Prevention & Rehabilitation 14:Supplement 2, S2-S113
CrossRef609
Gregory A. Nichols, Soma Nag, Wiley Chan. (2007) Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. American Heart Journal 154:3, 554-560
CrossRef610
Scott M. Grundy. (2007) Cardiovascular and Metabolic Risk Factors: How Can We Improve Outcomes in the High-Risk Patient?. The American Journal of Medicine 120:9, S3-S8
CrossRef611
Alexander Riad, Jing Du, Sebastian Stiehl, Dirk Westermann, Zarah Mohr, Meike Sobirey, Wolfram Doehner, Volker Adams, Matthias Pauschinger, Heinz Peter Schultheiss, Carsten Tschöpe. (2007) Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. European Journal of Pharmacology 569:3, 204-211
CrossRef612
Jeffrey A. Pfefferkorn, Yuntao Song, Kuai-Lin Sun, Steven R. Miller, Bharat K. Trivedi, Chulho Choi, Roderick J. Sorenson, Larry D. Bratton, Paul C. Unangst, Scott D. Larsen, Toni-Jo Poel, Xue-Min Cheng, Chitase Lee, Noe Erasga, Bruce Auerbach, Valerie Askew, Lisa Dillon, Jeffrey C. Hanselman, Zhiwu Lin, Gina Lu, Andrew Robertson, Karl Olsen, Thomas Mertz, Catherine Sekerke, Alexander Pavlovsky, Melissa S. Harris, Graeme Bainbridge, Nicole Caspers, Huifen Chen, Matthias Eberstadt. (2007) Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorganic & Medicinal Chemistry Letters 17:16, 4538-4544
CrossRef613
Xue-Qiao Zhao, Binh An P. Phan, Baocheng Chu, Frank Bray, Andrew B. Moore, Nayak L. Polissar, J. Theodore Dodge, Colin D. Lee, Thomas S. Hatsukami, Chun Yuan. (2007) Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: Study design of Carotid Plaque Composition Study. American Heart Journal 154:2, 239-246
CrossRef614
Evan A. Stein, Leiv Ose, Kjetil Retterstøl, Serena Tonstad, Margo Schleman, Susan Harris, Philip Sager. (2007) Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. Journal of Clinical Lipidology 1:4, 280-286
CrossRef615
Kosmas I. Paraskevas, George Hamilton, Dimitri P. Mikhailidis. (2007) Statins: An essential component in the management of carotid artery disease. Journal of Vascular Surgery 46:2, 373-386.e9
CrossRef616
Fatima Akdim, Karim El Harchaoui, Erik SG Stroes, John JP Kastelein. (2007) Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012. Future Lipidology 2:4, 387-393
CrossRef617
Kevin Jon Williams, Jonathan E Feig, Edward A Fisher. (2007) Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. Current Opinion in Lipidology 18:4, 443-450
CrossRef618
Jordan Asher, Mark Houston. (2007) Statins and C-Reactive Protein Levels. The Journal of Clinical Hypertension 9:8, 622-628
CrossRef619
Anne Carol Goldberg. (2007) Combination therapy of dyslipidemia. Current Treatment Options in Cardiovascular Medicine 9:4, 249-258
CrossRef620
C. Farsang, V. Athyros, A. Gaw. (2007) A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study*. Current Medical Research and Opinion 23:8, 1945-1956
CrossRef621
O. Wiklund, L. Håversen, C. Pettersson, L. M. Hultén. (2007) How can we prevent cardiovascular disease in diabetes. Journal of Internal Medicine 262:2, 199-207
CrossRef622
Srinivasan Rajagopalan, Evo Alemao, Liz Finch, Don Yin. (2007) Impact of new Joint British Societies’ (JBS 2) guidelines on prevention of cardiovascular disease: evaluation of serum total cholesterol goal achievement in UK clinical practice*. Current Medical Research and Opinion 23:8, 2027-2034
CrossRef623
Krista M. Dale, C. Michael White, Nickole N. Henyan, Jeffrey Kluger, Craig I. Coleman. (2007) Impact of Statin Dosing Intensity on Transaminase and Creatine Kinase. The American Journal of Medicine 120:8, 706-712
CrossRef624
Stephen J. Nicholls, E. Murat Tuzcu, Steven E. Nissen. (2007) Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?. Current Atherosclerosis Reports 9:4, 266-273
CrossRef625
K. K. Ray, C. P. Cannon, E. Braunwald. (2007) Recent trials of lipid lowering. International Journal of Clinical Practice 61:7, 1145-1159
CrossRef626
L. R. Erhardt, F. D. R. Hobbs. (2007) A global survey of physicians’ perceptions on cholesterol management: the From The Heart study. International Journal of Clinical Practice 61:7, 1078-1085
CrossRef627
Helena Gylling, David E. Laaksonen, Mustafa Atalay, Maarit Hallikainen, Leo Niskanen, Tatu A. Miettinen. (2007) Markers of absorption and synthesis of cholesterol in men with type 1 diabetes. Diabetes/Metabolism Research and Reviews 23:5, 372-377
CrossRef628
Birna Bjarnason-Wehrens, Klaus Held, Eike Hoberg, Marthin Karoff, Bernhard Rauch. (2007) Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha). Clinical Research in Cardiology Supplements 2:3, 1-54
CrossRef629
Bernd Genser, Winfried März. (2007) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis. Clinical Research in Cardiology 96:7, 526-526
CrossRef630
Peter P. Toth, Chris J. Cadman. (2007) Implications of recent statin trials for primary care practice. Journal of Clinical Lipidology 1:3, 182-190
CrossRef631
Helen M. Colhoun. (2007) Lipid goals in metabolic syndrome and diabetes. Current Atherosclerosis Reports 9:4, 286-295
CrossRef632
John C. LaRosa. (2007) Low-Density Lipoprotein Cholesterol Reduction: The End Is More Important Than the Means. The American Journal of Cardiology 100:2, 240-242
CrossRef633
Luis Castilla-Guerra, Manuel Balbuena García, María del Carmen Fernández-Moreno. (2007) Estatinas en la prevención secundaria del ictus en la comunidad. Atención Primaria 39:7, 373-376
CrossRef634
Lluís Masana. (2007) ¿Qué tablas de riesgo cardiovascular debemos utilizar?. Revista Española de Cardiología 60:7, 690-692
CrossRef635
Jobien K. Olijhoek, Yolanda van der Graaf, Steven M. Haffner, Frank L.J. Visseren. (2007) Defining the metabolic syndrome: Resolving unresolved issues?. European Journal of Internal Medicine 18:4, 309-313
CrossRef636
Alawi A. Alsheikh-Ali, Prasad V. Maddukuri, Hui Han, Richard H. Karas. (2007) Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer. Journal of the American College of Cardiology 50:5, 409-418
CrossRef637
Wilbert S. Aronow, William H. Frishman, Angela Cheng-Lai. (2007) Cardiovascular Drug Therapy in the Elderly. Cardiology in Review 15:4, 195-215
CrossRef638
Jarett D. Berry, Donald M. Lloyd-Jones, Daniel B. Garside, Philip Greenland. (2007) Framingham risk score and prediction of coronary heart disease death in young men. American Heart Journal 154:1, 80-86
CrossRef639
Graham Jackson. (2007) Stable and also unstable coronary disease - COURAGE and the importance of optimal medical therapy. International Journal of Clinical Practice 61:6, 883-883
CrossRef640
Ramprasad Gadi, Frederick F. Samaha. (2007) Dyslipidemia in type 2 diabetes mellitus. Current Diabetes Reports 7:3, 228-234
CrossRef641
Marie-Hélène Bouchard, Alice Dragomir, Lucie Blais, Anick Bérard, Danielle Pilon, Sylvie Perreault. (2007) Impact of adherence to statins on coronary artery disease in primary prevention. British Journal of Clinical Pharmacology 63:6, 698-708
CrossRef642
J Rumi Jaumdally, Chetan Varma, Gregory YH Lip. (2007) Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. Expert Opinion on Pharmacotherapy 8:9, 1235-1243
CrossRef643
David C. Goff, Hertzel C. Gerstein, Henry N. Ginsberg, William C. Cushman, Karen L. Margolis, Robert P. Byington, John B. Buse, Saul Genuth, Jeffrey L. Probstfield, Denise G. Simons-Morton. (2007) Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. The American Journal of Cardiology 99:12, S4-S20
CrossRef644
Henry N. Ginsberg, Denise E. Bonds, Laura C. Lovato, John R. Crouse, Marshall B. Elam, Peter E. Linz, Patrick J. O’Connor, Lawrence A. Leiter, Daniel Weiss, Edward Lipkin, Jerome L. Fleg. (2007) Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. The American Journal of Cardiology 99:12, S56-S67
CrossRef645
Douwe J. Mulder, Paul L. Haelst, Martgriet H. Wobbes, Rijk O. Gans, Felix Zijlstra, Johan F. May, Andries J. Smit, Jan Willem Cohen Tervaert, Jasper J. Doormaal. (2007) The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress. Cardiovascular Drugs and Therapy 21:2, 91-97
CrossRef646
F. Chenot, P. F. Montant, O. Marcovitch, M. Blaimont, A. de Meester, O. S. Descamps. (2007) Co-administration of ezetimibe and simvastatin in acute myocardial infarction. European Journal of Clinical Investigation 37:5, 357-363
CrossRef647
Harm H.H. Feringa, Stefanos E. Karagiannis, Virginie H. van Waning, Eric Boersma, Olaf Schouten, Jeroen J. Bax, Don Poldermans. (2007) The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. Journal of Vascular Surgery 45:5, 936-943
CrossRef648
Michael H. Davidson, Jennifer G. Robinson. (2007) Safety of Aggressive Lipid Management. Journal of the American College of Cardiology 49:17, 1753-1762
CrossRef649
Brian R. Chambers, Neil G. Roberts. (2007) Asymptomatic carotid artery stenosis. Current Treatment Options in Cardiovascular Medicine 9:2, 81-89
CrossRef650
E. Murat Tuzcu, Stephen J. Nicholls. (2007) Statins. Journal of the American College of Cardiology 49:20, 2010-2012
CrossRef651
(2007) Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española de Cardiología 60:5, 525.e1-525.e64
CrossRef652
Pierre Amarenco. (2007) Lipid lowering and recurrent stroke: a definitive answer?. International Journal of Stroke 2:2, 111-113
CrossRef653
Sandra J. Lewis. (2007) Perspectives and current strategies for dyslipidemia in women. Current Cardiovascular Risk Reports 1:2, 159-166
CrossRef654
A. Lawrence Gould, Glenn M. Davies, Evo Alemao, Donald D. Yin, John R. Cook. (2007) Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clinical Therapeutics 29:5, 778-794
CrossRef655
Giuseppe Boriani, Cinzia Valzania, Igor Diemberger, Mauro Biffi, Cristian Martignani, Matteo Bertini, Matteo Ziacchi, Giulia Domenichini, Davide Saporito, Claudio Rapezzi, Angelo Branzi. (2007) Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opinion on Investigational Drugs 16:5, 605-623
CrossRef656
M. C. Kontos, S. E. Joyner, C. S. Roberts, F. P. Anderson, J. P. Ornato, J. L. Tatum, R. L. Jesse. (2007) Implication of the New Low-Density Lipoprotein Goals in Dyslipidemia Management of Patients With Acute Coronary Syndrome. Mayo Clinic Proceedings 82:5, 551-555
CrossRef657
C. J. Lavie, R. V. Milani, J. H. O'Keefe. (2007) Statin Wars-Emphasis on Potency vs Event Reduction and Safety?. Mayo Clinic Proceedings 82:5, 539-542
CrossRef658
Kastelein, John J.P., van Leuven, Sander I., Burgess, Leslie, Evans, Greg W., Kuivenhoven, Jan A., Barter, Philip J., Revkin, James H., Grobbee, Diederick E., Riley, Ward A., Shear, Charles L., Duggan, William T., Bots, Michiel L., . (2007) Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. New England Journal of Medicine 356:16, 1620-1630
Full Text659
Boden, William E., O'Rourke, Robert A., Teo, Koon K., Hartigan, Pamela M., Maron, David J., Kostuk, William J., Knudtson, Merril, Dada, Marcin, Casperson, Paul, Harris, Crystal L., Chaitman, Bernard R., Shaw, Leslee, Gosselin, Gilbert, Nawaz, Shah, Title, Lawrence M., Gau, Gerald, Blaustein, Alvin S., Booth, David C., Bates, Eric R., Spertus, John A., Berman, Daniel S., Mancini, G.B. John, Weintraub, William S., . (2007) Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine 356:15, 1503-1516
Full Text660
M. D. Blagden, R. Chipperfield. (2007) Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Current Medical Research and Opinion 23:4, 767-775
CrossRef661
Jaakko Tuomilehto. (2007) Rosuvastatin: the most efficient treatment option for patients with dyslipidemia. Future Lipidology 2:2, 127-141
CrossRef662
L. Wei, T. M. MacDonald, A. D. Watson, M. J. Murphy. (2007) Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiology and Drug Safety 16:4, 385-392
CrossRef663
John A. Farmer. (2007) Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Current Atherosclerosis Reports 9:2, 162-168
CrossRef664
Allan D Sniderman. (2007) Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go. Current Opinion in Endocrinology, Diabetes and Obesity 14:2, 116-123
CrossRef665
John J. P. Kastelein, Sander I. van Leuven, Gregory W. Evans, Ward A. Riley, James H. Revkin, Charles L. Shear, Michiel L. Bots. (2007) Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*. Current Medical Research and Opinion 23:4, 885-894
CrossRef666
Sanjiv J. Shah, Bryan Ristow, Sadia Ali, Bee Ya Na, Nelson B. Schiller, Mary A. Whooley. (2007) Acute Myocardial Infarction in Patients With Versus Without Aortic Valve Sclerosis and Effect of Statin Therapy (from the Heart and Soul Study). The American Journal of Cardiology 99:8, 1128-1133
CrossRef667
Félix Miguel García, Alejandra García Ortiz, M. José Montero Alonso, Alejandro Merino Senovilla, Ruperto Sanz Cantalapiedra, José Ángel Maderuelo Fernández. (2007) PAPPS cardiovascular 2005: un análisis crítico. Atención Primaria 39:4, 201-206
CrossRef668
Gerd Schmitz, Anna Schmitz-Mądry, Peter Ugocsai. (2007) Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Current Opinion in Lipidology 18:2, 164-173
CrossRef669
Eberhard RITZ, Ralf DIKOW, Marie-Luise GROSS. (2007) Dialysis, cardiovascular disease, and the future. Hemodialysis International 11:s1, S2-S11
CrossRef670
Alberico L. Catapano, Terje R. Pedersen, Guy de Backer. (2007) Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. European Journal of Cardiovascular Prevention & Rehabilitation 14:2, 340-345
CrossRef671
G FLETCHER, V BUFALINO, F COSTA, L GOLDSTEIN, D JONES, L SMAHA, S SMITHJR, N STONE. (2007) Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. The American Journal of Cardiology 99:6, S1-S35
CrossRef672
Navin K Kapur. (2007) Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Review of Cardiovascular Therapy 5:2, 161-175
CrossRef673
B. Greg Brown, Xue-Qiao Zhao, Marian C. Cheung. (2007) Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. Journal of Clinical Lipidology 1:1, 88-94
CrossRef674
Herbert Schuster. (2007) The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Review of Cardiovascular Therapy 5:2, 177-193
CrossRef675
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura, Toru Kita, Akira Kitabatake, Noriaki Nakaya, Toshiie Sakata, Kazuyuki Shimada, Kunio Shirato. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The Lancet 369:9567, 1090-1098
CrossRef676
Dan Fintel, Amie Joyce, Joan Mackell, Jennifer Graff, Erik Kuntze, Daniel A. Ollendorf. (2007) Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients. Value in Health 10:2, 161-169
CrossRef677
Eric J. Stanek, Chaitanya Sarawate, Vincent J. Willey, Scott L. Charland, Mark J. Cziraky. (2007) Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Current Medical Research and Opinion 23:3, 553-563
CrossRef678
Bernard Prigent. (2007) Canadian Journal of Cardiology 23:4, 319
CrossRef679
Stephen J Nicholls, Adnan K Chhatriwalla, Pia Lundman. (2007) Impact of statins on atherosclerotic plaque. Future Cardiology 3:2, 157-164
CrossRef680
W. März, T.B. Grammer. (2007) Senkung des LDL-Cholesterins. Der Internist 48:3, 319-326
CrossRef681
Christie M. Ballantyne, Robert Weiss, Tiziano Moccetti, Anja Vogt, Bernd Eber, Froukje Sosef, Emma Duffield. (2007) Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). The American Journal of Cardiology 99:5, 673-680
CrossRef682
ZHEN KUN YANG, WEI FENG SHEN, RUI YAN ZHANG, YE KONG, JIAN SHENG ZHANG, JIAN HU, QI ZHANG, FENG HUA DING. (2007) Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention with Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease. Journal of Interventional Cardiology 20:1, 10-16
CrossRef683
S. Böhler, H. Scharnagl, F. Freisinger, T. Stojakovic, H. Glaesmer, J. Klotsche, L. Pieper, D. Pittrow, W. Kirch, H. Schneider, G.K. Stalla, H. Lehnert, A.M. Zeiher, S. Silber, U. Koch, G. Ruf, W. März, H-U. Wittchen. (2007) Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 190:2, 397-407
CrossRef684
Lisa Christopher-Stine. (2007) Statin myopathy: an update. Current Opinion in Internal Medicine 6:1, 102-108
CrossRef685
L. Castilla Guerra, M.C. Fernández Moreno, M.D. Jiménez Hernández, J.M. López Chozas. (2007) Papel actual de las estatinas en la prevención del ictus. Revista Clínica Española 207:2, 83-85
CrossRef686
Matthew Silva, Michele L. Matthews, Courtney Jarvis, Nicole M. Nolan, Paul Belliveau, Michael Malloy, Pritesh Gandhi. (2007) Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clinical Therapeutics 29:2, 253-260
CrossRef687
Daniel J Rader. (2007) Mechanisms of Disease: HDL metabolism as a target for novel therapies. Nature Clinical Practice Cardiovascular Medicine 4:2, 102-109
CrossRef688
Javier Sanz, Pedro R Moreno, Valentin Fuster. (2007) Update on advances in atherothrombosis. Nature Clinical Practice Cardiovascular Medicine 4:2, 78-89
CrossRef689
(2007) References. American Journal of Kidney Diseases 49:2, S160-S179
CrossRef690
Peter H. Jones. (2007) Clinical Significance of Recent Lipid Trials on Reducing Risk in Patients with Type 2 Diabetes Mellitus. The American Journal of Cardiology 99:4, 133-140
CrossRef691
Michael Miller. (2007) Optimal Treatment of Dyslipidemia in High-Risk Patients: Intensive Statin Treatment or Combination Therapy?. Preventive Cardiology 10:1, 31-35
CrossRef692
Ryozo Nagai, Tohru Izumi, Masahiko Kurabayashi, Hiroyuki Daida, Taiki Tojo, Akira Hasegawa, Katsumi Miyauchi, Dobun Hayashi, Takahide Kohro, Yoshihiro Okada, Tsutomu Yamazaki, The JCADII Investigators. (2007) Rationale and Design of a Study to Examine Lower Targets for Low-Density Lipoprotein-Cholesterol and Blood Pressure in Coronary Artery Disease Patients. Circulation Journal 72:4, 515-520
CrossRef693
Cheol-Ho Kim, Kwang-Il Kim, Jae-Hyung Kim, Jae-Eun Jun, Jong-Hwa Bae, Jae-Woo Lee, Kyung-Hoon Choe, Soon-Pyo Hong, Bang-Hun Lee. (2007) Prospective Study to Evaluate the Efficacy and Safety of Pitavastatin in Patients with Risk Factor of Cardiovascular Disease(PEACE Study). Korean Circulation Journal 37:1, 16
CrossRef694
Tracie C. Collins, Peter H. Jones. (2007) Statin therapy: Is the percent reduction or the attained low-density lipoprotein cholesterol level more important?. Current Atherosclerosis Reports 9:1, 10-17
CrossRef695
Hiroaki Takashima, Yukio Ozaki, Tatsuya Yasukawa, Katsuhisa Waseda, Kenji Asai, Yoshinori Wakita, Yasuo Kuroda, Takashi Kosaka, Yasushi Kuhara, Takayuki Ito. (2007) Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque. Circulation Journal 71:11, 1678-1684
CrossRef696
Gy??rgy Paragh, L??szlo M??rk, K??roly Z??molyi, Gyula Pados, P??ter Ofner. (2007) Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Hungary. Clinical Drug Investigation 27:9, 647-660
CrossRef697
Lluís Masana. (2007) Which Cardiovascular Risk Tables Should We Use?. Revista Española de Cardiología (English Edition) 60:7, 690-692
CrossRef698
G.L. Moneta. (2007) Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. Yearbook of Vascular Surgery 2007, 90-92
CrossRef699
Ryoko Mitsutake, Shin-ichiro Miura, Keisuke Okamura, Hideya Niimura, Akira Kawamura, Keijiro Saku. (2007) Successful Intensive Lipid-lowering Therapy Using Atorvastatin Stabilizes Coronary Artery Plaque as Assessed by Multi-detector Row Computed Tomography. Internal Medicine 46:12, 859-863
CrossRef700
Marcello Arca. (2007) Atorvastatin Efficacy in the Prevention of Cardiovascular Events in Patients with Diabetes Mellitus and/or Metabolic Syndrome. Drugs 67:Supplement 1, 43-54
CrossRef701
Maurizio Paciaroni, Michael Hennerici, Giancarlo Agnelli, Julien Bogousslavsky. (2007) Statins and Stroke Prevention. Cerebrovascular Diseases 24:2-3, 170-182
CrossRef702
W.J. Howard. (2007) High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. Yearbook of Medicine 2007, 521-523
CrossRef703
Carmen de Pablo y Zarzosa, Alberto Grima-Serrano, Emilio Luengo-Pérez, Pilar Mazón-Ramos. (2007) Prevención cardiovascular y rehabilitación cardiaca. Revista Española de Cardiología 60, 68-78
CrossRef704
Hidekatsu YANAI, Hiroshi YOSHIDA. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:5, 299-304
CrossRef705
Marcello Arca, Achille Gaspardone. (2007) Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. Drugs 67:Supplement 1, 29-42
CrossRef706
Anna Frisinghelli, Antonio Mafrici. (2007) Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease. Clinical Drug Investigation 27:9, 591-604
CrossRef707
Rubin Minhas. (2007) Statin utilisation - recognising the role of the invisible hand. International Journal of Clinical Practice 61:1, 3-6
CrossRef708
Tadateru Takayama, Takafumi Hiro, Masakazu Yamagishi, Hiroyuki Daida, Satoshi Saito, Tetsu Yamaguchi, Masunori Matsuzaki. (2007) Rationale and Design for a Study Using Intravascular Ultrasound to Evaluate Effects of Rosuvastatin on Coronary Artery Atheroma in Japanese Subjects. Circulation Journal 71:2, 271-275
CrossRef709
Mark R Goldstein. (2007) Cholesterol lowering in patients with CHD and metabolic syndrome. The Lancet 369:9555, 25
CrossRef710
B. Fuentes, M.A. Ortega-Casarrubios, P. Martínez, E. Díez-Tejedor. (2007) Action on Vascular Risk Factors: Importance of Blood Pressure and Lipid Lowering in Stroke Secondary Prevention. Cerebrovascular Diseases 24:1, 96-106
CrossRef711
Juan Ascaso, Pedro Gonzalez Santos, Antonio Hernandez Mijares, Alipio Mangas Rojas, Luis Masana, Jesus Millan, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco Perez Jimenez, Xavier Pint??, Ignacio Plaza, Juan Rubi??s, Manuel Z????iga. (2007) Management of Dyslipidemia in the Metabolic Syndrome. American Journal of Cardiovascular Drugs 7:1, 39-58
CrossRef712
Juan J. Rivera, Roger S. Blumenthal, Dominique Ashen. (2007) Low-Density Lipoprotein Cholesterol in High-Risk Asymptomatic Individuals. Journal of the CardioMetabolic Syndrome 2:1, 49-52
CrossRef713
W.J. Howard. (2007) High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. Yearbook of Endocrinology 2007, 106
CrossRef714
Achille Gaspardone, Marcello Arca. (2007) Atorvastatin. Drugs 67:Supplement 1, 55-62
CrossRef715
(2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
CrossRef716
Valentine Charlton-Menys, Paul N Durrington. (2007) Squalene Synthase Inhibitors. Drugs 67:1, 11-16
CrossRef717
Michael Clearfield. (2007) Clinical trials report. Current Atherosclerosis Reports 9:1, 5-9
CrossRef718
Michael H. Davidson. (2007) Squalene synthase inhibition: A novel target for the management of dyslipidemia. Current Atherosclerosis Reports 9:1, 78-80
CrossRef719
Hongkeun Cho. (2007) High Density Lipoprotein Cholesterol Comes of Age. Korean Circulation Journal 37:5, 187
CrossRef720
Wilbert S. Aronow. (2007) Intensive Statin Treatment or Combination Therapy in High-Risk Patients. Preventive Cardiology 10:1, 7-8
CrossRef721
Verna Welch, Simon S K Tang. (2007) Treatment and Control of BP and Lipids in Patients with Hypertension and Additional Risk Factors. American Journal of Cardiovascular Drugs 7:5, 381-389
CrossRef722
Kyeong Ho Yun, Hyun-Young Park, Jun-Ho Choi, Mi-Jin Song, Eun Mi Park, Yun Kyung Kim, Sang Jae Rhee, Eun Mi Lee, Je Lee, Nam Jin Yoo, Nam-Ho Kim, Seok Kyu Oh, Jin-Won Jeong. (2007) Comparison of Efficacy and Safety after Administering High Potency Statin to High Risk Patients: Rosuvastatin 10 mg versus Atorvastatin 20 mg. Korean Circulation Journal 37:4, 154
CrossRef723
HP Rang, MM Dale, JM Ritter, RJ Flower. 2007. Atherosclerosis and lipoprotein metabolism. , 321-330.
CrossRef724
Dibyendu De, Ish Khanna. 2007. Chapter 12 Recent Trends in HDL Modulating Therapies. , 177-191.
CrossRef725
Wun-Jae Kim. (2007) Oral Chemotherapy. Journal of the Korean Medical Association 50:5, 464
CrossRef726
Thomas I. Barron, Kathleen Bennett, John Feely. (2006) Impact of high dose statin trials on hospital prescribers. European Journal of Clinical Pharmacology 63:1, 65-72
CrossRef727
Stephen D Wiviott, Christopher P Cannon. (2006) The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Current Opinion in Lipidology 17:6, 626-630
CrossRef728
Munir Boodhwani, Shigetoshi Mieno, Pierre Voisine, Jun Feng, Neel Sodha, Jian Li, Frank W. Sellke. (2006) High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. The Journal of Thoracic and Cardiovascular Surgery 132:6, 1299-1306
CrossRef729
Benjamin Ansell, F. D. Richard Hobbs. (2006) The potential for CETP inhibition to reduce cardiovascular disease risk. Current Medical Research and Opinion 22:12, 2467-2478
CrossRef730
Bruno Vergès. (2006) Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Current Opinion in Lipidology 17:6, 653-658
CrossRef731
Jonathan R Jaffe, Soma S Nag, Pamela B Landsman, Charles M Alexander. (2006) Reassessment of cardiovascular risk in diabetes. Current Opinion in Lipidology 17:6, 644-652
CrossRef732
Wilbert S Aronow. (2006) Management of hyperlipidemia with statins in the older patient. Clinical Interventions in Aging 1:4, 433-438
CrossRef733
B Greg Brown, Karen Hinckley Stukovsky, Xue-Qiao Zhao. (2006) Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Current Opinion in Lipidology 17:6, 631-636
CrossRef734
Marc Hartmann, Clemens von Birgelen, Gary S. Mintz, Gert K. van Houwelingen, Holger Eggebrecht, Dirk Böse, Heinrich Wieneke, Patrick M.J. Verhorst, Raimund Erbel. (2006) Relation Between Plaque Progression and Low-Density Lipoprotein Cholesterol During Aging as Assessed With Serial Long-Term (≥12 Months) Follow-Up Intravascular Ultrasound of the Left Main Coronary Artery. The American Journal of Cardiology 98:11, 1419-1423
CrossRef735
(2006) Statin Therapy after Stroke or Transient Ischemic Attack. New England Journal of Medicine 355:22, 2368-2371
Full Text736
S S Prichard. (2006) Management of hyperlipidemia in patients on peritoneal dialysis: Current approaches. Kidney International 70, S115-S117
CrossRef737
Michael H. Davidson, James M. McKenney, Charles L. Shear, James H. Revkin. (2006) Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels. Journal of the American College of Cardiology 48:9, 1774-1781
CrossRef738
Antonio Maiques Galán. (2006) Nuevas indicaciones y objetivos terapéuticos en las dislipemias. Atención Primaria 38:9, 473-475
CrossRef739
Anders G. Olsson. (2006) Expanding options with a wider range of rosuvastatin doses. Clinical Therapeutics 28:11, 1747-1763
CrossRef740
Edoardo Casiglia, Mario Saugo, Laura Schiavon, Valérie Tikhonoff, Giulio Rigoni, Giancarlo Basso, Alberto Mazza, Enzo Rizzato, Francesco Guglielmi, Bortolo Martini, Anna Bascelli, Sandro Caffi, Achille C. Pessina. (2006) Reduction of cardiovascular risk and mortality: A population-based approach. Advances in Therapy 23:6, 905-920
CrossRef741
Vera Bittner. (2006) Perspectives on dyslipidemia and coronary heart disease in women: an update. Current Opinion in Cardiology 21:6, 602-607
CrossRef742
Jacob A Udell, Joel G Ray. (2006) Primary and secondary prevention of heart failure with statins. Expert Review of Cardiovascular Therapy 4:6, 917-926
CrossRef743
Richard V. Milani, Carl J. Lavie. (2006) Cholesteryl Ester Transfer Protein Inhibition. Journal of the American College of Cardiology 48:9, 1791-1792
CrossRef744
Allen J. Taylor, Hyun J. Lee, Lance E. Sullenberger. (2006) The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3*. Current Medical Research and Opinion 22:11, 2243-2250
CrossRef745
David D. Waters, John C. LaRosa, Philip Barter, Jean-Charles Fruchart, Antonio M. Gotto, Roddy Carter, Andrei Breazna, John J.P. Kastelein, Scott M. Grundy. (2006) Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study. Journal of the American College of Cardiology 48:9, 1793-1799
CrossRef746
Adnan K Chhatriwalla, Stephen J Nicholls, Steven E Nissen. (2006) The ASTEROID trial: coronary plaque regression with high-dose statin therapy. Future Cardiology 2:6, 651-654
CrossRef747
Jennifer G. Robinson, Neil J. Stone. (2006) Identifying Patients for Aggressive Cholesterol Lowering: The Risk Curve Concept. The American Journal of Cardiology 98:10, 1405-1408
CrossRef748
Michael H Davidson, Jennifer G Robinson. 2006. Management of Elevated Low-Density Lipoprotein Cholesterol. , 255-294.
CrossRef749
Kiran K. Khush, David D. Waters. (2006) Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials. Journal of Cardiac Failure 12:8, 664-674
CrossRef750
Alberico L. Catapano, Michael H. Davidson, Christie M. Ballantyne, William E. Brady, Russell A. Gazzara, Joanne E. Tomassini, Andrew M. Tershakovec. (2006) Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients*. Current Medical Research and Opinion 22:10, 2041-2053
CrossRef751
Stefano Bellosta, Rodolfo Paoletti, Alberto Corsini. 2006. Safety of Dyslipidemic Agents. , 389-408.
CrossRef752
Manuel Portela Romero, Julio Pombo Romero, Rosendo Bugarín González, Margarita Tasende Souto. (2006) Hipercolesterolemia familiar heterocigota: estudio de utilización de estatinas en condiciones de práctica clínica. Atención Primaria 38:6, 333-338
CrossRef753
Stella S. Daskalopoulou, Dimitri P. Mikhailidis. (2006) Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Current Medical Research and Opinion 22:10, 2037-2039
CrossRef754
J. SHEPHERD. (2006) Who should receive a statin these days? Lessons from recent clinical trials. Journal of Internal Medicine 260:4, 305-319
CrossRef755
Daniel G. Hackam, Mary K. Tan, Peter J. Lin, Pravinsagar G. Mehta, Shahin Jaffer, Martin Kates, Mona Oh, Etienne A. Grima, Anatoly Langer, Shaun G. Goodman. (2006) Supporting a call to action for peripheral artery disease: Insights from two prospective clinical registries. Journal of Vascular Surgery 44:4, 776-781
CrossRef756
Kausik K Ray, Christopher P Cannon. (2006) Intensive statin therapy for treating acute coronary syndromes. Expert Opinion on Investigational Drugs 15:10, 1151-1159
CrossRef757
Vera Bittner. 2006. Women and Coronary Heart Disease. , 689-720.
CrossRef758
Judith Hey-Hadavi. (2006) Commentary on “Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.” Atorvastatin’s effect in Alzheimer’s dementia (LEADe) study. Alzheimer's and Dementia 2:4, 282-283
CrossRef759
Ronald Goldberg. 2006. Type 2 Diabetes. , 187-254.
CrossRef760
Charles Reasner. 2006. The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease. , 409-440.
CrossRef761
Alice YY Cheng, Lawrence A Leiter. (2006) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Current Opinion in Internal Medicine 5:5, 461-465
CrossRef762
Gerd Assmann, Heike Benecke, Albrecht Neiss, Paul Cullen, Helmut Schulte, Kurt Bestehorn. (2006) Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events including Physicians?? Experience and Evaluation). European Journal of Cardiovascular Prevention & Rehabilitation 13:5, 776-783
CrossRef763
Peter P Toth, Antonio M Gotto. 2006. High-Density Lipoprotein Cholesterol. , 295-340.
CrossRef764
Stéphane Bissonnette, Rafik Habib, Fotini Sampalis, Stella Boukas, John S. Sampalis. (2006) Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study – the Ezetrol® Add-On Study. Canadian Journal of Cardiology 22:12, 1035-1044
CrossRef765
M. John Chapman. (2006) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacology & Therapeutics 111:3, 893-908
CrossRef766
Julie Ramos, Qamar A Khan, Martin Thoenes, Bobby V Khan. (2006) Atorvastatin: beyond lipid-lowering effects in the diabetic population. Future Cardiology 2:5, 527-533
CrossRef767
H.-J. Rupprecht. (2006) Kardiovaskuläre Sekundärprävention. Clinical Research in Cardiology 95:S6, vi1-vi5
CrossRef768
C. Luley. (2006) Fettstoffwechselstörungen—Cholesterin und Triglyceride. Clinical Research in Cardiology 95:S6, vi17-vi22
CrossRef769
(2006) Guía sobre el manejo de la angina estable. Versión resumida. Revista Española de Cardiología 59:9, 919-970
CrossRef770
Tina J. Chahil, Henry N. Ginsberg. (2006) Diabetic Dyslipidemia. Endocrinology & Metabolism Clinics of North America 35:3, 491-510
CrossRef771
Nitin Khosla, Henry R. Black. (2006) Expanding the definition of hypertension to incorporate global cardiovascular risk. Current Hypertension Reports 8:5, 384-390
CrossRef772
Prakash Deedwania, Philip Barter, Rafael Carmena, Jean-Charles Fruchart, Scott M Grundy, Steven Haffner, John JP Kastelein, John C LaRosa, Holly Schachner, James Shepherd, David D Waters. (2006) Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. The Lancet 368:9539, 919-928
CrossRef773
Ruth McPherson, Jiri Frohlich, George Fodor, Jacques Genest. (2006) Canadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Canadian Journal of Cardiology 22:11, 913-927
CrossRef774
Peter P. Toth. (2006) Clinical Trials Report. Current Atherosclerosis Reports 8:5, 353-355
CrossRef775
Anders G. Olsson. (2006) Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data. Current Atherosclerosis Reports 8:5, 382-389
CrossRef776
J.V. Nixon. (2006) Lower Is Better?The Contemporary Concept of Low-Density Lipoprotein Lowering in the Preventive Management of Cardiovascular Risk: Does This Apply to All Patients?. Preventive Cardiology 9:4, 219-227
CrossRef777
Haruo Nakamura, Kikuo Arakawa, Hiroshige Itakura, Akira Kitabatake, Yoshio Goto, Takayoshi Toyota, Noriaki Nakaya, Shoji Nishimoto, Masaharu Muranaka, Akira Yamamoto, Kyoichi Mizuno, Yasuo Ohashi. (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. The Lancet 368:9542, 1155-1163
CrossRef778
Michael H Davidson, Jennifer G Robinson. (2006) Lipid-lowering effects of statins: a comparative review. Expert Opinion on Pharmacotherapy 7:13, 1701-1714
CrossRef779
John Mulhall, Patrick Teloken, Gerald Brock, Edward Kim. (2006) Obesity, Dyslipidemias and Erectile Dysfunction: A Report of a Subcommittee of the Sexual Medicine Society of North America. The Journal of Sexual Medicine 3:5, 778-786
CrossRef780
Glen J. Pearson, Gordon A. Francis, Jacques S. Romney, Dawna M. Gilchrist, Andrea Opgenorth, Gabor T. Gyenes. (2006) The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Canadian Journal of Cardiology 22:11, 939-945
CrossRef781
Mohammed H. Moghadasian. (2006) Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice. Atherosclerosis 188:1, 28-34
CrossRef782
T. A. Jacobson. (2006) The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?. Mayo Clinic Proceedings 81:9, 1225-1231
CrossRef783
Michel de Lorgeril, Patricia Salen. (2006) Cholesterol lowering and mortality: Time for a new paradigm?. Nutrition, Metabolism and Cardiovascular Diseases 16:6, 387-390
CrossRef784
Maurizio Trevisan, Saverio Stranges. (2006) Cholesterol lowering and mortality: A great success story!. Nutrition, Metabolism and Cardiovascular Diseases 16:6, 391-394
CrossRef785
Christopher P. Cannon, Benjamin A. Steinberg, Sabina A. Murphy, Jessica L. Mega, Eugene Braunwald. (2006) Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. Journal of the American College of Cardiology 48:3, 438-445
CrossRef786
Anthony S Wierzbicki. (2006) Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidology 1:4, 463-476
CrossRef787
Franz H. Messerli, George L. Bakris, R. David Ferrera, Mark C. Houston, Robert J. Petrella, John M. Flack, William Sun, EunMee Lee, Joel M. Neutel, . (2006) Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial. The Journal of Clinical Hypertension 8:8, 571-583
CrossRef788
David H. Fitchett, Lawrence A. Leiter, Shaun G. Goodman, Anatoly Langer. (2006) Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients. Canadian Journal of Cardiology 22:10, 835-839
CrossRef789
Jessica L. Mega, David A. Morrow, Christopher P. Cannon, Sabina Murphy, Richard Cairns, Paul M. Ridker, Eugene Braunwald. (2006) Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. Journal of Thrombosis and Thrombolysis 22:1, 71-76
CrossRef790
Marc Issandou. (2006) Pharmacological regulation of low density lipoprotein receptor expression: Current status and future developments. Pharmacology & Therapeutics 111:2, 424-433
CrossRef791
Stephen J Nicholls, Ilke Sipahi, Paul Schoenhagen. (2006) The ACTIVATE study: lessons for the future of atherosclerotic therapy. Future Lipidology 1:4, 421-428
CrossRef792
Bernd Genser, Winfried März. (2006) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis. Clinical Research in Cardiology 95:8, 393-404
CrossRef793
Jennifer G Robinson, Michael H Davidson. (2006) How low to target LDL?. Nature Clinical Practice Endocrinology & Metabolism 2:8, 414-415
CrossRef794
Stephen D Wiviott, Christopher P Cannon. (2006) Update on lipid-lowering therapy and LDL-cholesterol targets. Nature Clinical Practice Cardiovascular Medicine 3:8, 424-436
CrossRef795
Jean-Claude Tardif. (2006) Prevention challenges: The era of atherosclerosis regression. Canadian Journal of Cardiology 22, 27C-30C
CrossRef796
Martin Dunkelgrun, Olaf Schouten, Harm HH Feringa, Radosav Vidakovic, Don Poldermans. (2006) Beneficial effects of statins on perioperative cardiovascular outcome. Current Opinion in Anaesthesiology 19:4, 418-422
CrossRef797
A S Wierzbicki. (2006) Statins and hypertension. Journal of Human Hypertension 20:8, 554-556
CrossRef798
Jennifer G Robinson, Michael H Davidson. (2006) Managing cholesterol in the elderly. Aging Health 2:4, 623-638
CrossRef799
Jacques Genest. (2006) Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Canadian Journal of Cardiology 22:10, 863-868
CrossRef800
J. V. PATEL, E. A. HUGHES. (2006) Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. International Journal of Clinical Practice 60:8, 914-921
CrossRef801
A. G. Olsson. (2006) The lower the better? Experiences from cardiovascular disease and stroke prevention. Acta Neurologica Scandinavica 114:s185, 58-62
CrossRef802
Penny Owen, Ramsey Sabit. (2006) Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology 17:4, 486-488
CrossRef803
Patricia M Kearney, Colin Baigent. (2006) Statins: are any questions unanswered?. Current Opinion in Lipidology 17:4, 418-425
CrossRef804
Andrew T. Yan, Raymond T. Yan, Mary Tan, Daniel G. Hackam, Kori L. Leblanc, Heather Kertland, Jennifer L. Tsang, Shahin Jaffer, Martin L. Kates, Lawrence A. Leiter, David H. Fitchett, Anatoly Langer, Shaun G. Goodman. (2006) Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. The American Journal of Medicine 119:8, 676-683
CrossRef805
William L. Isley. (2006) Low-density lipoprotein cholesterol lowering in the prevention of CHD: How low should we go?. Current Treatment Options in Cardiovascular Medicine 8:4, 289-297
CrossRef806
W.G. Goettsch, E.M. Heintjes, J.J.P. Kastelein, T.J. Rabelink, Saga Johansson, R.M.C. Herings. (2006) Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. Pharmacoepidemiology and Drug Safety 15:7, 435-443
CrossRef807
Michaela Diamant, Maarten E. Tushuizen. (2006) The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?. Current Diabetes Reports 6:4, 279-286
CrossRef808
Nathaniel M Hawkins, Francis G Dunn. (2006) The management of hypertension in ischaemic heart disease. Current Opinion in Cardiology 21:4, 273-278
CrossRef809
Peter H. Jones. (2006) Dyslipidemia in Older Adults. The American Journal of Geriatric Cardiology 15:4, 239-244
CrossRef810
Katie M Speidel, Daniel E Hilleman. (2006) Pharmacoeconomic considerations with statin therapy. Expert Opinion on Pharmacotherapy 7:10, 1291-1304
CrossRef811
Jeffrey A. Switzer, David C. Hess. (2006) Statin therapy for coronary heart disease and its effect on stroke. Current Atherosclerosis Reports 8:4, 337-342
CrossRef812
Matthew K Ito, Robert L Talbert, Sotirios Tsimikas. (2006) Statin-Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction. Pharmacotherapy 26:7part2, 85S-97S
CrossRef813
Richard C. Mohs, Claudia Kawas, Maria C. Carrillo. (2006) Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease. Alzheimer's and Dementia 2:3, 131-139
CrossRef814
Jennifer G Robinson, Michael H Davidson. (2006) Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Review of Cardiovascular Therapy 4:4, 461-476
CrossRef815
David E Newby. (2006) Can intensive statin therapy cause regression of coronary atherosclerosis?. Nature Clinical Practice Cardiovascular Medicine 3:7, 354-355
CrossRef816
Amresh Raina, Thomas Pickering, Daichi Shimbo. (2006) Statin use in heart failure: A cause for concern?. American Heart Journal 152:1, 39-49
CrossRef817
D WATERS. (2006) What the Statin Trials Have Taught Us. The American Journal of Cardiology 98:1, 129-134
CrossRef818
J OKEEFEJR, L CORDAIN, P JONES, H ABUISSA. (2006) Coronary Artery Disease Prognosis and C-Reactive Protein Levels Improve in Proportion to Percent Lowering of Low-Density Lipoprotein. The American Journal of Cardiology 98:1, 135-139
CrossRef819
Ken Kitayama, Daisuke Nakai, Keita Kono, Arthur Gerritsen van der Hoop, Hitoshi Kurata, Elly C. de Wit, Louis H. Cohen, Toshimori Inaba, Takafumi Kohama. (2006) Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. European Journal of Pharmacology 539:1-2, 89-98
CrossRef820
Robert M. Guthrie. (2006) How Safe Is Aggressive Statin Therapy?. Progress in Cardiovascular Nursing 21:3, 140-145
CrossRef821
Benjamin M. Scirica, David A. Morrow, Christopher P. Cannon, Kausik K. Ray, Marc S. Sabatine, Petr Jarolim, Amy Shui, Carolyn H. McCabe, Eugene Braunwald. (2006) Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT–TIMI 22 Study. Journal of the American College of Cardiology 47:11, 2326-2331
CrossRef822
A. Middleton, A. S. Binbrek, F. A. H. Fonseca, W. Wilpshaar, C. Watkins, T. E. Strandberg. (2006) Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Current Medical Research and Opinion 22:6, 1181-1191
CrossRef823
Philip Barter, Kerry-Anne Rye. (2006) Are we lowering LDL cholesterol sufficiently?. Nature Clinical Practice Cardiovascular Medicine 3:6, 290-291
CrossRef824
Sarkis B Baghdasarian, Paul D Thompson. (2006) How safe are very low LDL cholesterol levels?. Nature Clinical Practice Cardiovascular Medicine 3:6, 306-307
CrossRef825
F. Civeira, E. Bustamante, E. Jarauta, E. Meriño-Ibarra. (2006) Lipoproteínas clásicas, terapéuticas modernas. Farmacología de las lipoproteínas de alta densidad. Clínica e Investigación en Arteriosclerosis 18, 10-19
CrossRef826
O Christopher Raffel, Harvey D White. (2006) Drug Insight: statin use in the elderly. Nature Clinical Practice Cardiovascular Medicine 3:6, 318-328
CrossRef827
Erin D. MacDougall, Farah Kramer, Patti Polinsky, Shelley Barnhart, Bardia Askari, Fredrik Johansson, Rebecca Varon, Michael E. Rosenfeld, Kazuhiro Oka, Lawrence Chan, Stephen M. Schwartz, Karin E. Bornfeldt. (2006) Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice. The American Journal of Pathology 168:6, 2064-2073
CrossRef828
Demiana William Faltaos, Saik Urien, Valerie Carreau, Marina Chauvenet, Jean Sebastian Hulot, Philippe Giral, Eric Bruckert, Philippe Lechat. (2006) Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundamental and Clinical Pharmacology 20:3, 321-330
CrossRef829
John R. Crouse, Marshall B. Elam, Jennifer G. Robinson, Walter T. Ambrosius, Henry N. Ginsberg. (2006) Cholesterol Management: Targeting a Lower Low-Density Lipoprotein Cholesterol Concentration Increases Adult Treatment Panel-III Goal Attainment. The American Journal of Cardiology 97:11, 1667-1669
CrossRef830
George Steiner. (2006) Statement of the Problem. The American Journal of Cardiology 97:12, 3-8
CrossRef831
Stephan von Haehling, Anja Sandek, Thomas Thum. (2006) Annual Meeting of the American Heart Association. Expert Opinion on Investigational Drugs 15:5, 563-569
CrossRef832
Philip T Rodgers, Dawn C Fuke. (2006) New and Emerging Strategies for Reducing Cardiometabolic Risk Factors. Pharmacotherapy 26:5part2, 13S-31S
CrossRef833
Sidney C. Smith, Jerilyn Allen, Steven N. Blair, Robert O. Bonow, Lawrence M. Brass, Gregg C. Fonarow, Scott M. Grundy, Loren Hiratzka, Daniel Jones, Harlan M. Krumholz, Lori Mosca, Richard C. Pasternak, Thomas Pearson, Marc A. Pfeffer, Kathryn A. Taubert. (2006) AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Journal of the American College of Cardiology 47:10, 2130-2139
CrossRef834
H J Milionis, E N Liberopoulos, A Achimastos, M S Elisaf, D P Mikhailidis. (2006) Statins: another class of antihypertensive agents?. Journal of Human Hypertension 20:5, 320-335
CrossRef835
Mark D. Kelemen. (2006) Angina Pectoris: Evaluation in the Office. Medical Clinics of North America 90:3, 391-416
CrossRef836
Mohan Shenoy, Carrie B. Chapman, M. Zaim Nawaz, NancyK. Sweitzer. (2006) Diagnosis and Management of Stage A Heart Failure. Congestive Heart Failure 12:3, 146-152
CrossRef837
Sid Gilman. (2006) Pharmacologic management of ischemic stroke: Relevance to stem cell therapy. Experimental Neurology 199:1, 28-36
CrossRef838
G. WALLDIUS, I. JUNGNER. (2006) The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. Journal of Internal Medicine 259:5, 493-519
CrossRef839
Graham Jackson. (2006) ASTEROID - when spinning a star leads to a collision with reality. International Journal of Clinical Practice 60:5, 505-505
CrossRef840
Jessica M. Ma, Cynthia A. Jackevicius, Uchenwa Genus, Vladimir Dzavik. (2006) The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention. Canadian Journal of Cardiology 22:5, 419-423
CrossRef841
A. S. Wierzbicki. (2006) FIELDS of dreams, fields of tears: a perspective on the fibrate trials. International Journal of Clinical Practice 60:4, 442-449
CrossRef842
Michael F Bullano, Debra A Wertz, Grace W Yang, Siddhesh Kamat, Gerald M Borok, Sanjay Gandhi, Kenneth L McDonough, Vincent J Willey. (2006) Effect of Rosuvastatin Compared with Other Statins on Lipid Levels and National Cholesterol Education Program Goal Attainment for Low-Density Lipoprotein Cholesterol in a Usual Care Setting. Pharmacotherapy 26:4, 469-478
CrossRef843
Khan Pohlel, Parker Grow, Tarek Helmy, Nanette K Wenger. (2006) Treating dyslipidemia in the elderly. Current Opinion in Internal Medicine 5:2, 150-153
CrossRef844
Scott M. Grundy. (2006) Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nature Reviews Drug Discovery 5:4, 295-309
CrossRef845
Tomohiro Sakamoto, Sunao Kojima, Hisao Ogawa, Hideki Shimomura, Kazuo Kimura, Yasuhiro Ogata, Naritsugu Sakaino, Akira Kitagawa. (2006) Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction in Japanese. The American Journal of Cardiology 97:8, 1165-1171
CrossRef846
Harold Bays. (2006) Statin Safety: An Overview and Assessment of the Data—2005. The American Journal of Cardiology 97:8, S6-S26
CrossRef847
Stella S. Daskalopoulou, Dimitri P. Mikhailidis. (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion 22:3, 511-528
CrossRef848
Josh Todd, John A. Farmer. (2006) Optimal low-density lipoprotein levels: Evidence from epidemiology and clinical trials. Current Atherosclerosis Reports 8:2, 157-162
CrossRef849
Leibson Philip R.. (2006) IDEAL and FIELD. Preventive Cardiology 9:2, 115-120
CrossRef850
Charles J. Lowenstein, Munekazu Yamakuchi. 2006. Statins, Inflammation, and Cardiomyopathy: Old Pathways, New Targets. , 155-166.
CrossRef851
Jones Peter H.. (2006) REVIEW PAPER. Rationale for Intensive Statin Treatment in High-Risk Patients. Preventive Cardiology 9:2, 91-95
CrossRef852
Leif R. Erhardt, A. Gotto. (2006) The evolution of European guidelines: Changing the management of cholesterol levels. Atherosclerosis 185:1, 12-20
CrossRef853
Roy Blank. (2006) Amlodipine/atorvastatin single pill for the management of hypertensive patients with additional cardiovascular risk factors. Future Cardiology 2:2, 145-159
CrossRef854
Eric P. Brass, Shannon E. Allen, Jeffrey M. Melin. (2006) Potential Impact on Cardiovascular Public Health of Over-the-Counter Statin Availability. The American Journal of Cardiology 97:6, 851-856
CrossRef855
Lawrence A. Leiter. (2006) PROVE-IT proved it: Lower is better – Pro. Canadian Journal of Cardiology 22, 91B-94B
CrossRef856
Jeffrey A Switzer, David C Hess. (2006) Statins in stroke: prevention, protection and recovery. Expert Review of Neurotherapeutics 6:2, 195-202
CrossRef857
Stephen D. Persell, Donald M. Lloyd-Jones, David W. Baker. (2006) Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. Journal of General Internal Medicine 21:2, 171-176
CrossRef858
Rakesh S Birjmohun, Erik SG Stroes, John JP Kastelein. (2006) Raising high-density lipoprotein cholesterol for better prevention of cardiovascular disease. Future Lipidology 1:1, 47-54
CrossRef859
Xavier Pintó. (2006) Las estatinas, los hábitos de vida y el tratamiento de la hipercolesterolemia: los tiempos cambian y los criterios también. Medicina Clínica 126:6, 217-219
CrossRef860
Simon W. Beaven, Peter Tontonoz. (2006) Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia. Annual Review of Medicine 57:1, 313-329
CrossRef861
Rasha YA Mukhtar, John PD Reckless. (2006) Statin-induced myositis: a commonly encountered or rare side effect?. Current Opinion in Internal Medicine 5:1, 34-41
CrossRef862
Michel R. Hoenig, Barbara E. Rolfe, Julie H. Campbell. (2006) Cholestanol: A serum marker to guide LDL cholesterol-lowering therapy. Atherosclerosis 184:2, 247-254
CrossRef863
Sameer K Mehta, James A de Lemos. (2006) Appropriate invasive and conservative strategies for patients with non-ST elevation acute coronary syndromes. Current Opinion in Internal Medicine 5:1, 24-28
CrossRef864
J.L. Martín-Ventura, L.M. Blanco-Colio, A. Gómez-Hernández, B. Muñoz-García, M. Vega, J. Serrano, L. Ortega, G. Hernández, J. Egido, J. Tuñón. (2006) El tratamiento con dosis altas de atorvastatina disminuye la inflamación en la aterosclerosis carotídea humana. Clínica e Investigación en Arteriosclerosis 18:1, 18-23
CrossRef865
Matthias Briel, Alain J Nordmann, Heiner C Bucher. (2006) Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Current Opinion in Internal Medicine 5:1, 29-33
CrossRef866
STEPHANE G. CARLIER, KAORU TANAKA. (2006) Studying Coronary Plaque Regression with IVUS: A Critical Review of Recent Studies. Journal of Interventional Cardiology 19:1, 11-15
CrossRef867
P K Shah. (2006) HDL/apoA-I infusion for atherosclerosis management: an emerging therapeutic paradigm. Future Lipidology 1:1, 55-64
CrossRef868
CINDY L. GRINES. (2006) The Role of Statins in Reversing Atherosclerosis: What the Latest Regression Studies Show. Journal of Interventional Cardiology 19:1, 3-9
CrossRef869
Leonid Yatskar, Edward A. Fisher, Arthur Schwartzbard. (2006) Ezetimibe: Rationale and role in the management of hypercholesterolemia. Clinical Cardiology 29:2, 52-55
CrossRef870
Stephen D. Persell, Donald M. Lloyd-Jones, David W. Baker. (2006) Implications of Changing National Cholesterol Education Program Goals for the Treatment and Control of Hypercholesterolemia. Journal of General Internal Medicine 0:0, 060111052548001-???
CrossRef871
R. Bilous. (2006) Will ASCOT change the form of anti-hypertensive therapy?. Diabetic Medicine 23:1, 13-14
CrossRef872
H. T. Ong. (2006) Evidence-Based Prescribing of Statins: A Developing World Perspective. PLoS Medicine 3:3, e50
CrossRef873
E. Hodenberg, Th. Breidenbach, J. Melichercik. (2006) Die Bedeutung der Cholesterinsenkung bei Patienten nach aortokoronarer Bypassoperation. Clinical Research in Cardiology 95:S1, i78-i82
CrossRef874
Matthew A. Silva, Anna C. Swanson, Pritesh J. Gandhi, Gary R. Tataronis. (2006) Statin-related adverse events: A meta-analysis. Clinical Therapeutics 28:1, 26-35
CrossRef875
Katsumi Miyauchi, Takeshi Kimura, Takeshi Morimoto, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Takafumi Hiro, Hiroyuki Daida, Masunori Matsuzaki. (2006) Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS). Circulation Journal 70:12, 1624-1628
CrossRef876
Paul J. Garcia, Craig W. Spellman. (2006) Should all diabetic patients receive statins?. Current Atherosclerosis Reports 8:1, 13-18
CrossRef877
Atsushi Iwata, Shin-ichiro Miura, Kazuyuki Shirai, Akira Kawamura, Sayo Tomita, Yoshino Matsuo, Bo Zhang, Hiroaki Nishikawa, Koichiro Kumagai, Kunihiro Matsuo, Keijiro Saku. (2006) Lower Level of Low-density Lipoprotein Cholesterol by Statin Prevents Progression of Coronary Restenosis after Successful Stenting in Acute Myocardial Infarction. Internal Medicine 45:15, 885-890
CrossRef878
Ernst J. Schaefer, Bela F. Asztalos. (2006) The effects of statins on high-density lipoproteins. Current Atherosclerosis Reports 8:1, 41-49
CrossRef879
James M. McKenney, Michael H. Davidson, Charles L. Shear, James H. Revkin. (2006) Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density LipoproteinCholesterolLevelsonaBackgroundofAtorvastatin. Journal of the American College of Cardiology 48:9, 1782
CrossRef880
Shinji Koba, Jun Sasaki. (2006) Treatment of Hyperlipidemia from Japanese Evidence. Journal of Atherosclerosis and Thrombosis 13:6, 267-280
CrossRef881
Eva Lonn. (2006) Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Canadian Journal of Cardiology 22:1, 47-53
CrossRef882
B.J. Gersh. (2006) Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease. Yearbook of Cardiology 2006, 280-281
CrossRef883
Ezra A. Amsterdam. (2006) The IDEAL Trial: Less Is More. Preventive Cardiology 9:1, 66-66
CrossRef884
AJ Scheen. (2006) Does the metabolic syndrome help to select patients requiring high statin dose?. The Lancet 368:9539, 893
CrossRef885
Terry A Jacobson. (2006) Overcoming ???Ageism??? Bias in the Treatment of Hypercholesterolaemia. Drug Safety 29:5, 421-448
CrossRef886
Alfonso del Río Ligorit. (2006) Cardiología preventiva y rehabilitación. Revista Española de Cardiología 59, 50-54
CrossRef887
Borja Ibanez, Juan Badimon. (2006) Ezetimibe: one step beyond in the battle against atherosclerosis. Future Lipidology 1:3, 255
CrossRef888
Nicola Abate, Manisha Chandalia. (2006) Should all patients with metabolic syndrome be treated with statins?. Current Diabetes Reports 6:1, 72-76
CrossRef889
Alfredo Bardají, Joaquín Alonso, Xavier García-Moll, Héctor Bueno. (2006) Actualización en cardiopatía isquémica 2005. Revista Española de Cardiología 59, 3-19
CrossRef890
Kumar Rajamani, Seemant Chaturvedi. (2006) New strategies in the medical treatment of carotid artery disease. Current Cardiology Reports 8:1, 33-37
CrossRef891
Lionel H Opie, Patrick J Commerford, Bernard J Gersh. (2006) Controversies in stable coronary artery disease. The Lancet 367:9504, 69-78
CrossRef892
W HOWARD. (2006) Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary DiseaseLaRosa JC, for the Treating to New Targets (TNT) Investigators (State Univ of New York, Brooklyn; et al) N Engl J Med352:1425–1435, 2005§. Yearbook of Endocrinology 2006, 118-120
CrossRef893
W HOWARD, W FRISHMAN. (2006) Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary DiseaseLaRosa JC, for the Treating to New Targets (TNT) Investigators (State Univ of New York, Brooklyn; et al) N Engl J Med 352:1425–1435, 2005§. Yearbook of Medicine 2006, 480-482
CrossRef894
Hannes Franz Alber, Matthias Frick, Alois Suessenbacher, Jakob Doerler, Michael Schirmer, Eva-Maria Stocker, Wolfgang Dichtl, Otmar Pachinger, Franz Weidinger. (2006) Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—A randomized, placebo-controlled study. American Heart Journal 151:1, 139.e1-139.e7
CrossRef895
Connie Newman, John Tsai, Michael Szarek, Don Luo, Eric Gibson. (2006) Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 Patients. The American Journal of Cardiology 97:1, 61-67
CrossRef896
Benjamin A. Steinberg, Alexandria J. M. Braganza, Gemma Eminowicz, Peter M. Dibattiste, Gregory C. Flaker, Sabina A. Murphy, Christopher P. Cannon. (2005) Are Statins Being Underdosed in Clinical Practice?. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:4, 169-173
CrossRef897
Michael Schachter. (2005) Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. Cardiovascular Drugs and Therapy 19:6, 415-422
CrossRef898
Richard A Krasuski. (2005) HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. Current Opinion in Lipidology 16:6, 652-657
CrossRef899
Takashi Miida, Akihiro Takahashi, Naohito Tanabe, Takeshi Ikeuchi. (2005) Can statin therapy really reduce the risk of Alzheimerʼs disease and slow its progression?. Current Opinion in Lipidology 16:6, 619-623
CrossRef900
Pierre Amarenco. (2005) Effect of statins in stroke prevention. Current Opinion in Lipidology 16:6, 614-618
CrossRef901
Gregg C. Fonarow, Karol E. Watson. (2005) Treating to Low-Density Lipoprotein Goal. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:4, 174-176
CrossRef902
V. Barrios, N. Amabile, F. Paganelli, J-W Chen, C. Allen, A. O. Johnson-Levonas, R. Massaad, K. Vandormael. (2005) Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. International Journal of Clinical Practice 59:12, 1377-1386
CrossRef903
Eyal Leibovitz, Rafi Bitzur, Dror Harats, Dov Gavish. (2005) Beyond guidelines: achieving the optimum in LDL cholesterol control. Current Opinion in Lipidology 16:6, 635-639
CrossRef904
Ian Graham. (2005) What impact will current trial data have on future guideline recommendations?. The American Journal of Medicine 118:12, 42-47
CrossRef905
Jean Rouleau. (2005) Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) trial. The American Journal of Medicine 118:12, 28-35
CrossRef906
Steven E. Nissen. (2005) Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. The American Journal of Medicine 118:12, 22-27
CrossRef907
Thomas T. Tsai, Brahmajee K. Nallamothu, Debabrata Mukherjee, Melvyn Rubenfire, Jianming Fang, Paul Chan, Eva Kline-Rogers, Amisha Patel, David F. Armstrong, Kim A. Eagle, A.D. Goldberg. (2005) Effect of Statin Use in Patients With Acute Coronary Syndromes and a Serum Low-Density Lipoprotein ≤80 mg/dl. The American Journal of Cardiology 96:11, 1491-1493
CrossRef908
Sander J. Robins. (2005) Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome. Current Cardiology Reports 7:6, 457-464
CrossRef909
Vera Bittner. (2005) Perspectives on Dyslipidemia and Coronary Heart Disease in Women. Journal of the American College of Cardiology 46:9, 1628-1635
CrossRef910
Ralph L Sacco, James K Liao. (2005) Drug Insight: statins and stroke. Nature Clinical Practice Cardiovascular Medicine 2:11, 576-584
CrossRef911
Antonio M. Gotto, John C. Larosa. (2005) The benefits of statin therapy-what questions remain?. Clinical Cardiology 28:11, 499-503
CrossRef912
Jennifer G. Robinson, Brian Smith, Nidhi Maheshwari, Helmut Schrott. (2005) Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?. Journal of the American College of Cardiology 46:10, 1855-1862
CrossRef913
Kausik K Ray, Christopher P Cannon. (2005) Optimal goals for statin use in patients with coronary artery disease. Current Opinion in Cardiology 20:6, 525-529
CrossRef914
Daniel Steinberg. (2005) Hypercholesterolemia and inflammation in atherogenesis: Two sides of the same coin. Molecular Nutrition & Food Research 49:11, 995-998
CrossRef915
Paolo Calabr??, Edward T.H Yeh. (2005) The pleiotropic effects of statins. Current Opinion in Cardiology 20:6, 541-546
CrossRef916
John C. LaRosa. (2005) At the Heart of the Statin Benefit* *Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 46:10, 1863
CrossRef917
Jerzy-Roch Nofer, Michael Walter, Gerd Assmann. (2005) Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Review of Cardiovascular Therapy 3:6, 1071-1086
CrossRef918
Roger S. Kirby, Michael Kirby. (2005) The urologist as an advocate of men’s health: 10 suggested steps toward helping patients achieve better overall health. Urology 66:5, 52-56
CrossRef919
Michael H. Davidson. (2005) Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy. The American Journal of Cardiology 96:9, 3-13
CrossRef920
Pim van der Harst, Lodewijk J. Wagenaar, Hendrik Buikema, Adriaan A. Voors, H.W. Thijs Plokker, Wim J. Morshuis, A. Jacob Six, Piet W. Boonstra, Georg Nickenig, Sven Wassmann, Dirk J. van Veldhuisen, Wiek H. van Gilst. (2005) Effect of Intensive Versus Moderate Lipid Lowering on Endothelial Function and Vascular Responsiveness to Angiotensin II in Stable Coronary Artery Disease. The American Journal of Cardiology 96:10, 1361-1364
CrossRef921
P. Armario, R. Hernández del Rey, M.N. Görbig Romeu. (2005) ¿Hasta dónde hay que reducir el colesterol en el paciente de alto riesgo cardiovascular?. Hipertensión 22:8, 318-331
CrossRef922
Kevin C. Maki, Ron Galant, Michael H. Davidson. (2005) Non–High-Density Lipoprotein Cholesterol: The Forgotten Therapeutic Target. The American Journal of Cardiology 96:9, 59-64
CrossRef923
Robert Dellavalle, Amanda Drake, Marla Graber, Lauren Heilig, Eric Hester, Kathryn Johnson, Kristie McNealy, Lisa Schilling, Robert Dellavalle. 2005. Statins and fibrates for preventing melanoma. .
CrossRef924
(2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet 366:9493, 1267-1278
CrossRef925
Pablo Gómez-Fernández. (2005) Estatinas y efectos beneficiosos. Medicina Clínica 125:15, 578-579
CrossRef926
Grant H Skrepnek. (2005) Cost–effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert Review of Pharmacoeconomics & Outcomes Research 5:5, 603-623
CrossRef927
Sheila A Doggrell. (2005) More support for high-dose atorvastatin in coronary artery disease. Expert Opinion on Pharmacotherapy 6:13, 2365-2368
CrossRef928
Kausik K. Ray, Christopher P. Cannon, Carolyn H. McCabe, Richard Cairns, Andrew M. Tonkin, Frank M. Sacks, Graham Jackson, Eugene Braunwald. (2005) Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 46:8, 1405-1410
CrossRef929
Gerd Assmann, Paul Cullen, Jean-Charles Fruchart, Heiner Greten, Marek Naruszewicz, Anders Olsson, Rodolfo Paoletti, Walter Riesen, Monika Stoll, Matti Tikkanen, Arnold von Eckardstein. (2005) Implications of emerging risk factors for therapeutic intervention. Nutrition, Metabolism and Cardiovascular Diseases 15:5, 373-381
CrossRef930
Iris Baumgartner. (2005) Systemic antiatherosclerotic treatment for the peripheral arterial occlusive disease patient. Expert Opinion on Pharmacotherapy 6:13, 2181-2192
CrossRef931
Stephen D. Wiviott, Christopher P. Cannon, David A. Morrow, Kausik K. Ray, Marc A. Pfeffer, Eugene Braunwald. (2005) Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. Journal of the American College of Cardiology 46:8, 1411-1416
CrossRef932
J.M. Mostaza, C. Lahoz. (2005) Implicaciones clínicas del estudio TNT. Clínica e Investigación en Arteriosclerosis 17:5, 249-254
CrossRef933
Antonio M. Gotto. (2005) Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. Journal of the American College of Cardiology 46:7, 1219-1224
CrossRef934
Rebecca J Cheung, Matthew K Ito. (2005) Clinical utility of extended-release niacin: update and summary. Future Cardiology 1:5, 571-578
CrossRef935
Mark Y Chan, Chi Hang Lee. (2005) Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opinion on Pharmacotherapy 6:11, 1883-1895
CrossRef936
Bo Ziedén, Anders G. Olsson. (2005) The role of statins in the prevention of ischemic stroke. Current Atherosclerosis Reports 7:5, 364-368
CrossRef937
Harold Bays, James McKenney, Michael Davidson. (2005) Torcetrapib/atorvastatin combination therapy. Expert Review of Cardiovascular Therapy 3:5, 789-820
CrossRef938
Jeanne P. Dieleman, Jacobus T. van Wyk, Marc A. M. van Wijk, Gé van Herpen, Sabine M. J. M. Straus, Hans Dunselman, Miriam C. J. M. Sturkenboom. (2005) Differences between statins on clinical endpoints: a population-based cohort study. Current Medical Research and Opinion 21:9, 1461-1468
CrossRef939
Keith C Ferdinand. (2005) Rosuvastatin: a risk–benefit assessment for intensive lipid lowering. Expert Opinion on Pharmacotherapy 6:11, 1897-1910
CrossRef940
Peter P. Toth. (2005) New insights in the treatment of dyslipidemia: A focus on cardiovascular event reduction and the antiatherosclerotic effects of atorvastatin. Current Atherosclerosis Reports 7:5, 335-343
CrossRef941
Claire S Duvernoy. (2005) Coronary heart disease in women: what do we know now?. Future Cardiology 1:5, 617-628
CrossRef942
Steven E. Nissen. (2005) Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis: Evidence for an Early Benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Trial. The American Journal of Cardiology 96:5, 61-68
CrossRef943
David D. Waters. (2005) Safety of High-Dose Atorvastatin Therapy. The American Journal of Cardiology 96:5, 69-75
CrossRef944
G Assmann. (2005) Kardiovaskuläre Risikoabschätzung – PROCAM und neue Algorithmen der Stratifizierung / Assessment of Cardiovascular Risk – PROCAM and New Algorithms. Biomedizinische Technik/Biomedical Engineering 50:7-8, 227-232
CrossRef945
Howard S. Weintraub. (2005) Treatment of multiple-risk patients: Using combination therapy to treat beyond LDL lowering. Current Hypertension Reports 7:4, 265-270
CrossRef946
Francisco A. H. Fonseca, Alvaro Ruiz, Ernesto G. Cardona-Muñoz, Jose M. Silva, Nery Fuenmayor, Marcelo Marotti. (2005) The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin*. Current Medical Research and Opinion 21:8, 1307-1315
CrossRef947
E. Ros. (2005) Grosor íntima-media como variable sustitutiva de aterosclerosis. Clínica e Investigación en Arteriosclerosis 17:4, 173-175
CrossRef948
Steven Haffner. (2005) Rationale for New American Diabetes Association Guidelines: Are National Cholesterol Education Program Goals Adequate for the Patient with Diabetes Mellitus?. The American Journal of Cardiology 96:4, 33-36
CrossRef949
Wanner, Christoph, Krane, Vera, März, Winfried, Olschewski, Manfred, Mann, Johannes F.E., Ruf, Günther, Ritz, Eberhard, . (2005) Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. New England Journal of Medicine 353:3, 238-248
Full Text950
(2005) Intensive Lipid Lowering with Atorvastatin in Coronary Disease. New England Journal of Medicine 353:1, 93-96
Full Text951
M. R. Cowie. (2005) Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. International Journal of Clinical Practice 59:7, 839-846
CrossRef952
Scott M. Grundy. (2005) The Changing Face of Cardiovascular Risk* *Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 46:1, 173-175
CrossRef953
Danielle Duffy, Daniel J Rader. (2005) Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Current Opinion in Cardiology 20:4, 301-306
CrossRef954
Gary E. Sander, Thomas D. Giles. (2005) Medical Management of Myocardial Ischemia. The American Journal of Geriatric Cardiology 14:4, 205-209
CrossRef955
Charles Daniel Meyers, Nathan Wong, Moti L Kashyap. (2005) Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials. Future Cardiology 1:4, 461-471
CrossRef956
Abrams, Jonathan, . (2005) Chronic Stable Angina. New England Journal of Medicine 352:24, 2524-2533
Full Text957
Ezra A. Amsterdam. (2005) Rimonabant: Unique and Promising. Preventive Cardiology 8:3, 140-140
CrossRef958
Annemarie Colbin. (2005) The Cholesterol Controversy. Alternative and Complementary Therapies 11:3, 126-130
CrossRef959
Graham Jackson. (2005) Lipids and cardiovascular risk reduction - new targets, new challenges. International Journal of Clinical Practice 59:6, 617-618
CrossRef960
Kausik K Ray, Christopher P Cannon. (2005) Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opinion on Pharmacotherapy 6:6, 915-927
CrossRef961
David R.P. Guay. (2005) Geriatric pharmacotherapy updates. The American Journal of Geriatric Pharmacotherapy 3:2, 115-122
CrossRef962
(2005) Increased clinical benefit of atorvastatin at high doses in stable coronary heart disease. Nature Clinical Practice Cardiovascular Medicine 2:6, 272-272
CrossRef963
Sander I van Leuven, John JP Kastelein. (2005) Atorvastatin. Expert Opinion on Pharmacotherapy 6:7, 1191-1203
CrossRef964
Rafael Marín, Álex de la Sierra, Pedro Armario, Carlos Campo, José R. Banegas, Manuel Gorostidi. (2005) Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Medicina Clínica 125:1, 24-34
CrossRef965
Philip R Liebson. (2005) Womens? Health Study (Aspirin) and TNT. Preventive Cardiology 8:3, 181-185
CrossRef966
Bruce B. Lerman, Richard B. Devereux, Peter M. Okin. (2005) An Introduction. Journal of the American College of Cardiology 45:11, B2-B3
CrossRef967
A. D. Mooradian. (2005) Commentary. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:5, 598-598
CrossRef968
D. L. Hurley, W. L. Isley. (2005) Getting There: Statin Plus Ezetimibe for Low-Density Lipoprotein Cholesterol Goals. Mayo Clinic Proceedings 80:5, 585-586
CrossRef969
Pitt, Bertram, . (2005) Low-Density Lipoprotein Cholesterol in Patients with Stable Coronary Heart Disease — Is It Time to Shift Our Goals?. New England Journal of Medicine 352:14, 1483-1484
Full Text970
(2005) News In Brief. Nature Reviews Drug Discovery 4:4, 269-269
CrossRef971
José Vivancos-Mora, Antonio C. Gil-Núñez. (2005) Lipids and Stroke: The Opportunity of Lipid-Lowering Treatment. Cerebrovascular Diseases 20:2, 53-67
CrossRef972
Hirotaka Nagashima, Hiroshi Kasanuki. (2005) The Status of Lipid Management in 1,836 Patients with Coronary Artery Disease: A multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society. Journal of Atherosclerosis and Thrombosis 12:6, 338-342
CrossRef
- Letters
